CATH Search:   
       by CATH code, keyword
QuickSearch:   
by PDB,NDB,UniProt,PROSITE Code or Search Term(s)  
(use 'Shift Left-Click' to collapse/expand all levels downwards; use 'Control Left-Click' to collapse/expand all levels upwards)
 
(-)
Class: Mainly Beta (13760)
(-)
Architecture: Beta Barrel (4804)
(-)
Topology: Thrombin, subunit H (1535)
(-)
Homologous Superfamily: [code=2.40.10.120, no name defined] (40)
(-)
Hcv (Hepatitis c virus (isolate 1)) (1)
1DXWA:22-94STRUCTURE OF HETERO COMPLEX OF NON STRUCTURAL PROTEIN (NS) OF HEPATITIS C VIRUS (HCV) AND SYNTHETIC PEPTIDIC COMPOUND
(-)
Hepatitis c virus (isolate 1). (1)
1W3CA:7-94; B:7-94CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS3 PROTEASE IN COMPLEX WITH A PEPTIDOMIMETIC INHIBITOR
(-)
Hepatitis c virus (isolate 1). Organism_taxid: 31645. Strain: isolatetaiwan. (3)
1DXPA:7-94; B:7-94INHIBITION OF THE HEPATITIS C VIRUS NS3/4A PROTEASE. THE CRYSTAL STRUCTURES OF TWO PROTEASE-INHIBITOR COMPLEXES (APO STRUCTURE)
1DY8A:7-94; B:7-94INHIBITION OF THE HEPATITIS C VIRUS NS3/4A PROTEASE. THE CRYSTAL STRUCTURES OF TWO PROTEASE-INHIBITOR COMPLEXES (INHIBITOR II)
1DY9A:7-94; B:7-94INHIBITION OF THE HEPATITIS C VIRUS NS3/4A PROTEASE. THE CRYSTAL STRUCTURES OF TWO PROTEASE-INHIBITOR COMPLEXES (INHIBITOR I)
(-)
Hepatitis c virus (isolate bk). Organism_taxid: 11105. Strain: (isolate bk). Variant: isolate bk. (1)
1NS3A:7-94; B:7-94STRUCTURE OF HCV PROTEASE (BK STRAIN)
(-)
Hepatitis c virus (isolate bk). Organism_taxid: 11105. Strain: bk strain isolate. (1)
1JXPA:7-94; B:7-94BK STRAIN HEPATITIS C VIRUS (HCV) NS3-NS4A
(-)
Hepatitis c virus subtype 1a. Organism_taxid: 31646. Strain: h77 strain of genotype 1a. (2)
3EYDA:1-94; C:29-94STRUCTURE OF HCV NS3-4A PROTEASE WITH AN INHIBITOR DERIVED FROM A BORONIC ACID
3KN2A:1-94; C:29-94HCV NS3 PROTEASE DOMAIN WITH KETOAMIDE INHIBITOR
(-)
Hepatitis c virus. Organism_taxid: 11103. (8)
1N1LA:29-94; B:29-94CRYSTAL STRUCTURE OF HCV NS3 PROTEASE DOMAIN:NS4A PEPTIDE COMPLEX WITH COVALENTLY BOUND INHIBITOR (GW472467X)
1RTLA:1-94; B:29-94CRYSTAL STRUCTURE OF HCV NS3 PROTEASE DOMAIN: NS4A PEPTIDE COMPLEX WITH COVALENTLY BOUND PYRROLIDINE-5,5-TRANSLACTAM INHIBITOR
2O8MA:-3-94; B:29-94CRYSTAL STRUCTURE OF THE S139A MUTANT OF HEPATITIS C VIRUS NS3/4A PROTEASE
2OBOA:-1-94; C:29-94STRUCTURE OF HEPATITIS C VIRAL NS3 PROTEASE DOMAIN COMPLEXED WITH NS4A PEPTIDE AND KETOAMIDE SCH476776
2OBQA:1-94; C:29-94DISCOVERY OF THE HCV NS3/4A PROTEASE INHIBITOR SCH503034. KEY STEPS IN STRUCTURE-BASED OPTIMIZATION
2OC0A:1-94; C:29-94STRUCTURE OF NS3 COMPLEXED WITH A KETOAMIDE INHIBITOR SCH491762
2OC7A:1-94; C:29-94STRUCTURE OF HEPATITIS C VIRAL NS3 PROTEASE DOMAIN COMPLEXED WITH NS4A PEPTIDE AND KETOAMIDE SCH571696
2OC8A:-1-94; C:29-94STRUCTURE OF HEPATITIS C VIRAL NS3 PROTEASE DOMAIN COMPLEXED WITH NS4A PEPTIDE AND KETOAMIDE SCH503034
(-)
Hepatitis c virus. Organism_taxid: 11103. (9)
1CU1A:705-720,A:3-94; B:1705-1720,B:1003-1094CRYSTAL STRUCTURE OF AN ENZYME COMPLEX FROM HEPATITIS C VIRUS
1RGQB:1-97; A:32-97M9A HCV PROTEASE COMPLEX WITH PENTAPEPTIDE KETO-AMIDE INHIBITOR
2A4GA:1-94; C:29-94HEPATITIS C PROTEASE NS3-4A SERINE PROTEASE WITH KETOAMIDE INHIBITOR SCH225724 BOUND
2A4QA:1-94; C:29-94HCV NS3 PROTEASE WITH NS4A PEPTIDE AND A COVALENTLY BOUND MACROCYCLIC KETOAMIDE COMPOUND.
2A4RA:1-94; C:29-94HCV NS3 PROTEASE DOMAIN WITH A KETOAMIDE INHIBITOR COVALENTLY BOUND.
2GVFA:-1-94; C:29-94HCV NS3-4A PROTEASE DOMAIN COMPLEXED WITH A MACROCYCLIC KETOAMIDE INHIBITOR, SCH419021
2OC1A:-1-94; C:29-94STRUCTURE OF THE HCV NS3/4A PROTEASE INHIBITOR CVS4819
3KEEA:7-94; B:7-94; C:7-94; D:7-94HCV NS3/NS4A COMPLEXED WITH NON-COVALENT MACROCYCLIC COMPOUND TMC435
3KF2B:1-94; A:29-94THE HCV NS3/NS4A PROTEASE APO STRUCTURE
(-)
Hepatitis c virus. Organism_taxid: 11103. Strain: 1b. (1)
2K1QA:22-94NMR STRUCTURE OF HEPATITIS C VIRUS NS3 SERINE PROTEASE COMPLEXED WITH THE NON-COVALENTLY BOUND PHENETHYLAMIDE INHIBITOR
(-)
Hepatitis c virus. Organism_taxid: 11103. Strain: bk. (1)
1BT7A:22-94THE SOLUTION NMR STRUCTURE OF THE N-TERMINAL PROTEASE DOMAIN OF THE HEPATITIS C VIRUS (HCV) NS3-PROTEIN, FROM BK STRAIN, 20 STRUCTURES
(-)
Hepatitis c virus. Organism_taxid: 11103. Strain: h strain. (1)
2F9UA:1-94; C:29-94HCV NS3 PROTEASE DOMAIN WITH NS4A PEPTIDE AND A KETOAMIDE INHIBITOR WITH A P2 NORBORANE
(-)
Hepatitis c virus. Organism_taxid: 11103. Strain: h strain. (1)
2XCFA:1-94; B:29-94CRYSTAL STRUCTURE OF HCV NS3 PROTEASE WITH A BORONATE INHIBITOR
(-)
Hepatitis c virus. Organism_taxid: 11103. Strain: h. (3)
1A1RB:33-120; A:55-120HCV NS3 PROTEASE DOMAIN:NS4A PEPTIDE COMPLEX
2F9VA:-1-94; C:29-94HCV NS3 PROTEASE DOMAIN WITH NS4A PEPTIDE AND A KETOAMIDE INHIBITOR WITH P1 AND P2 CYCLOPROPYLALANNINES
2OINB:1027-1120; A:55-120CRYSTAL STRUCTURE OF HCV NS3-4A R155K MUNTANT
(-)
Hepatitis c virus. Organism_taxid: 11103. Strain: h. (1)
2XCNA:1-94; B:29-94CRYSTAL STRUCTURE OF HCV NS3 PROTEASE WITH A BORONATE INHIBITOR
(-)
Hepatitis c virus. Organism_taxid: 11103. Strain: h1a. (1)
2FM2A:1-94; C:29-94HCV NS3-4A PROTEASE DOMAIN COMPLEXED WITH A KETOAMIDE INHIBITOR, SCH446211
(-)
Hepatitis c virus. Organism_taxid: 11103. Strain: hcv-h strain. (1)
2P59B:1027-1120; A:55-120CRYSTAL STRUCTURE OF HEPATITIS C VIRUS NS3.4A PROTEASE
(-)
Hepatitis c virus. Strain: h. (1)
2QV1B:1027-1120; A:55-120CRYSTAL STRUCTURE OF HCV NS3-4A V36M MUTANT
(-)
Thermotoga maritima msb8. Organism_taxid: 243274. Strain: msb8. (1)
2F4LA:77-119; B:77-119; C:77-119; D:77-119CRYSTAL STRUCTURE OF A PUTATIVE ACETAMIDASE (TM0119) FROM THERMOTOGA MARITIMA MSB8 AT 2.50 A RESOLUTION
(-)
Homologous Superfamily: [code=2.40.10.170, no name defined] (33)
(-)
Baker's yeast (Saccharomyces cerevisiae) (3)
2HLDE:8-82; W:8-82; F:7-82; O:7-82; X:7-82; D:6-82; M:6-82; N:6-82; V:6-82CRYSTAL STRUCTURE OF YEAST MITOCHONDRIAL F1-ATPASE
2WPDF:7-82; D:6-82; E:6-82THE MG.ADP INHIBITED STATE OF THE YEAST F1C10 ATP SYNTHASE
2XOKE:8-82; F:7-82; D:6-82REFINED STRUCTURE OF YEAST F1C10 ATPASE COMPLEX TO 3 A RESOLUTION
(-)
Bovine (Bos taurus) (17)
1E1QD:9-81; E:9-81; F:9-81BOVINE MITOCHONDRIAL F1-ATPASE AT 100K
1E1RD:9-81; E:9-81; F:9-81BOVINE MITOCHONDRIAL F1-ATPASE INHIBITED BY MG2+ADP AND ALUMINIUM FLUORIDE
1E79D:9-81; E:9-81; F:9-81BOVINE F1-ATPASE INHIBITED BY DCCD (DICYCLOHEXYLCARBODIIMIDE)
1H8ED:9-81; E:9-81; F:9-81(ADP.ALF4)2(ADP.SO4) BOVINE F1-ATPASE (ALL THREE CATALYTIC SITES OCCUPIED)
1H8HD:9-81; E:9-81; F:9-81BOVINE MITOCHONDRIAL F1-ATPASE CRYSTALLISED IN THE PRESENCE OF 5MM AMPPNP
1OHHD:9-81; E:9-81; F:9-81BOVINE MITOCHONDRIAL F1-ATPASE COMPLEXED WITH THE INHIBITOR PROTEIN IF1
1W0JD:9-81; E:9-81; F:9-81BERYLLIUM FLUORIDE INHIBITED BOVINE F1-ATPASE
1W0KD:9-81; E:9-81; F:9-81ADP INHIBITED BOVINE F1-ATPASE
2CK3D:9-81; E:9-81; F:9-81AZIDE INHIBITED BOVINE F1-ATPASE
2JDID:9-81; E:9-81; F:9-81GROUND STATE STRUCTURE OF F1-ATPASE FROM BOVINE HEART MITOCHONDRIA (BOVINE F1-ATPASE CRYSTALLISED IN THE ABSENCE OF AZIDE)
2JIZD:9-81; E:9-81; F:9-81; K:9-81; L:9-81; M:9-81THE STRUCTURE OF F1-ATPASE INHIBITED BY RESVERATROL.
2JJ1D:9-81; E:9-81; F:9-81; K:9-81; L:9-81; M:9-81THE STRUCTURE OF F1-ATPASE INHIBITED BY PICEATANNOL.
2JJ2D:9-81; E:9-81; F:9-81; K:9-81; L:9-81; M:9-81THE STRUCTURE OF F1-ATPASE INHIBITED BY QUERCETIN.
2W6ID:9-81; E:9-81; F:9-81LOW RESOLUTION STRUCTURES OF BOVINE MITOCHONDRIAL F1-ATPASE DURING CONTROLLED DEHYDRATION: HYDRATION STATE 4B.
2W6JD:9-81; E:9-81; F:9-81LOW RESOLUTION STRUCTURES OF BOVINE MITOCHONDRIAL F1-ATPASE DURING CONTROLLED DEHYDRATION: HYDRATION STATE 5.
2WSSD:9-81; E:9-81; F:9-81; M:9-81; N:9-81; O:9-81THE STRUCTURE OF THE MEMBRANE EXTRINSIC REGION OF BOVINE ATP SYNTHASE
2XNDD:9-81; E:9-81; F:9-81CRYSTAL STRUCTURE OF BOVINE F1-C8 SUB-COMPLEX OF ATP SYNTHASE
(-)
Cattle (Bos taurus) (4)
1BMFD:9-81; E:9-81; F:9-81BOVINE MITOCHONDRIAL F1-ATPASE
1COWD:9-81; E:9-81; F:9-81BOVINE MITOCHONDRIAL F1-ATPASE COMPLEXED WITH AUROVERTIN B
1EFRD:9-81; E:9-81; F:9-81BOVINE MITOCHONDRIAL F1-ATPASE COMPLEXED WITH THE PEPTIDE ANTIBIOTIC EFRAPEPTIN
1NBMD:9-81; E:9-81; F:9-81THE STRUCTURE OF BOVINE F1-ATPASE COVALENTLY INHIBITED WITH 4-CHLORO-7-NITROBENZOFURAZAN
(-)
Cow (Bos taurus) (1)
2V7QD:9-81; F:9-81; E:10-81THE STRUCTURE OF F1-ATPASE INHIBITED BY I1-60HIS, A MONOMERIC FORM OF THE INHIBITOR PROTEIN, IF1.
(-)
Norway rat (Rattus norvegicus) (2)
1MABB:9-81RAT LIVER F1-ATPASE
2F43B:9-81RAT LIVER F1-ATPASE
(-)
Ps3 (Bacillus sp) (1)
1SKYE:1-82CRYSTAL STRUCTURE OF THE NUCLEOTIDE FREE ALPHA3BETA3 SUB-COMPLEX OF F1-ATPASE FROM THE THERMOPHILIC BACILLUS PS3
(-)
Spinach (Spinacia oleracea) (2)
1FX0B:19-97CRYSTAL STRUCTURE OF THE CHLOROPLAST F1-ATPASE FROM SPINACH
1KMHB:19-97CRYSTAL STRUCTURE OF SPINACH CHLOROPLAST F1-ATPASE COMPLEXED WITH TENTOXIN
(-)
Ta2 (Bacillus sp) (1)
2QE7D:2-76; E:2-76; F:2-76CRYSTAL STRUCTURE OF THE F1-ATPASE FROM THE THERMOALKALIPHILIC BACTERIUM BACILLUS SP. TA2.A1
(-)
Thermotoga maritima. Organism_taxid: 2336. (1)
3DCLA:10-23,A:63-139; B:10-23,B:63-139; C:10-23,C:63-139; D:10-23,D:63-139; E:10-23,E:63-139CRYSTAL STRUCTURE OF TM1086
(-)
Yeast (Saccharomyces cerevisiae) (1)
3FKSE:8-82; N:8-82; W:8-82; M:7-82; O:7-82; V:7-82; X:7-82; D:6-82; F:5-82YEAST F1 ATPASE IN THE ABSENCE OF BOUND NUCLEOTIDES
(-)
Homologous Superfamily: Phage tail proteins (1)
(-)
Enterobacteria phage lambda. Organism_taxid: 10710. (1)
1K0HA:1-117SOLUTION STRUCTURE OF BACTERIOPHAGE LAMBDA GPFII
(-)
Homologous Superfamily: Phage tail proteins (gpFII-like) (1)
(-)
Salmonella typhimurium lt2. Organism_taxid: 99287. Strain: lt2, sgsc1412. (1)
2PP6A:23-93CRYSTAL STRUCTURE OF THE ATP-BINDING SUGAR TRANSPORTER-LIKE PROTEIN FROM SALMONELLA TYPHIMURIUM
(-)
Homologous Superfamily: predicted glycosyltransferase like domains (4)
(-)
Pseudomonas aeruginosa pao1. Organism_taxid: 208964. Strain: pao1. (1)
1YWUA:1-125SOLUTION NMR STRUCTURE OF PSEUDOMONAS AERUGINOSA PROTEIN PA4608. NORTHEAST STRUCTURAL GENOMICS TARGET PAT7
(-)
Pseudomonas putida kt2440. Organism_taxid: 160488. Strain: kt2440. (1)
2GJGA:122-247CRYSTAL STRUCTURE OF A PILZ-CONTAINING PROTEIN (PP4397) FROM PSEUDOMONAS PUTIDA KT2440 AT 2.25 A RESOLUTION
(-)
Vibrio cholerae o1. Organism_taxid: 127906. Strain: n16961. (1)
1YLNA:137-248THE CRYSTAL STRUCTURE OF THE PROTEIN OF UNKNOWN FUNCTION VCA0042 FROM VIBRIO CHOLERAE O1
(-)
Vibrio cholerae o395. Organism_taxid: 345073. Strain: o395. (1)
2RDEA:137-247; B:137-247CRYSTAL STRUCTURE OF VCA0042 COMPLEXED WITH C-DI-GMP
(-)
Homologous Superfamily: Probable tRNA pseudouridine synthase domain (3)
(-)
[unclassified] (1)
2HVYB:1-74CRYSTAL STRUCTURE OF AN H/ACA BOX RNP FROM PYROCOCCUS FURIOSUS
(-)
Pyrococcus furiosus. Organism_taxid: 2261. (1)
2EY4C:1-73; D:1-75CRYSTAL STRUCTURE OF A CBF5-NOP10-GAR1 COMPLEX
(-)
Pyrococcus furiosus. Organism_taxid: 2261. (1)
2RFKC:1-74SUBSTRATE RNA POSITIONING IN THE ARCHAEAL H/ACA RIBONUCLEOPROTEIN COMPLEX
(-)
Homologous Superfamily: STY4665 C-terminal domain-like (1)
(-)
Salmonella typhi. Organism_taxid: 601. (1)
2IPQX:418-438,X:472-528CRYSTAL STRUCTURE OF C-TERMINAL DOMAIN OF SALMONELLA ENTERICA PROTEIN STY4665, PFAM DUF1528
(-)
Homologous Superfamily: translation elongation factor selb, chain A, domain 4 (3)
(-)
Methanococcus maripaludis. Organism_taxid: 39152. Strain: jj. (3)
1WB1  [entry was replaced by entry 4AC9 without any CATH domain information]
1WB2  [entry was replaced by entry 4ACA without any CATH domain information]
1WB3  [entry was replaced by entry 4ACB without any CATH domain information]
(-)
Homologous Superfamily: Trypsin-like serine proteases (1488)
(-)
[unclassified] (24)
1GL0E:28-120,E:233-244; E:17-27,E:121-232STRUCTURE OF THE COMPLEX BETWEEN BOVINE ALPHA-CHYMOTRYPSIN AND PMP-D2V, AN INHIBITOR FROM THE INSECT LOCUSTA MIGRATORIA
1GL1A:28-120,A:233-243; B:28-120,B:233-243; C:28-120,C:233-243; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232STRUCTURE OF THE COMPLEX BETWEEN BOVINE ALPHA-CHYMOTRYPSIN AND PMP-C, AN INHIBITOR FROM THE INSECT LOCUSTA MIGRATORIA
1GVKB:28-120,B:233-245; B:16-27,B:121-232PORCINE PANCREATIC ELASTASE ACYL ENZYME AT 0.95 A RESOLUTION
1HAXB:28-120,B:233-245; B:16-27,B:121-232SNAPSHOTS OF SERINE PROTEASE CATALYSIS: (A) ACYL-ENZYME INTERMEDIATE BETWEEN PORCINE PANCREATIC ELASTASE AND HUMAN BETA-CASOMORPHIN-7 AT PH 5
1HAZB:28-120,B:233-245; B:16-27,B:121-232SNAPSHOTS OF SERINE PROTEASE CATALYSIS: (C) ACYL-ENZYME INTERMEDIATE BETWEEN PORCINE PANCREATIC ELASTASE AND HUMAN BETA-CASOMORPHIN-7 JUMPED TO PH 9 FOR 1 MINUTE
1QIXB:28-120,B:233-245; B:16-27,B:121-232PORCINE PANCREATIC ELASTASE COMPLEXED WITH HUMAN BETA-CASOMORPHIN-7
2BB4A:28-120,A:233-245; A:16-27,A:121-232PORCINE PANCREATIC ELASTASE COMPLEXED WITH BETA-CASOMORPHIN-7 AND ASP-PHE AT PH 5.0
2BD2A:28-120,A:233-245; A:16-27,A:121-232PORCINE PANCREATIC ELASTASE COMPLEXED WITH BETA-CASOMORPHIN-7 AND ARG-PHE AT PH 5.0
2BD3A:28-120,A:233-245; A:16-27,A:121-232PORCINE PANCREATIC ELASTASE COMPLEXED WITH BETA-CASOMORPHIN-7 AND LYS-ALA-NH2 AT PH 5.0
2BD4A:28-120,A:233-245; A:16-27,A:121-232PORCINE PANCREATIC ELASTASE COMPLEXED WITH BETA-CASOMORPHIN-7 AND LYS-SER AT PH 5.0
2BD5A:28-120,A:233-245; A:16-27,A:121-232PORCINE PANCREATIC ELASTASE COMPLEXED WITH BETA-CASOMORPHIN-7 AND LYS-SER AT PH 5 AND IMMERSED IN PH 9 BUFFER FOR 30 SECONDS
2BD7A:28-120,A:233-245; A:16-27,A:121-232PORCINE PANCREATIC ELASTASE COMPLEXED WITH BETA-CASOMORPHIN-7 AND ARG-PHE AT PH 5.0 (50 MIN SOAK)
2BD8A:28-120,A:233-245; A:16-27,A:121-232PORCINE PANCREATIC ELASTASE COMPLEXED WITH BETA-CASOMORPHIN-7 AND ARG-PHE AT PH 5.0 (50 MIN SOAK) AND IMMERSED IN PH 9 BUFFER FOR 30 SECONDS
2BDAA:28-120,A:233-245; A:16-27,A:121-232PORCINE PANCREATIC ELASTASE COMPLEXED WITH N-ACETYL-NPI AND ALA-ALA AT PH 5.0
2C4FH:16-27,H:121-232; H:28-120,H:233-246CRYSTAL STRUCTURE OF FACTOR VII.STF COMPLEXED WITH PD0297121
2H1UA:28-120,A:233-245; A:16-27,A:121-232PORCINE PANCREATIC ELASTASE COMPLEXED WITH METPHELEUGLU AT PH 5.0
2R0LA:16-27,A:121-230; A:28-120,A:231-243SHORT FORM HGFA WITH INHIBITORY FAB75
2TPIZ:19-27,Z:121-232; Z:28-120,Z:233-245ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
3BV9B:28-120,B:233-247; B:16-27,B:121-232STRUCTURE OF THROMBIN BOUND TO THE INHIBITOR FM19
(-)
2_ (2)
1ACBE:28-120,E:233-243; E:16-27,E:121-232CRYSTAL AND MOLECULAR STRUCTURE OF THE BOVINE ALPHA-CHYMOTRYPSIN-EGLIN C COMPLEX AT 2.0 ANGSTROMS RESOLUTION
1PPGE:16-27,E:121-232; E:28-120,E:233-243THE REFINED 2.3 ANGSTROMS CRYSTAL STRUCTURE OF HUMAN LEUKOCYTE ELASTASE IN A COMPLEX WITH A VALINE CHLOROMETHYL KETONE INHIBITOR
(-)
Achromobacter lyticus. Organism_taxid: 224 (2)
1ARBA:1-24,A:134-231; A:25-131,A:233-262THE PRIMARY STRUCTURE AND STRUCTURAL CHARACTERISTICS OF ACHROMOBACTER LYTICUS PROTEASE I, A LYSINE-SPECIFIC SERINE PROTEASE
1ARCA:1-24,A:134-231; A:25-131,A:233-262THE PRIMARY STRUCTURE AND STRUCTURAL CHARACTERISTICS OF ACHROMOBACTER LYTICUS PROTEASE I, A LYSINE-SPECIFIC SERINE PROTEASE
(-)
Arrowhead (Sagittaria sagittifolia) (1)
3E8LA:16-27,A:118-225; B:16-27,B:118-225; A:28-117,A:226-237; B:28-117,B:226-237THE CRYSTAL STRUCTURE OF THE DOUBLE-HEADED ARROWHEAD PROTEASE INHIBITOR A IN COMPLEX WITH TWO TRYPSINS
(-)
Atlantic cod (Gadus morhua) (1)
2EEKA:16-27,A:121-232; A:28-120,A:233-243CRYSTAL STRUCTURE OF ATLANTIC COD TRYPSIN COMPLEXED WITH BENZAMIDINE
(-)
Atlantic salmon (Salmo salar) (12)
1A0JA:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; A:28-120,A:233-245; B:28-120,B:233-245; C:28-120,C:233-245; D:28-120,D:233-245CRYSTAL STRUCTURE OF A NON-PSYCHROPHILIC TRYPSIN FROM A COLD-ADAPTED FISH SPECIES.
1BITA:16-27,A:121-232; A:28-120,A:233-245THE CRYSTAL STRUCTURE OF ANIONIC SALMON TRYPSIN IN A SECOND CRYSTAL FORM
1BZXE:16-27,E:121-232; E:28-120,E:233-245THE CRYSTAL STRUCTURE OF ANIONIC SALMON TRYPSIN IN COMPLEX WITH BOVINE PANCREATIC TRYPSIN INHIBITOR
1ELTA:28-120,A:233-242; A:16-27,A:121-232STRUCTURE OF NATIVE PANCREATIC ELASTASE FROM NORTH ATLANTIC SALMON AT 1.61 ANGSTROMS RESOLUTION
1HJ8A:16-27,A:121-232; A:28-120,A:233-2451.00 AA TRYPSIN FROM ATLANTIC SALMON
1UTJA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS, X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
1UTKA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS, X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
1UTLM:16-27,M:121-232; M:28-120,M:233-245TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS, X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
1UTMA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS, X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
2STAE:16-27,E:121-232; E:28-120,E:233-245ANIONIC SALMON TRYPSIN IN COMPLEX WITH SQUASH SEED INHIBITOR (CUCURBITA MAXIMA TRYPSIN INHIBITOR I)
2STBE:16-27,E:121-232; E:28-120,E:233-245ANIONIC SALMON TRYPSIN IN COMPLEX WITH SQUASH SEED INHIBITOR (CUCURBITA PEPO TRYPSIN INHIBITOR II)
2TBSA:16-27,A:121-232; A:28-120,A:233-245COLD-ADAPTION OF ENZYMES: STRUCTURAL COMPARISON BETWEEN SALMON AND BOVINE TRYPSINS
(-)
Atlantic sand fiddler crab (Celuca pugilator) (1)
1AZZA:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-246; B:28-120,B:233-246FIDDLER CRAB COLLAGENASE COMPLEXED TO ECOTIN
(-)
Aureus mu50 (Staphylococcus aureus subsp) (1)
1QY6A:1-14,A:116-216; A:15-115STRUCTUE OF V8 PROTEASE FROM STAPHYLOCOCCUS AUREUS
(-)
Bacillus intermedius. Organism_taxid: 1400. Strain: 3-19 (2)
1P3CA:18-114,A:203-215; A:1-17,A:115-202GLUTAMYL ENDOPEPTIDASE FROM BACILLUS INTERMEDIUS
1P3EA:18-115,A:203-215; A:1-17,A:116-202STRUCTURE OF GLU ENDOPEPTIDASE IN COMPLEX WITH MPD
(-)
Black rat (Rattus rattus) (11)
1AMHA:16-27,A:121-232; A:28-120,A:233-245; B:28-120,B:233-245; B:16-27,B:121-232UNCOMPLEXED RAT TRYPSIN MUTANT WITH ASP 189 REPLACED WITH SER (D189S)
1ANBA:16-27,A:121-232; A:28-120,A:233-245ANIONIC TRYPSIN MUTANT WITH SER 214 REPLACED BY GLU
1ANCA:16-27,A:121-232; A:28-120,A:233-245ANIONIC TRYPSIN MUTANT WITH SER 214 REPLACED BY LYS
1ANDA:16-27,A:121-232; A:28-120,A:233-245ANIONIC TRYPSIN MUTANT WITH ARG 96 REPLACED BY HIS
1ANEA:16-27,A:121-232; A:28-120,A:233-245ANIONIC TRYPSIN WILD TYPE
1BRAA:16-27,A:121-232; A:28-120,A:233-245RELOCATING A NEGATIVE CHARGE IN THE BINDING POCKET OF TRYPSIN
1DPOA:16-27,A:121-232; A:28-120,A:233-242STRUCTURE OF RAT TRYPSIN
1FY8E:14-27,E:121-232; E:28-120,E:233-245CRYSTAL STRUCTURE OF THE DELTAILE16VAL17 RAT ANIONIC TRYPSINOGEN-BPTI COMPLEX
1TONA:28-120,A:233-245; A:16-27,A:121-232RAT SUBMAXILLARY GLAND SERINE PROTEASE, TONIN. STRUCTURE SOLUTION AND REFINEMENT AT 1.8 ANGSTROMS RESOLUTION
1TRMA:16-27,A:121-232; A:28-120,A:233-245; B:28-120,B:233-245; B:16-27,B:121-232THE THREE-DIMENSIONAL STRUCTURE OF ASN102 MUTANT OF TRYPSIN. ROLE OF ASP102 IN SERINE PROTEASE CATALYSIS
3RP2A:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-241; B:28-120,B:233-241THE STRUCTURE OF RAT MAST CELL PROTEASE II AT 1.9-ANGSTROMS RESOLUTION
(-)
Bos taurus (Bos taurus) (2)
1GHBG:151-245; F:16-146A SECOND ACTIVE SITE IN CHYMOTRYPSIN? THE X-RAY CRYSTAL STRUCTURE OF N-ACETYL-D-TRYPTOPHAN BOUND TO GAMMA-CHYMOTRYPSIN
3GCHC:151-245; B:16-146CHEMISTRY OF CAGED ENZYMES. BINDING OF PHOTOREVERSIBLE CINNAMATES TO CHYMOTRYPSIN
(-)
Bos taurus. Bovine (1)
1BTYA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF BETA-TRYPSIN IN COMPLEX WITH BENZAMIDINE
(-)
Bos taurus. Organism_taxid: 9913 (6)
2BY5X:16-27,X:121-232; X:28-120,X:233-244IS RADIATION DAMAGE DEPENDENT ON THE DOSE-RATE USED DURING MACROMOLECULAR CRYSTALLOGRAPHY DATA COLLECTION
2BY6X:16-27,X:121-232; X:28-120,X:233-244IS RADIATION DAMAGE DEPENDENT ON THE DOSE-RATE USED DURING MACROMOLECULAR CRYSTALLOGRAPHY DATA COLLECTION
2BY7X:16-27,X:121-232; X:28-120,X:233-244IS RADIATION DAMAGE DEPENDENT ON THE DOSE-RATE USED DURING MACROMOLECULAR CRYSTALLOGRAPHY DATA COLLECTION
2BY8X:16-27,X:121-232; X:28-120,X:233-244IS RADIATION DAMAGE DEPENDENT ON THE DOSE-RATE USED DURING MACROMOLECULAR CRYSTALLOGRAPHY DATA COLLECTION
2BY9X:16-27,X:121-232; X:28-120,X:233-244IS RADIATION DAMAGE DEPENDENT ON THE DOSE-RATE USED DURING MACROMOLECULAR CRYSTALLOGRAPHY DATA COLLECTION
2BYAX:16-27,X:121-232; X:28-120,X:233-244IS RADIATION DAMAGE DEPENDENT ON THE DOSE-RATE USED DURING MACROMOLECULAR CRYSTALLOGRAPHY DATA COLLECTION
(-)
Bos taurus. Organism_taxid: 9913. (1)
1BTXA:16-27,A:121-232; A:28-120,A:233-245EPISELECTION: NOVEL KI ~NANOMOLAR INHIBITORS OF SERINE PROTEASES SELECTED BY BINDING OR CHEMISTRY ON AN ENZYME SURFACE
(-)
Bos taurus. Organism_taxid: 9913. Bos taurus. Organism_taxid: 9913. (2)
1GCTC:151-245; B:16-146IS GAMMA-CHYMOTRYPSIN A TETRAPEPTIDE ACYL-ENZYME ADDUCT OF GAMMA-CHYMOTRYPSIN?
2GCTC:151-245; B:16-146STRUCTURE OF GAMMA-CHYMOTRYPSIN IN THE RANGE PH 2.0 TO PH 10.5 SUGGESTS THAT GAMMA-CHYMOTRYPSIN IS A COVALENT ACYL-ENZYME ADDUCT AT LOW PH
(-)
Bovine (Bos taurus) (36)
1EB2A:16-27,A:121-232; A:28-120,A:233-245TRYPSIN INHIBITOR COMPLEX (BPO)
1HJ9A:16-27,A:121-232; A:28-120,A:233-245ATOMIC RESOLUTION STRUCTURES OF TRYPSIN PROVIDE INSIGHT INTO STRUCTURAL RADIATION DAMAGE
1OXGA:28-120,A:233-243; A:16-27,A:121-232CRYSTAL STRUCTURE OF A COMPLEX FORMED BETWEEN ORGANIC SOLVENT TREATED BOVINE ALPHA-CHYMOTRYPSIN AND ITS AUTOCATALYTICALLY PRODUCED HIGHLY POTENT 14-RESIDUE PEPTIDE AT 2.2 RESOLUTION
1QL7A:16-27,A:121-232; A:28-120,A:233-245FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1QL8A:16-27,A:121-232; A:28-120,A:233-245FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1SMFE:16-27,E:121-232; E:28-120,E:233-245STUDIES ON AN ARTIFICIAL TRYPSIN INHIBITOR PEPTIDE DERIVED FROM THE MUNG BEAN INHIBITOR
1TGTA:16-27,A:121-232; A:28-120,A:233-245ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
1UTNA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS, X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
1UTOA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS, X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
1UTPA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS, X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
1UTQA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS, X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
1Y59T:16-27,T:121-232; T:28-120,T:233-244DIANHYDROSUGAR-BASED BENZAMIDINE, FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN MUTANT
1Y5AT:16-27,T:121-232; T:28-120,T:233-244DIANHYDROSUGAR-BASED BENZAMIDINE, FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN MUTANT
1Y5BT:16-27,T:121-232; T:28-120,T:233-244DIANHYDROSUGAR-BASED BENZAMIDINE, FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN MUTANT
1Y5UT:16-27,T:121-232; T:28-120,T:233-244DIANHYDROSUGAR-BASED BENZAMIDINE, FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN MUTANT
2BLVA:16-27,A:121-232; A:28-120,A:233-244TRYPSIN BEFORE A HIGH DOSE X-RAY "BURN"
2BLWA:16-27,A:121-232; A:28-120,A:233-244TRYPSIN AFTER A HIGH DOSE X-RAY "BURN"
2CMYA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL COMPLEX BETWEEN BOVINE TRYPSIN AND VERONICA HEDERIFOLIA TRYPSIN INHIBITOR
2J9NA:16-27,A:118-225; A:28-117,A:226-237ROBOTICALLY HARVESTED TRYPSIN COMPLEXED WITH BENZAMIDINE CONTAINING POLYPEPTIDE MEDIATED CRYSTAL CONTACTS
2QYIA:16-27,A:121-232; C:316-327,C:421-532; A:28-120,A:233-244; C:328-420,C:533-544CRYSTAL STRUCTURE OF A BINARY COMPLEX BETWEEN AN ENGINEERED TRYPSIN INHIBITOR AND BOVINE TRYPSIN
2TGTA:16-27,A:121-232; A:28-120,A:233-245ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
2UUYA:21-32,A:123-230; A:33-122,A:231-242STRUCTURE OF A TICK TRYPTASE INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
2ZDKA:16-27,A:121-232; A:28-120,A:233-244EXPLORING TRYPSIN S3 POCKET
2ZDLA:16-27,A:121-232; A:28-120,A:233-244EXPLORING TRYPSIN S3 POCKET
2ZDMA:16-27,A:121-232; A:28-120,A:233-244EXPLORING TRYPSIN S3 POCKET
2ZDNA:16-27,A:121-232; A:28-120,A:233-244EXPLORING TRYPSIN S3 POCKET
2ZFSA:16-27,A:121-232; A:28-120,A:233-244EXPLORING TRYPSIN S3 POCKET
2ZFTA:16-27,A:121-232; A:28-120,A:233-244EXPLORING TRYPSIN S3 POCKET
2ZHDA:16-27,A:121-232; A:28-120,A:233-244EXPLORING TRYPSIN S3 POCKET
2ZQ1A:16-27,A:121-232; A:28-120,A:233-244EXPLORING TRYPSIN S3 POCKET
2ZQ2A:16-27,A:121-232; A:28-120,A:233-244EXPLORING TRYPSIN S3 POCKET
3AASA:1-12,A:103-210; A:13-102,A:211-222BOVINE BETA-TRYPSIN BOUND TO META-GUANIDINO SCHIFF BASE COPPER (II) CHELATE
3AAUA:1-12,A:103-210; A:13-102,A:211-222BOVINE BETA-TRYPSIN BOUND TO META-DIGUANIDINO SCHIFF BASE COPPER (II) CHELATE
3AAVA:1-12,A:103-210; B:1-12,B:103-210; A:13-102,A:211-222; B:13-102,B:211-222BOVINE BETA-TRYPSIN BOUND TO META-DIAMIDINO SCHIFF BASE COPPER (II) CHELATE
3BG4C:149-245; B:16-146THE CRYSTAL STRUCTURE OF GUAMERIN IN COMPLEX WITH CHYMOTRYPSIN AND THE DEVELOPMENT OF AN ELASTASE-SPECIFIC INHIBITOR
3I29A:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF A BINARY COMPLEX BETWEEN AN MUTANT TRYPSIN INHIBITOR WITH BOVINE TRYPSIN
(-)
Bovine,cow (Bos taurus) (7)
3GY2A:16-27,A:121-232; A:28-120,A:233-244A COMPARATIVE STUDY ON THE INHIBITION OF BOVINE BETA-TRYPSIN BY BIS-BENZAMIDINES DIMINAZENE AND PENTAMIDINE BY X-RAY CRYSTALLOGRAPHY AND ITC
3GY3A:16-27,A:121-232; A:28-120,A:233-244A COMPARATIVE STUDY ON THE INHIBITION OF BOVINE BETA-TRYPSIN BY BIS-BENZAMIDINES DIMINAZENE AND PENTAMIDINE BY X-RAY CRYSTALLOGRAPHY AND ITC
3GY4A:16-27,A:121-232; A:28-120,A:233-244A COMPARATIVE STUDY ON THE INHIBITION OF BOVINE BETA-TRYPSIN BY BIS-BENZAMIDINES DIMINAZENE AND PENTAMIDINE BY X-RAY CRYSTALLOGRAPHY AND ITC
3GY5A:16-27,A:121-232; A:28-120,A:233-244A COMPARATIVE STUDY ON THE INHIBITION OF BOVINE BETA-TRYPSIN BY BIS-BENZAMIDINES DIMINAZENE AND PENTAMIDINE BY X-RAY CRYSTALLOGRAPHY AND ITC
3GY6A:16-27,A:121-232; A:28-120,A:233-244A COMPARATIVE STUDY ON THE INHIBITION OF BOVINE BETA-TRYPSIN BY THE BIS-BENZAMIDINES DIMINAZENE AND PENTAMIDINE
3GY7A:16-27,A:121-232; A:28-120,A:233-244A COMPARATIVE STUDY ON THE INHIBITION OF BOVINE BETA-TRYPSIN BY BIS-BENZAMIDINES DIMINAZENE AND PENTAMIDINE BY X-RAY CRYSTALLOGRAPHY AND ITC
3GY8A:16-27,A:121-232; A:28-120,A:233-244A COMPARATIVE STUDY ON THE INHIBITION OF BOVINE BETA-TRYPSIN BY BIS-BENZAMIDINES DIMINAZENE AND PENTAMIDINE BY X-RAY CRYSTALLOGRAPHY AND ITC
(-)
Bovine,cow,domestic cattle,domestic cow (Bos taurus) (1)
3ITIA:1-12,A:103-210; A:13-102,A:211-222STRUCTURE OF BOVINE TRYPSIN WITH THE MAD TRIANGLE B3C
(-)
Brown rat,rat,rats (Rattus norvegicus) (3)
3FP6E:16-27,E:121-232; E:28-120,E:233-245ANIONIC TRYPSIN IN COMPLEX WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI) DETERMINED TO THE 1.49 A RESOLUTION LIMIT
3FP7E:16-27,E:121-232; E:28-120,E:233-245ANIONIC TRYPSIN VARIANT S195A IN COMPLEX WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI) CLEAVED AT THE SCISSILE BOND (LYS15-ALA16) DETERMINED TO THE 1.46 A RESOLUTION LIMIT
3FP8E:16-27,E:121-232; E:28-120,E:233-245ANIONIC TRYPSIN VARIANT S195A IN COMPLEX WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI) DETERMINED TO THE 1.46 A RESOLUTION LIMIT
(-)
Cattle (Bos taurus) (308)
1A0HB:333-437,B:565-579; E:333-437,E:565-579; B:321-332,B:438-564; E:321-332,E:438-564THE X-RAY CRYSTAL STRUCTURE OF PPACK-MEIZOTHROMBIN DESF1: KRINGLE/THROMBIN AND CARBOHYDRATE/KRINGLE/THROMBIN INTERACTIONS AND LOCATION OF THE LINKER CHAIN
1AB9C:150-245; B:16-146CRYSTAL STRUCTURE OF BOVINE GAMMA-CHYMOTRYPSIN
1AFQC:150-245; B:16-146CRYSTAL STRUCTURE OF BOVINE GAMMA-CHYMOTRYPSIN COMPLEXED WITH A SYNTHETIC INHIBITOR
1AQ7A:16-27,A:121-232; A:28-120,A:233-244TRYPSIN WITH INHIBITOR AERUGINOSIN 98-B
1AUJA:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN COMPLEXED TO META-CYANO-BENZYLIC INHIBITOR
1AVGH:28-120,H:233-247; H:16-27,H:121-232THROMBIN INHIBITOR FROM TRIATOMA PALLIDIPENNIS
1AZ8A:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN COMPLEXED TO BIS-PHENYLAMIDINE INHIBITOR
1BBRK:28-120,K:233-247; N:28-120,N:233-247; K:16-27,K:121-232; N:16-27,N:121-232; E:149B-247; H:16-149ATHE STRUCTURE OF RESIDUES 7-16 OF THE A ALPHA CHAIN OF HUMAN FIBRINOGEN BOUND TO BOVINE THROMBIN AT 2.3 ANGSTROMS RESOLUTION
1BJUA:16-27,A:121-232; A:28-120,A:233-245BETA-TRYPSIN COMPLEXED WITH ACPU
1BJVA:16-27,A:121-232; A:28-120,A:233-245BETA-TRYPSIN COMPLEXED WITH APPU
1BTHH:28-120,H:233-242; K:28-120,K:233-242; H:16-27,H:121-232; K:16-27,K:121-232STRUCTURE OF THROMBIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR
1BTPA:16-27,A:121-232; A:28-120,A:233-245UNIQUE BINDING OF A NOVEL SYNTHETIC INHIBITOR, N-[3-[4-[4-(AMIDINOPHENOXY)-CARBONYL]PHENYL]-2-METHYL-2-PROPENOYL]-N-ALLYLGLYCINE METHANESULFONATE TO BOVINE TRYPSIN, REVEALED BY THE CRYSTAL STRUCTURE OF THE COMPLEX
1BTWA:16-27,A:121-232; A:28-120,A:233-245EPISELECTION: NOVEL KI ~NANOMOLAR INHIBITORS OF SERINE PROTEASES SELECTED BY BINDING OR CHEMISTRY ON AN ENZYME SURFACE
1BTZA:16-27,A:121-232; A:28-120,A:233-245EPISELECTION: NOVEL KI ~NANOMOLAR INHIBITORS OF SERINE PROTEASES SELECTED BY BINDING OR CHEMISTRY ON AN ENZYME SURFACE
1C1NA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1OA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1PA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1QA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1RA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1SA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1TA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2DA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2EA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2FA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2GA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2HA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2IA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2JA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2KA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2LA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C2MA:16-27,A:121-232; A:28-120,A:233-245RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C5PA:16-27,A:121-232; A:28-120,A:233-245STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5QA:16-27,A:121-232; A:28-120,A:233-245STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5RA:16-27,A:121-232; A:28-120,A:233-245STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5SA:16-27,A:121-232; A:28-120,A:233-245STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5TA:16-27,A:121-232; A:28-120,A:233-245STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5UA:16-27,A:121-232; A:28-120,A:233-245STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5VA:16-27,A:121-232; A:28-120,A:233-245STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C9TA:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; E:16-27,E:121-232; F:16-27,F:121-232; A:28-120,A:233-245; B:28-120,B:233-245; C:28-120,C:233-245; D:28-120,D:233-245; E:28-120,E:233-245; F:28-120,F:233-245COMPLEX OF BDELLASTASIN WITH BOVINE TRYPSIN
1CA0C:149-245; H:149-245; B:16-146; G:16-146BOVINE CHYMOTRYPSIN COMPLEXED TO APPI
1CBWC:149-245; H:149-245; B:16-146; G:16-146BOVINE CHYMOTRYPSIN COMPLEXED TO BPTI
1CE5A:16-27,A:121-232; A:28-120,A:233-245BOVINE PANCREAS BETA-TRYPSIN IN COMPLEX WITH BENZAMIDINE
1CGIE:28-120,E:233-245; E:16-27,E:121-232THREE-DIMENSIONAL STRUCTURE OF THE COMPLEXES BETWEEN BOVINE CHYMOTRYPSINOGEN*A AND TWO RECOMBINANT VARIANTS OF HUMAN PANCREATIC SECRETORY TRYPSIN INHIBITOR (KAZAL-TYPE)
1CGJE:28-120,E:233-245; E:16-27,E:121-232THREE-DIMENSIONAL STRUCTURE OF THE COMPLEXES BETWEEN BOVINE CHYMOTRYPSINOGEN*A AND TWO RECOMBINANT VARIANTS OF HUMAN PANCREATIC SECRETORY TRYPSIN INHIBITOR (KAZAL-TYPE)
1CHGA:28-120,A:233-242; A:16-27,A:121-232CHYMOTRYPSINOGEN,2.5 ANGSTROMS CRYSTAL STRUCTURE, COMPARISON WITH ALPHA-CHYMOTRYPSIN,AND IMPLICATIONS FOR ZYMOGEN ACTIVATION
1CHOG:149-245; F:16-146CRYSTAL AND MOLECULAR STRUCTURES OF THE COMPLEX OF ALPHA-*CHYMOTRYPSIN WITH ITS INHIBITOR TURKEY OVOMUCOID THIRD DOMAIN AT 1.8 ANGSTROMS RESOLUTION
1D6RA:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF CANCER CHEMOPREVENTIVE BOWMAN-BIRK INHIBITOR IN TERNARY COMPLEX WITH BOVINE TRYPSIN AT 2.3 A RESOLUTION. STRUCTURAL BASIS OF JANUS-FACED SERINE PROTEASE INHIBITOR SPECIFICITY
1DLKB:28-120,B:233-243; D:28-120,D:233-243; B:16-27,B:121-232; D:16-27,D:121-232CRYSTAL STRUCTURE ANALYSIS OF DELTA-CHYMOTRYPSIN BOUND TO A PEPTIDYL CHLOROMETHYL KETONE INHIBITOR
1EJMA:16-27,A:121-232; C:16-27,C:121-232; E:16-27,E:121-232; A:28-120,A:233-245; C:28-120,C:233-245; E:28-120,E:233-245CRYSTAL STRUCTURE OF THE BPTI ALA16LEU MUTANT IN COMPLEX WITH BOVINE TRYPSIN
1EKBB:16-27,B:121-232; B:28-120,B:233-243THE SERINE PROTEASE DOMAIN OF ENTEROPEPTIDASE BOUND TO INHIBITOR VAL-ASP-ASP-ASP-ASP-LYS-CHLOROMETHANE
1EUFA:16-27,A:121-232; A:28-120,A:233-243BOVINE DUODENASE(NEW SERINE PROTEASE), CRYSTAL STRUCTURE
1EX3A:28-120,A:233-243; A:16-27,A:121-232CRYSTAL STRUCTURE OF BOVINE CHYMOTRYPSINOGEN A (TETRAGONAL)
1F0TA:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN COMPLEXED WITH RPR131247
1F0UA:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN COMPLEXED WITH RPR128515
1F2SE:16-27,E:121-232; E:28-120,E:233-245CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN BOVINE BETA-TRYPSIN AND MCTI-A, A TRYPSIN INHIBITOR OF SQUASH FAMILY AT 1.8 A RESOLUTION
1FONA:11-111,A:228-240; B:11-111,B:228-240; A:9-10,A:112-227; B:9-10,B:112-227CRYSTAL STRUCTURE OF BOVINE PROCARBOXYPEPTIDASE A-S6 SUBUNIT III, A HIGHLY STRUCTURED TRUNCATED ZYMOGEN E
1G36A:16-27,A:121-232; A:28-120,A:233-245TRYPSIN INHIBITOR COMPLEX
1G3BA:16-27,A:121-232; A:28-120,A:233-245BOVINE BETA-TRYPSIN BOUND TO META-AMIDINO SCHIFF BASE MAGNESIUM(II) CHELATE
1G3CA:16-27,A:121-232; A:28-120,A:233-245BOVINE BETA-TRYPSIN BOUND TO PARA-AMIDINO SCHIFF BASE IRON(III) CHELATE
1G3DA:16-27,A:121-232; A:28-120,A:233-245BOVINE BETA-TRYPSIN BOUND TO META-AMIDINO SCHIFF BASE COPPER (II) CHELATE
1G3EA:16-27,A:121-232; A:28-120,A:233-245BOVINE BETA-TRYPSIN BOUND TO PARA-AMIDINO SCHIFF-BASE COPPER (II) CHELATE
1G9IE:16-27,E:121-232; E:28-120,E:233-245CRYSTAL STRUCTURE OF BETA-TRYSIN COMPLEX IN CYCLOHEXANE
1GBTA:16-27,A:121-232; A:28-120,A:233-245STRUCTURE OF AN ACYL-ENZYME INTERMEDIATE DURING CATALYSIS: (GUANIDINOBENZOYL) TRYPSIN
1GCDA:28-120,A:233-243; A:16-27,A:121-232REFINED CRYSTAL STRUCTURE OF "AGED" AND "NON-AGED" ORGANOPHOSPHORYL CONJUGATES OF GAMMA-CHYMOTRYPSIN
1GG6C:149-245; B:16-146CRYSTAL STRUCTURE OF GAMMA CHYMOTRYPSIN WITH N-ACETYL-PHENYLALANINE TRIFLUOROMETHYL KETONE BOUND AT THE ACTIVE SITE
1GGDC:151-245; B:16-146CRYSTAL STRUCTURE OF GAMMA CHYMOTRYPSIN WITH N-ACETYL-LEUCIL-PHENYLALANINE ALDEHYDE BOUND AT THE ACTIVE SITE
1GHAG:151-245; F:16-146A SECOND ACTIVE SITE IN CHYMOTRYPSIN? THE X-RAY CRYSTAL STRUCTURE OF N-ACETYL-D-TRYPTOPHAN BOUND TO GAMMA-CHYMOTRYPSIN
1GHZA:16-27,A:121-232; A:28-120,A:233-245A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI0A:16-27,A:121-232; A:28-120,A:233-245A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI1A:16-27,A:121-232; A:28-120,A:233-245A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI2A:16-27,A:121-232; A:28-120,A:233-245A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI3A:16-27,A:121-232; A:28-120,A:233-245A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI4A:16-27,A:121-232; A:28-120,A:233-245A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI5A:16-27,A:121-232; A:28-120,A:233-245A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI6A:16-27,A:121-232; A:28-120,A:233-245A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GJ6A:16-27,A:121-232; A:28-120,A:233-245ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1GMCG:151-245; F:16-146THE X-RAY CRYSTAL STRUCTURE OF THE TETRAHEDRAL INTERMEDIATE OF GAMMA-CHYMOTRYPSIN IN HEXANE
1GMDG:151-245; F:16-146X-RAY CRYSTAL STRUCTURE OF GAMMA-CHYMOTRYPSIN IN HEXANE
1GMHG:150-245; F:16-146REFINED CRYSTAL STRUCTURE OF "AGED" AND "NON-AGED" ORGANOPHOSPHORYL CONJUGATES OF GAMMA-CHYMOTRYPSIN
1HJAC:149-245; B:16-146LYS 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH ALPHA-CHYMOTRYPSIN
1HRTH:28-120,H:233-247; H:16-27,H:121-232THE STRUCTURE OF A COMPLEX OF BOVINE ALPHA-THROMBIN AND RECOMBINANT HIRUDIN AT 2.8 ANGSTROMS RESOLUTION
1ID5H:28-120,H:233-244; H:16-27,H:121-232CRYSTAL STRUCTURE OF BOVINE THROMBIN COMPLEX WITH PROTEASE INHIBITOR ECOTIN
1J8AA:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF BENZAMIDINE INHIBITED BOVINE PANCREATIC TRYPSIN AT 105K TO 1.21A RESOLUTION FROM LABORATORY SOURCE WITH HIGH NUMBER OF WATERS MODELLED
1JIRA:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF TRYPSIN COMPLEX WITH AMYLAMINE IN CYCLOHEXANE
1JRSA:16-27,A:121-232; A:28-120,A:233-245HEMIACETAL COMPLEX BETWEEN LEUPEPTIN AND TRYPSIN
1JRTA:16-27,A:121-232; A:28-120,A:233-245HEMIACETAL COMPLEX BETWEEN LEUPEPTIN AND TRYPSIN
1K1IA:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN-INHIBITOR COMPLEX
1K1JA:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN-INHIBITOR COMPLEX
1K1LA:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN-INHIBITOR COMPLEX
1K1MA:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN-INHIBITOR COMPLEX
1K1NA:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN-INHIBITOR COMPLEX
1K1OA:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN-INHIBITOR COMPLEX
1K1PA:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN-INHIBITOR COMPLEX
1K2I1:28-120,1:233-243; 1:18-27,1:121-232CRYSTAL STRUCTURE OF GAMMA-CHYMOTRYPSIN IN COMPLEX WITH 7-HYDROXYCOUMARIN
1KIGH:16-27,H:121-232; H:28-120,H:233-246BOVINE FACTOR XA
1LQEA:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF TRYPSIN IN COMPLEX WITH 79.
1MAXA:16-27,A:121-232; A:28-120,A:233-245BETA-TRYPSIN PHOSPHONATE INHIBITED
1MAYA:16-27,A:121-232; A:28-120,A:233-245BETA-TRYPSIN PHOSPHONATE INHIBITED
1MKWH:28-120,H:233-243; K:28-120,K:233-243; H:16-27,H:121-232; K:16-27,K:121-232THE CO-CRYSTAL STRUCTURE OF UNLIGANDED BOVINE ALPHA-THROMBIN AND PRETHROMBIN-2: MOVEMENT OF THE YPPW SEGMENT AND ACTIVE SITE RESIDUES UPON LIGAND BINDING
1MKXH:28-120,H:233-243; K:28-120,K:233-243; H:16-27,H:121-232; K:16-27,K:121-232THE CO-CRYSTAL STRUCTURE OF UNLIGANDED BOVINE ALPHA-THROMBIN AND PRETHROMBIN-2: MOVEMENT OF THE YPPW SEGMENT AND ACTIVE SITE RESIDUES UPON LIGAND BINDING
1MTNC:149-245; G:149-245; B:16-146; F:16-146BOVINE ALPHA-CHYMOTRYPSIN:BPTI CRYSTALLIZATION
1MTSA:16-27,A:121-232; A:28-120,A:233-245FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1MTUA:16-27,A:121-232; A:28-120,A:233-245FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1MTVA:16-27,A:121-232; A:28-120,A:233-245FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1MTWA:16-27,A:121-232; A:28-120,A:233-245FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1N6XA:16-27,A:121-232; A:28-120,A:233-245RIP-PHASING ON BOVINE TRYPSIN
1N6YA:16-27,A:121-232; A:28-120,A:233-245RIP-PHASING ON BOVINE TRYPSIN
1N8OC:149-245; B:16-146CRYSTAL STRUCTURE OF A COMPLEX BETWEEN BOVINE CHYMOTRYPSIN AND ECOTIN
1NC6A:16-27,A:121-232; A:28-120,A:233-245POTENT, SMALL MOLECULE INHIBITORS OF HUMAN MAST CELL TRYPTASE. ANTI-ASTHMATIC ACTION OF A DIPEPTIDE-BASED TRANSITION STATE ANALOGUE CONTAINING BENZOTHIAZOLE KETONE
1NTPA:16-27,A:121-232; A:28-120,A:233-245USE OF THE NEUTRON DIFFRACTION H/D EXCHANGE TECHNIQUE TO DETERMINE THE CONFORMATIONAL DYNAMICS OF TRYPSIN
1O2HA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2IA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2JA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2KA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2LA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2MA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2NA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2OA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2PA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2QA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2RA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2SA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2TA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2UA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2VA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2WA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2XA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2YA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2ZA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O30A:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O31A:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O32A:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O33A:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O34A:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O35A:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O36A:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O37A:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O38A:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O39A:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3AA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3BA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3CA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3DA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3EA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3FA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3GA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3HA:16-27,A:121-232; A:28-120,A:233-244ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3IA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3JA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3KA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3LA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3MA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3NA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3OA:16-27,A:121-232; A:28-120,A:233-245ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1OX1A:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF THE BOVINE TRYPSIN COMPLEX WITH A SYNTHETIC 11 PEPTIDE INHIBITOR
1OYQA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN INHIBITOR COMPLEX
1P2IA:16-27,A:121-232; A:28-120,A:233-245STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1P2JA:16-27,A:121-232; A:28-120,A:233-242STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1P2KA:16-27,A:121-232; A:28-120,A:233-245STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1P2MA:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1P2NA:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1P2OA:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1P2QA:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1PPEE:16-27,E:121-232; E:28-120,E:233-245THE REFINED 2.0 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN BOVINE BETA-TRYPSIN AND CMTI-I, A TRYPSIN INHIBITOR FROM SQUASH SEEDS (CUCURBITA MAXIMA): TOPOLOGICAL SIMILARITY OF THE SQUASH SEED INHIBITORS WITH THE CARBOXYPEPTIDASE A INHIBITOR FROM POTATOES
1PYTC:428-520,C:633-645; D:728-820,D:933-944; C:416-427,C:521-632; D:716-727,D:821-932TERNARY COMPLEX OF PROCARBOXYPEPTIDASE A, PROPROTEINASE E, AND CHYMOTRYPSINOGEN C
1QA0A:7-18,A:109-216; A:19-108,A:217-229BOVINE TRYPSIN 2-AMINOBENZIMIDAZOLE COMPLEX
1QB1A:7-18,A:109-216; A:19-108,A:217-229BOVINE TRYPSIN WITH 1-[2-[5-[AMINO(IMINO)METHYL]-2-HYDROXYPHENOXY]-6-[3-(4,5-DIHYDRO-1-METHYL-1H-IMIDAZOL-2-YL)PHENOXY]PYRIDIN-4-YL]PIPERIDINE-3-CARBOXYLIC ACID (ZK-806974)
1QB6A:7-18,A:109-216; A:19-108,A:217-229BOVINE TRYPSIN 3,3'-[3,5-DIFLUORO-4-METHYL-2, 6-PYRIDINEDIYLBIS(OXY)]BIS(BENZENECARBOXIMIDAMIDE) (ZK-805623) COMPLEX
1QB9A:7-18,A:109-216; A:19-108,A:217-229BOVINE TRYPSIN 7-[[2-[[1-(1-IMINOETHYL)PIPERIDIN-4-YL]OXY]-9H-CARBOZOL-9-YL] METHYL]NAPHTHALENE-2-CARBOXIMIDAMIDE (ZK-806450) COMPLEX
1QBNA:7-18,A:109-216; A:19-108,A:217-229BOVINE TRYPSIN 2-[AMINO(IMINO)METHYL]-2-HYDROXYPHENOXY]-6-[3-(4,5-DIHYDRO-1H-IMIDAZOL-2-YL)PHENOXY]PYRIDINE-4-CARBOXYLIC ACID (ZK-806688) COMPLEX
1QBOA:7-18,A:109-216; A:19-108,A:217-229BOVINE TRYPSIN 7-[[6-[[1-(1-IMINOETHYL)PIPERIDIN-4-YL]OXY]-2-METHYL-BENZIMIDAZOL-1-YL]METHYL]NAPHTHALENE-2-CARBOXIMIDAMID ZK-806711 INHIBITOR COMPLEX
1QCPA:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF THE RWJ-51084 BOVINE PANCREATIC BETA-TRYPSIN AT 1.8 A
1RXPA:16-27,A:121-232; A:28-120,A:233-245STRUCTURE OF TRYPSIN (ORTHORHOMBIC) WITH 1-(4-TERT-BUTYLCARBAMOYL- PIPERAZINE-1-CARBONYL)-3-(3-GUANIDINO-PROPYL)-4-OXO-AZETIDINE-2-CARBOXYLIC ACID
1S0QA:660-671,A:762-869; A:672-761,A:870-881NATIVE BOVINE PANCREATIC TRYPSIN
1S0RA:1-12,A:103-210; A:13-102,A:211-222BOVINE PANCREATIC TRYPSIN INHIBITED WITH BENZAMIDINE AT ATOMIC RESOLUTION
1SBWA:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF MUNG BEAN INHIBITOR LYSINE ACTIVE FRAGMENT COMPLEX WITH BOVINE BETA-TRYPSIN AT 1.8A RESOLUTION
1SFIA:16-27,A:121-232; A:28-120,A:233-245HIGH RESOLUTION STRUCTURE OF A POTENT, CYCLIC PROTEASE INHIBITOR FROM SUNFLOWER SEEDS
1T7CA:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232CRYSTAL STRUCTURE OF THE P1 GLU BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1T8LA:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232CRYSTAL STRUCTURE OF THE P1 MET BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1T8MA:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232CRYSTAL STRUCTURE OF THE P1 HIS BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1T8NA:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232CRYSTAL STRUCTURE OF THE P1 THR BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1T8OA:28-120,A:233-243; C:28-120,C:233-243; A:16-27,A:121-232; C:16-27,C:121-232CRYSTAL STRUCTURE OF THE P1 TRP BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1TAWA:16-27,A:121-232; A:28-120,A:233-245BOVINE TRYPSIN COMPLEXED TO APPI
1TBQH:28-120,H:233-247; K:28-120,K:233-247; H:16-27,H:121-232; K:16-27,K:121-232CRYSTAL STRUCTURE OF INSECT DERIVED DOUBLE DOMAIN KAZAL INHIBITOR RHODNIIN IN COMPLEX WITH THROMBIN
1TBRH:28-120,H:233-247; K:28-120,K:233-247; H:16-27,H:121-232; K:16-27,K:121-232CRYSTAL STRUCTURE OF INSECT DERIVED DOUBLE DOMAIN KAZAL INHIBITOR RHODNIIN IN COMPLEX WITH THROMBIN
1TGBA:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF BOVINE TRYPSINOGEN AT 1.8 ANGSTROMS RESOLUTION. II. CRYSTALLOGRAPHIC REFINEMENT, REFINED CRYSTAL STRUCTURE AND COMPARISON WITH BOVINE TRYPSIN
1TGCA:16-27,A:121-232; A:28-120,A:233-245ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
1TGNA:17-27,A:121-232; A:28-120,A:233-245STRUCTURE OF BOVINE TRYPSINOGEN AT 1.9 ANGSTROMS RESOLUTION
1TGSZ:16-27,Z:121-232; Z:28-120,Z:233-245THREE-DIMENSIONAL STRUCTURE OF THE COMPLEX BETWEEN PANCREATIC SECRETORY INHIBITOR (KAZAL TYPE) AND TRYPSINOGEN AT 1.8 ANGSTROMS RESOLUTION. STRUCTURE SOLUTION, CRYSTALLOGRAPHIC REFINEMENT AND PRELIMINARY STRUCTURAL INTERPRETATION
1TIOA:16-27,A:121-232; A:28-120,A:233-245HIGH PACKING DENSITY FORM OF BOVINE BETA-TRYPSIN IN CYCLOHEXANE
1TLDA:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF BOVINE BETA-TRYPSIN AT 1.5 ANGSTROMS RESOLUTION IN A CRYSTAL FORM WITH LOW MOLECULAR PACKING DENSITY. ACTIVE SITE GEOMETRY, ION PAIRS AND SOLVENT STRUCTURE
1TNGA:16-27,A:121-232; A:28-120,A:233-245PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1TNHA:16-27,A:121-232; A:28-120,A:233-245PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1TNIA:16-27,A:121-232; A:28-120,A:233-245PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1TNJA:16-27,A:121-232; A:28-120,A:233-245PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1TNKA:16-27,A:121-232; A:28-120,A:233-245PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1TNLA:16-27,A:121-232; A:28-120,A:233-245PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1TOCB:28-120,B:233-247; D:28-120,D:233-247; F:28-120,F:233-247; H:28-120,H:233-247; B:16-27,B:121-232; D:16-27,D:121-232; F:16-27,F:121-232; H:16-27,H:121-232STRUCTURE OF SERINE PROTEINASE
1TPAE:16-27,E:121-232; E:28-120,E:233-245THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
1TPOA:16-27,A:121-232; A:28-120,A:233-245THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
1TPPA:16-27,A:121-232; A:28-120,A:233-245THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
1TPSA:16-27,A:121-232; A:28-120,A:233-245ATOMIC STRUCTURE OF THE TRYPSIN-A90720A COMPLEX: A UNIFIED APPROACH TO STRUCTURE AND FUNCTION
1TX7A:16-27,A:121-232; A:28-120,A:233-244BOVINE TRYPSIN COMPLEXED WITH P-AMIDINOPHENYLMETHYLPHOSPHINIC ACID (AMPA)
1TX8A:16-27,A:121-232; A:28-120,A:233-244BOVINE TRYPSIN COMPLEXED WITH AMSO
1TYNA:16-27,A:121-232; A:28-120,A:233-245ATOMIC STRUCTURE OF THE TRYPSIN-CYCLOTHEONAMIDE A COMPLEX: LESSONS FOR THE DESIGN OF SERINE PROTEASE INHIBITORS
1UCYK:28-120,K:233-247; N:28-120,N:233-247; K:16-27,K:121-232; N:16-27,N:121-232; E:149B-247; H:16-149ATHROMBIN COMPLEXED WITH FIBRINOPEPTIDE A ALPHA (RESIDUES 7-19). THREE COMPLEXES, ONE WITH EPSILON-THROMBIN AND TWO WITH ALPHA-THROMBIN
1UVTH:28-120,H:233-241; H:16-27,H:121-232BOVINE THROMBIN--BM14.1248 COMPLEX
1UVUH:28-120,H:233-237; H:16-27,H:121-232BOVINE THROMBIN--BM12.1700 COMPLEX
1V2JT:16-27,T:121-232; T:28-120,T:233-245BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSRI) BT.C1
1V2KT:16-27,T:121-232; T:28-120,T:233-245FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(TRIPLE.GLU)BT.D2
1V2LT:16-27,T:121-232; T:28-120,T:233-245BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(TRIPLE.GLU)BT.D1
1V2MT:16-27,T:121-232; T:28-120,T:233-245BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(TRIPLE.GLU)BT.A1
1V2NT:16-27,T:121-232; T:28-120,T:233-245POTENT FACTOR XA INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(99/175/190)BT
1V2OT:16-27,T:121-232; T:28-120,T:233-245TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSYI)BT.B4
1V2PT:16-27,T:121-232; T:28-120,T:233-245TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSYI)BT.A4
1V2QT:16-27,T:121-232; T:28-120,T:233-245TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSWI)BT.B4
1V2RT:16-27,T:121-232; T:28-120,T:233-245TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSRI)BT.B4
1V2ST:16-27,T:121-232; T:28-120,T:233-245BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSFI.GLU)BT.D1
1V2TT:16-27,T:121-232; T:28-120,T:233-245TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSFI.GLU)BT.B4
1V2UT:16-27,T:121-232; T:28-120,T:233-245BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARINAT X(SSAI) BT.D1
1V2VT:16-27,T:121-232; T:28-120,T:233-245BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSAI) BT.C1
1V2WT:16-27,T:121-232; T:28-120,T:233-245TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSAI)BT.B4
1VGCC:151-245; B:16-146GAMMA-CHYMOTRYPSIN L-PARA-CHLORO-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX
1VITH:28-120,H:233-247; H:16-27,H:121-232; G:149B-247; F:16-149ATHROMBIN:HIRUDIN 51-65 COMPLEX
1XUFA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN-BABIM-ZN+2, PH 8.2
1XUGA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN-BABIM-ZN+2, PH 8.2
1XUHA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN-KETO-BABIM-CO+2, PH 8.2
1XUIA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN-KETO-BABIM, ZN+2-FREE, PH 8.2
1XUJA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN-KETO-BABIM-ZN+2, PH 8.2
1XUKA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN-BABIM-SULFATE, PH 5.9
1Y3UA:16-27,A:121-232; A:28-120,A:233-244TRYPSIN INHIBITOR COMPLEX
1Y3VA:16-27,A:121-232; A:28-120,A:233-244TRYPSIN INHIBITOR COMPLEX
1Y3WA:16-27,A:121-232; A:28-120,A:233-244TRYPSIN INHIBITOR COMPLEX
1Y3XA:16-27,A:121-232; A:28-120,A:233-244TRYPSIN INHIBITOR COMPLEX
1Y3YA:16-27,A:121-232; A:28-120,A:233-244TRYPSIN INHIBITOR COMPLEX
1YCPH:28-120,H:233-242; H:16-27,H:121-232; M:150-243; K:16-146THE CRYSTAL STRUCTURE OF FIBRINOGEN-AA PEPTIDE 1-23 (F8Y) BOUND TO BOVINE THROMBIN EXPLAINS WHY THE MUTATION OF PHE-8 TO TYROSINE STRONGLY INHIBITS NORMAL CLEAVAGE AT ARGININE-16
1YP9A:253-27,A:121-232; A:28-120,A:233-244TRYPSIN INHIBITOR COMPLEX
1YPHE:149-245; F:149-245; C:16-146; D:16-146HIGH RESOLUTION STRUCTURE OF BOVINE ALPHA-CHYMOTRYPSIN
1YYY1:16-27,1:121-232; 1:28-120,1:233-245TRYPSIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES
1ZR0A:16-27,A:121-232; C:16-27,C:121-232; A:28-120,A:233-245; C:28-120,C:233-245CRYSTAL STRUCTURE OF KUNITZ DOMAIN 1 OF TISSUE FACTOR PATHWAY INHIBITOR-2 WITH BOVINE TRYPSIN
1ZZZA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES
2A1DB:28-120,B:233-247; F:28-120,F:233-247; B:16-27,B:121-232; F:16-27,F:121-232STAPHYLOCOAGULASE BOUND TO BOVINE THROMBIN
2A7HA:7-18,A:109-216; A:19-108,A:217-228ON THE ROUTINE USE OF SOFT X-RAYS IN MACROMOLECULAR CRYSTALLOGRAPHY, PART III- THE OPTIMAL DATA COLLECTION WAVELENGTH
2AGEX:16-27,X:121-232; X:28-120,X:233-244SUCCINYL-AAPR-TRYPSIN ACYL-ENZYME AT 1.15 A RESOLUTION
2AGGX:16-27,X:121-232; X:28-120,X:233-244SUCCINYL-AAPK-TRYPSIN ACYL-ENZYME AT 1.28 A RESOLUTION
2AGIX:16-27,X:121-232; X:28-120,X:233-244THE LEUPEPTIN-TRYPSIN COVALENT COMPLEX AT 1.14 A RESOLUTION
2AH4X:16-27,X:121-232; X:28-120,X:233-244GUANIDINOBENZOYL-TRYPSIN ACYL-ENZYME AT 1.13 A RESOLUTION
2AYWA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN TRYPSIN AND A DESIGNED SYNTHETIC HIGHLY POTENT INHIBITOR IN THE PRESENCE OF BENZAMIDINE AT 0.97 A RESOLUTION
2BTCE:16-27,E:121-232; E:28-120,E:233-245BOVINE TRYPSIN IN COMPLEX WITH SQUASH SEED INHIBITOR (CUCURBITA PEPO TRYPSIN INHIBITOR II)
2BZAA:16-27,A:121-232; A:28-120,A:233-245BOVINE PANCREAS BETA-TRYPSIN IN COMPLEX WITH BENZYLAMINE
2CGAA:28-120,A:233-245; B:28-120,B:233-245; A:16-27,A:121-232; B:16-27,B:121-232BOVINE CHYMOTRYPSINOGEN A. X-RAY CRYSTAL STRUCTURE ANALYSIS AND REFINEMENT OF A NEW CRYSTAL FORM AT 1.8 ANGSTROMS RESOLUTION
2CHAC:149-245; G:149-245; B:16-146; F:16-146THE STRUCTURE OF CRYSTALLINE ALPHA-CHYMOTRYPSIN, $V.THE ATOMIC STRUCTURE OF TOSYL-ALPHA-CHYMOTRYPSIN AT 2 ANGSTROMS RESOLUTION
2D8WA:7-18,A:109-216; A:19-108,A:217-228STRUCTURE OF HYPER-VIL-TRYPSIN
2F3CE:16-27,E:118-225; E:28-117,E:226-237CRYSTAL STRUCTURE OF INFESTIN 1, A KAZAL-TYPE SERINEPROTEASE INHIBITOR, IN COMPLEX WITH TRYPSIN
2FI3E:16-27,E:121-232; E:28-120,E:233-244CRYSTAL STRUCTURE OF A BPTI VARIANT (CYS14->SER, CYS38->SER) IN COMPLEX WITH TRYPSIN
2FI4E:16-27,E:121-232; E:28-120,E:233-244CRYSTAL STRUCTURE OF A BPTI VARIANT (CYS14->SER) IN COMPLEX WITH TRYPSIN
2FI5E:16-27,E:121-232; E:28-120,E:233-244CRYSTAL STRUCTURE OF A BPTI VARIANT (CYS38->SER) IN COMPLEX WITH TRYPSIN
2FTLE:16-27,E:121-232; E:28-120,E:233-244CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH BPTI AT 100K
2FTMA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH THE BPTI VARIANT (TYR35->GLY)
2FX4A:16-27,A:121-232; A:28-120,A:233-244BOVINE TRYPSIN BOUND BY 4-PIPERIDINEBUTYRATE TO MAKE ACYLENZYME COMPLEX
2FX6A:16-27,A:121-232; A:28-120,A:233-244BOVINE TRYPSIN COMPLEXED WITH 2-AMINOBENZAMIDAZOLE
2G55A:7-18,A:109-216; A:19-108,A:217-228ANOMALOUS SUBSTRUCTURE OF TRYPSIN (P3121)
2G5NA:7-18,A:109-216; A:19-108,A:217-228INDOLE-AMIDINE COMPLEXES WITH BOVINE TRYPSIN
2G5VA:7-18,A:109-216; A:19-108,A:217-228INDOLE-AMIDINE COMPLEXES WITH BOVINE TRYPSIN
2G81E:16-27,E:121-232; E:28-120,E:233-244CRYSTAL STRUCTURE OF THE BOWMAN-BIRK INHIBITOR FROM VIGNA UNGUICULATA SEEDS IN COMPLEX WITH BETA-TRYPSIN AT 1.55 ANGSTRONS RESOLUTION
2G8TA:7-18,A:109-216; A:19-108,A:217-228INDOLE-AMIDINE COMPLEXES WITH BOVINE TRYPSIN
2GCHG:151-245; F:16-146REFINED CRYSTAL STRUCTURE OF GAMMA-CHYMOTRYPSIN AT 1.9 ANGSTROMS RESOLUTION
2GMTC:151-245; B:16-146THREE-DIMENSIONAL STRUCTURE OF CHYMOTRYPSIN INACTIVATED WITH (2S) N-ACETYL-L-ALANYL-L-PHENYLALANYL-CHLOROETHYL KETONE: IMPLICATIONS FOR THE MECHANISM OF INACTIVATION OF SERINE PROTEASES BY CHLOROKETONES
2ILNA:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-244; B:28-120,B:233-244CRYSTAL STRUCTURE OF THE BOWMAN-BIRK INHIBITOR FROM SNAIL MEDIC SEEDS IN COMPLEX WITH BOVINE TRYPSIN
2O9QA:19-30,A:121-228; A:31-120,A:229-241THE CRYSTAL STRUCTURE OF BOVINE TRYPSIN COMPLEXED WITH A SMALL INHIBITION PEPTIDE ORB2K
2ODYB:28-120,B:233-243; D:28-120,D:233-243; B:16-27,B:121-232; D:16-27,D:121-232THROMBIN-BOUND BOOPHILIN DISPLAYS A FUNCTIONAL AND ACCESSIBLE REACTIVE-SITE LOOP
2OTVA:16-27,A:121-238; A:28-120,A:239-250CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN BOVINE TRYPSIN AND NICOTINAMIDE AT 1.56 A RESOLUTION
2OXSA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF THE TRYPSIN COMPLEX WITH BENZAMIDINE AT HIGH TEMPERATURE (35 C)
2P8OC:151-245; B:16-146CRYSTAL STRUCTURE OF A BENZOHYDROXAMIC ACID/VANADATE COMPLEX BOUND TO CHYMOTRYPSIN A
2PLXA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN COMPLEXED TO A SYNTHETIC PEPTIDE FROM VERONICA HEDERIFOLIA
2PTCE:16-27,E:121-232; E:28-120,E:233-245THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
2PTNA:16-27,A:121-232; A:28-120,A:233-245ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
2TGAA:16-27,A:121-232; A:28-120,A:233-245ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
2TGDA:17-27,A:121-232; A:28-120,A:233-245LACK OF THE TRANSITION STATE STABILIZATION SITE IS A FACTOR IN THE INACTIVITY OF TRYPSINOGEN, A SERINE PROTEASE ZYMOGEN. STRUCTURE OF DFP INHIBITED BOVINE TRYPSINOGEN AT 2.1 ANGSTROMS RESOLUTION
2TGPZ:16-27,Z:121-232; Z:28-120,Z:233-245THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
2TIOA:16-27,A:121-232; A:28-120,A:233-245LOW PACKING DENSITY FORM OF BOVINE BETA-TRYPSIN IN CYCLOHEXANE
2VGCC:151-245; B:16-146GAMMA-CHYMOTRYPSIN D-PARA-CHLORO-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX
3BTDE:16-27,E:121-232; E:28-120,E:233-244THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN THE BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI.
3BTEE:16-27,E:121-232; E:28-120,E:233-243THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI.
3BTFE:16-27,E:121-232; E:28-120,E:233-245THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI.
3BTGE:16-27,E:121-232; E:28-120,E:233-244THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI
3BTHE:16-27,E:121-232; E:28-120,E:233-242THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI
3BTKE:16-27,E:121-232; E:28-120,E:233-243THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI
3BTME:16-27,E:121-232; E:28-120,E:233-244THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI
3BTQE:16-27,E:121-232; E:28-120,E:233-244THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI
3BTTE:16-27,E:121-232; E:28-120,E:233-244THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI
3BTWE:16-27,E:121-232; E:28-120,E:233-243THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI
3GCTG:151-245; F:16-146STRUCTURE OF GAMMA-*CHYMOTRYPSIN IN THE RANGE $P*H 2.0 TO $P*H 10.5 SUGGESTS THAT GAMMA-CHYMOTRYPSIN IS A COVALENT ACYL-ENZYME ADDUCT AT LOW $P*H
3PTBA:16-27,A:121-232; A:28-120,A:233-245THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
3PTNA:16-27,A:121-232; A:28-120,A:233-245ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
3TPIZ:16-27,Z:121-232; Z:28-120,Z:233-245THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
3VGCC:151-245; B:16-146GAMMA-CHYMOTRYPSIN L-NAPHTHYL-1-ACETAMIDO BORONIC ACID ACID INHIBITOR COMPLEX
4CHAC:149-245; G:149-245; B:16-146; F:16-146STRUCTURE OF ALPHA-*CHYMOTRYPSIN REFINED AT 1.68 ANGSTROMS RESOLUTION
4GCHG:151-245; F:16-146STRUCTURE AND ACTIVITY OF TWO PHOTOREVERSIBLE CINNAMATES BOUND TO CHYMOTRYPSIN
4TPIZ:16-27,Z:121-232; Z:28-120,Z:233-245THE REFINED 2.2-ANGSTROMS (0.22-NM) X-RAY CRYSTAL STRUCTURE OF THE TERNARY COMPLEX FORMED BY BOVINE TRYPSINOGEN, VALINE-VALINE AND THE ARG15 ANALOGUE OF BOVINE PANCREATIC TRYPSIN INHIBITOR
4VGCC:151-245; B:16-146GAMMA-CHYMOTRYPSIN D-NAPHTHYL-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX
5CHAC:149-245; G:149-245; B:16-146; F:16-146THE REFINEMENT AND THE STRUCTURE OF THE DIMER OF ALPHA-*CHYMOTRYPSIN AT 1.67-*ANGSTROMS RESOLUTION
5GCHG:151-245; F:16-146CHEMISTRY OF CAGED ENZYMES /II$. PHOTOACTIVATION OF INHIBITED CHYMOTRYPSIN
5PTPA:16-27,A:121-232; A:28-120,A:233-244STRUCTURE OF HYDROLASE (SERINE PROTEINASE)
6CHAC:149-245; G:149-245; B:16-146; F:16-146STRUCTURE OF A TETRAHEDRAL TRANSITION STATE COMPLEX OF ALPHA-*CHYMOTRYPSIN AT 1.8-*ANGSTROMS RESOLUTION
6GCHG:151-245; F:16-146STRUCTURE OF CHYMOTRYPSIN-*TRIFLUOROMETHYL KETONE INHIBITOR COMPLEXES. COMPARISON OF SLOWLY AND RAPIDLY EQUILIBRATING INHIBITORS
7GCHG:151-245; F:16-146STRUCTURE OF CHYMOTRYPSIN-*TRIFLUOROMETHYL KETONE INHIBITOR COMPLEXES. COMPARISON OF SLOWLY AND RAPIDLY EQUILIBRATING INHIBITORS
8GCHG:150-245; F:16-146GAMMA-CHYMOTRYPSIN IS A COMPLEX OF ALPHA-CHYMOTRYPSIN WITH ITS OWN AUTOLYSIS PRODUCTS
(-)
Cellulomonas bogoriensis. Organism_taxid: 301388 (1)
2EA3A:70-168; A:1-69,A:169-183CRYSTAL STRUCTURE OF CELLULOMONAS BOGORIENSIS CHYMOTRYPSIN
(-)
Chinese moccasin (Deinagkistrodon acutus) (2)
1OP0A:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF AAV-SP-I, A GLYCOSYLATED SNAKE VENOM SERINE PROTEINASE FROM AGKISTRODON ACUTUS
1OP2A:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF AAV-SP-II, A GLYCOSYLATED SNAKE VENOM SERINE PROTEINASE FROM AGKISTRODON ACUTUS
(-)
Chum salmon (Oncorhynchus keta) (4)
1MBQA:16-27,A:121-232; A:28-120,A:233-243ANIONIC TRYPSIN FROM PACIFIC CHUM SALMON
2ZPQA:1-12,A:103-209; A:13-102,A:210-220; B:13-102,B:210-220; B:1-12,B:103-209CRYSTAL STRUCTURE OF ANIONIC TRYPSIN ISOFORM 1 FROM CHUM SALMON
2ZPRA:1-12,A:103-209; B:1-12,B:103-209; A:13-102,A:210-221; B:13-102,B:210-221CRYSTAL STRUCTURE OF ANIONIC TRYPSIN ISOFORM 2 FROM CHUM SALMON
2ZPSA:1-12,A:103-209; A:13-102,A:210-221CRYSTAL STRUCTURE OF ANIONIC TRYPSIN ISOFORM 3 FROM CHUM SALMON
(-)
Common brandling worm (Eisenia fetida) (2)
1M9UA:28-120,A:233-242; B:28-120,B:233-242; C:28-120,C:233-242; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232CRYSTAL STRUCTURE OF EARTHWORM FIBRINOLYTIC ENZYME COMPONENT A FROM EISENIA FETIDA
1YM0A:16-27,A:121-230; A:28-120,A:231-245CRYSTAL STRUCTURE OF EARTHWORM FIBRINOLYTIC ENZYME COMPONENT B: A NOVEL, GLYCOSYLATED TWO-CHAINED TRYPSIN
(-)
Common vampire bat (Desmodus rotundus) (1)
1A5IA:28-120,A:233-244; A:16-27,A:121-232CATALYTIC DOMAIN OF VAMPIRE BAT (DESMODUS ROTUNDUS) SALIVA PLASMINOGEN ACTIVATOR IN COMPLEX WITH EGR-CMK (GLU-GLY-ARG CHLOROMETHYL KETONE)
(-)
Cow (Bos taurus) (5)
1ETRH:28-120,H:233-247; H:16-27,H:121-232REFINED 2.3 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF BOVINE THROMBIN COMPLEXES FORMED WITH THE BENZAMIDINE AND ARGININE-BASED THROMBIN INHIBITORS NAPAP, 4-TAPAP AND MQPA: A STARTING POINT FOR IMPROVING ANTITHROMBOTICS
1ETSH:28-120,H:233-247; H:16-27,H:121-232REFINED 2.3 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF BOVINE THROMBIN COMPLEXES FORMED WITH THE BENZAMIDINE AND ARGININE-BASED THROMBIN INHIBITORS NAPAP, 4-TAPAP AND MQPA: A STARTING POINT FOR IMPROVING ANTITHROMBOTICS
1ETTH:28-120,H:233-247; H:16-27,H:121-232REFINED 2.3 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF BOVINE THROMBIN COMPLEXES FORMED WITH THE BENZAMIDINE AND ARGININE-BASED THROMBIN INHIBITORS NAPAP, 4-TAPAP AND MQPA: A STARTING POINT FOR IMPROVING ANTITHROMBOTICS
1PPCE:16-27,E:121-232; E:28-120,E:233-245GEOMETRY OF BINDING OF THE BENZAMIDINE-AND ARGININE-BASED INHIBITORS N-ALPHA-(2-NAPHTHYL-SULPHONYL-GLYCYL)-DL-P-AMIDINOPHENYLALANYL-PIPERIDINE (NAPAP) AND (2R,4R)-4-METHYL-1-[N-ALPHA-(3-METHYL-1,2,3,4-TETRAHYDRO-8-QUINOLINESULPHONYL)-L-ARGINYL]-2-PIPERIDINE CARBOXYLIC ACID (MQPA) TO HUMAN ALPHA-THROMBIN: X-RAY CRYSTALLOGRAPHIC DETERMINATION OF THE NAPAP-TRYPSIN COMPLEX AND MODELING OF NAPAP-THROMBIN AND MQPA-THROMBIN
1TABE:16-27,E:121-232; E:28-120,E:233-245STRUCTURE OF THE TRYPSIN-BINDING DOMAIN OF BOWMAN-BIRK TYPE PROTEASE INHIBITOR AND ITS INTERACTION WITH TRYPSIN
(-)
Domestic pig (Sus scrofa domestica) (2)
1INCA:28-120,A:233-245; A:16-27,A:121-232CRYSTAL STRUCTURES OF THE COMPLEX OF PORCINE PANCREATIC ELASTASE WITH TWO VALINE-DERIVED BENZOXAZINONE INHIBITORS
1JIMA:28-120,A:233-245; A:16-27,A:121-232STEREOSPECIFIC REACTION OF 3-METHOXY-4-CHLORO-7-AMINOISOCOUMARIN WITH CRYSTALLINE PORCINE PANCREATIC ELASTASE
(-)
Early cattle grub (Hypoderma lineatum) (2)
1HYLA:30-121,A:235-246; B:30-121,B:235-246; A:16-29,A:122-234; B:16-29,B:122-234THE 1.8 A STRUCTURE OF COLLAGENASE FROM HYPODERMA LINEATUM
2HLCA:30-121,A:235-246; B:30-121,B:235-246; A:16-29,A:122-234; B:16-29,B:122-234HL COLLAGENASE STRUCTURE AT 1.7A RESOLUTION
(-)
Equine arteritis virus. Organism_taxid: 11047. (1)
1MBMA:8-83; B:8-83; C:8-83; D:9-83; A:84-155; B:84-155; C:84-155; D:84-155NSP4 PROTEINASE FROM EQUINE ARTERITIS VIRUS
(-)
Escherichia coli k12. Organism_taxid: 83333. Strain: k12. (3)
2QF0B:142-252; E:142-251; I:142-252; B:38-141; D:41-141; A:36-141; F:39-141; C:41-141; E:37-141; I:39-141; G:39-141; H:42-141; C:142-252; F:142-252; H:142-252; G:142-250; D:142-255; A:142-252STRUCTURE OF THE DELTA PDZ TRUNCATION OF THE DEGS PROTEASE
2QF3B:142-251; A:142-256; A:36-141; C:42-141; B:38-141; C:142-251STRUCTURE OF THE DELTA PDZ TRUNCATION OF THE DEGS PROTEASE
2QGRA:142-250; A:41-141STRUCTURE OF THE R178A MUTANT OF DELTA PDZ DEGS PROTEASE
(-)
Escherichia coli. Organism_taxid: 562. (11)
1KY9A:155-244; B:153-244; A:25-33,A:87-154,A:245-259; B:24-33,B:86-151CRYSTAL STRUCTURE OF DEGP (HTRA)
1SLVB:16-27,B:121-232; B:28-120,B:233-243RAT ANIONIC N143H, E151H TRYPSIN COMPLEXED TO A86H ECOTIN; COPPER-BOUND
1SLWB:16-27,B:121-232; B:28-120,B:233-243RAT ANIONIC N143H, E151H TRYPSIN COMPLEXED TO A86H ECOTIN; NICKEL-BOUND
1SLXB:16-27,B:121-232; B:28-120,B:233-244RAT ANIONIC N143H, E151H TRYPSIN COMPLEXED TO A86H ECOTIN; ZINC-BOUND
1SOTA:146-237; C:146-237; B:43-133; A:43-145,A:238-254; C:43-145,C:238-254; B:152-237CRYSTAL STRUCTURE OF THE DEGS STRESS SENSOR
1SOZA:146-237; C:146-237; A:42-145,A:238-254; B:42-145,B:238-254; C:42-145,C:238-254; B:146-237CRYSTAL STRUCTURE OF DEGS PROTEASE IN COMPLEX WITH AN ACTIVATING PEPTIDE
1TE0A:37-133; B:37-133; A:152-237; B:152-237STRUCTURAL ANALYSIS OF DEGS, A STRESS SENSOR OF THE BACTERIAL PERIPLASM
1VCWA:146-237; B:146-237; C:146-237; A:42-145,A:238-254; B:42-145,B:238-254; C:42-145,C:238-254CRYSTAL STRUCTURE OF DEGS AFTER BACKSOAKING THE ACTIVATING PEPTIDE
2R3UB:142-252; C:142-251; A:42-141; C:42-141; B:42-141; A:142-251CRYSTAL STRUCTURE OF THE PDZ DELETION MUTANT OF DEGS
2R3YA:146-237; B:146-237; C:146-237; B:42-145,B:238-254; C:42-145,C:238-254; A:42-145,A:238-254CRYSTAL STRUCTURE OF THE DEGS PROTEASE IN COMPLEX WITH THE YWF ACTIVATING PEPTIDE
2RCEB:142-252; G:142-253; C:142-253; A:142-252; F:142-252; D:142-256; H:142-251; E:142-251; I:142-251; C:37-141; F:37-141; B:37-141; D:40-141; E:37-141; A:38-141; I:37-141; G:37-141; H:41-141DFP MODIFIED DEGS DELTA PDZ
(-)
Escherichia coli. Organism_taxid: 562. (3)
1EZSC:416-427,C:521-632; D:716-727,D:821-932; C:428-520,C:633-645; D:728-820,D:933-945CRYSTAL STRUCTURE OF ECOTIN MUTANT M84R, W67A, G68A, Y69A, D70A BOUND TO RAT ANIONIC TRYPSIN II
1EZUC:416-427,C:521-632; D:716-727,D:821-932; C:428-520,C:633-645; D:728-820,D:933-945ECOTIN Y69F, D70P BOUND TO D102N TRYPSIN
1SLUB:16-27,B:121-232; B:28-120,B:233-243RAT ANIONIC N143H, E151H TRYPSIN COMPLEXED TO A86H ECOTIN
(-)
Escherichia coli. Strain: k12. (1)
3B8JA:142-252; A:41-141Q191A MUTANT OF DEGS-DELTAPDZ
(-)
Fmdv (Foot-and-mouth disease virus) (1)
2BHGA:99-205; B:100-205; A:7-98; B:7-993C PROTEASE FROM TYPE A10(61) FOOT-AND-MOUTH DISEASE VIRUS
(-)
Foot-and-mouth disease virus (strain a10-61). Organism_taxid: 12112. (1)
2J92A:99-207; B:99-206; A:7-98; B:7-983C PROTEASE FROM TYPE A10(61) FOOT-AND-MOUTH DISEASE VIRUS-CRYSTAL PACKING MUTANT (K51Q)
(-)
Foot-and-mouth disease virus. Organism_taxid: 12112. Strain: a10-61. (2)
2WV4A:99-207; B:99-207; A:7-98; B:6-98CRYSTAL STRUCTURE OF FOOT-AND-MOUTH DISEASE VIRUS 3C PROTEASE IN COMPLEX WITH A DECAMERIC PEPTIDE CORRESPONDING TO THE VP1-2A CLEAVAGE JUNCTION
2WV5A:99-206; C:7-98; D:7-98; B:99-206; C:99-206; D:99-206; A:7-98; B:7-98CRYSTAL STRUCTURE OF FOOT-AND-MOUTH DISEASE VIRUS 3C PROTEASE IN COMPLEX WITH A DECAMERIC PEPTIDE CORRESPONDING TO THE VP1-2A CLEAVAGE JUNCTION WITH A GLN TO GLU SUBSTITUTION AT P1
(-)
Fusarium oxysporum. Organism_taxid: 5507 (8)
1PPZA:16-27,A:118-229; A:28-117,A:230-238TRYPSIN COMPLEXES AT ATOMIC AND ULTRA-HIGH RESOLUTION
1PQ5A:16-27,A:118-229; A:28-117,A:230-239TRYPSIN AT PH 5, 0.85 A
1PQ7A:16-27,A:118-229; A:28-117,A:230-239TRYPSIN AT 0.8 A, PH5 / BORAX
1PQAA:16-27,A:118-229; A:28-117,A:230-238TRYPSIN WITH PMSF AT ATOMIC RESOLUTION
1TRYA:16-27,A:121-232; A:28-120,A:233-242STRUCTURE OF INHIBITED TRYPSIN FROM FUSARIUM OXYSPORUM AT 1.55 ANGSTROMS
1XVOA:16-27,A:118-229; A:28-117,A:230-239TRYPSIN FROM FUSARIUM OXYSPORUM AT PH 6
2G51A:16-27,A:118-229; A:28-117,A:230-239ANOMALOUS SUBSTRUCTURE OF TRYPSIN (P1)
2G52A:16-27,A:118-229; A:28-117,A:230-239ANOMALOUS SUBSTRUCTURE OF TRYPSIN (P21)
(-)
Fusarium oxysporum. Organism_taxid: 5507. (8)
1FN8A:16-27,A:121-232; A:28-120,A:233-242FUSARIUM OXYSPORUM TRYPSIN AT ATOMIC RESOLUTION
1FY4A:16-27,A:121-232; A:28-120,A:233-242FUSARIUM OXYSPORUM TRYPSIN AT ATOMIC RESOLUTION
1FY5A:16-27,A:121-232; A:28-120,A:233-242FUSARIUM OXYSPORUM TRYPSIN AT ATOMIC RESOLUTION
1GDNA:16-27,A:121-232; A:28-120,A:233-242FUSARIUM OXYSPORUM TRYPSIN AT ATOMIC RESOLUTION
1GDQA:16-27,A:121-232; A:28-120,A:233-242FUSARIUM OXYSPORUM TRYPSIN AT ATOMIC RESOLUTION
1GDUA:16-27,A:121-232; A:28-120,A:233-242FUSARIUM OXYSPORUM TRYPSIN AT ATOMIC RESOLUTION
1PQ8A:16-27,A:118-229; A:28-117,A:230-239TRYPSIN AT PH 4 AT ATOMIC RESOLUTION
1XVMA:16-27,A:118-229; A:28-117,A:230-239TRYPSIN FROM FUSARIUM OXYSPORUM- ROOM TEMPERATURE TO ATOMIC RESOLUTION
(-)
Golden hamster (Mesocricetus auratus) (1)
2RDLA:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-245; B:28-120,B:233-245HAMSTER CHYMASE 2
(-)
Hcv (Hepatitis c virus (isolate 1)) (1)
1DXWA:95-179STRUCTURE OF HETERO COMPLEX OF NON STRUCTURAL PROTEIN (NS) OF HEPATITIS C VIRUS (HCV) AND SYNTHETIC PEPTIDIC COMPOUND
(-)
Hepatitis a virus. Organism_taxid: 12092. (4)
1HAVA:1-100,A:204-215; B:1-100,B:204-213; A:101-203; B:101-203HEPATITIS A VIRUS 3C PROTEINASE
2H6MA:1-100,A:204-212; A:101-203AN EPISULFIDE CATION (THIIRANIUM RING) TRAPPED IN THE ACTIVE SITE OF HAV 3C PROTEINASE INACTIVATED BY PEPTIDE-BASED KETONE INHIBITORS
2H9HA:1-100,A:204-212; A:101-203AN EPISULFIDE CATION (THIIRANIUM RING) TRAPPED IN THE ACTIVE SITE OF HAV 3C PROTEINASE INACTIVATED BY PEPTIDE-BASED KETONE INHIBITORS
2HALA:1-100,A:204-212; A:101-203AN EPISULFIDE CATION (THIIRANIUM RING) TRAPPED IN THE ACTIVE SITE OF HAV 3C PROTEINASE INACTIVATED BY PEPTIDE-BASED KETONE INHIBITORS
(-)
Hepatitis a virus. Organism_taxid: 12092. (1)
1QA7B:1-100,B:204-215; D:1-100,D:204-215; A:1-100,A:204-213; C:1-100,C:204-213; A:101-203; B:101-203; C:101-203; D:101-203CRYSTAL COMPLEX OF THE 3C PROTEINASE FROM HEPATITIS A VIRUS WITH ITS INHIBITOR AND IMPLICATIONS FOR THE POLYPROTEIN PROCESSING IN HAV
(-)
Hepatitis c virus (isolate 1). (1)
1W3CA:95-176; B:95-176CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS3 PROTEASE IN COMPLEX WITH A PEPTIDOMIMETIC INHIBITOR
(-)
Hepatitis c virus (isolate 1). Organism_taxid: 31645. Strain: isolatetaiwan. (3)
1DXPA:95-175; B:95-175INHIBITION OF THE HEPATITIS C VIRUS NS3/4A PROTEASE. THE CRYSTAL STRUCTURES OF TWO PROTEASE-INHIBITOR COMPLEXES (APO STRUCTURE)
1DY8A:95-175; B:95-175INHIBITION OF THE HEPATITIS C VIRUS NS3/4A PROTEASE. THE CRYSTAL STRUCTURES OF TWO PROTEASE-INHIBITOR COMPLEXES (INHIBITOR II)
1DY9A:95-175; B:95-175INHIBITION OF THE HEPATITIS C VIRUS NS3/4A PROTEASE. THE CRYSTAL STRUCTURES OF TWO PROTEASE-INHIBITOR COMPLEXES (INHIBITOR I)
(-)
Hepatitis c virus (isolate bk). Organism_taxid: 11105. Strain: (isolate bk). Variant: isolate bk. (1)
1NS3A:95-179; B:95-179STRUCTURE OF HCV PROTEASE (BK STRAIN)
(-)
Hepatitis c virus (isolate bk). Organism_taxid: 11105. Strain: bk strain isolate. (1)
1JXPA:95-179; B:95-179BK STRAIN HEPATITIS C VIRUS (HCV) NS3-NS4A
(-)
Hepatitis c virus subtype 1a. Organism_taxid: 31646. Strain: h77 strain of genotype 1a. (2)
3EYDA:95-181; C:95-179STRUCTURE OF HCV NS3-4A PROTEASE WITH AN INHIBITOR DERIVED FROM A BORONIC ACID
3KN2A:95-181; C:95-179HCV NS3 PROTEASE DOMAIN WITH KETOAMIDE INHIBITOR
(-)
Hepatitis c virus. Organism_taxid: 11103. (8)
1N1LA:95-179; B:95-179CRYSTAL STRUCTURE OF HCV NS3 PROTEASE DOMAIN:NS4A PEPTIDE COMPLEX WITH COVALENTLY BOUND INHIBITOR (GW472467X)
1RTLA:95-180; B:95-179CRYSTAL STRUCTURE OF HCV NS3 PROTEASE DOMAIN: NS4A PEPTIDE COMPLEX WITH COVALENTLY BOUND PYRROLIDINE-5,5-TRANSLACTAM INHIBITOR
2O8MA:95-182; B:95-182CRYSTAL STRUCTURE OF THE S139A MUTANT OF HEPATITIS C VIRUS NS3/4A PROTEASE
2OBOA:95-182; C:95-179STRUCTURE OF HEPATITIS C VIRAL NS3 PROTEASE DOMAIN COMPLEXED WITH NS4A PEPTIDE AND KETOAMIDE SCH476776
2OBQA:95-180; C:95-179DISCOVERY OF THE HCV NS3/4A PROTEASE INHIBITOR SCH503034. KEY STEPS IN STRUCTURE-BASED OPTIMIZATION
2OC0A:95-181; C:95-179STRUCTURE OF NS3 COMPLEXED WITH A KETOAMIDE INHIBITOR SCH491762
2OC7A:95-181; C:95-179STRUCTURE OF HEPATITIS C VIRAL NS3 PROTEASE DOMAIN COMPLEXED WITH NS4A PEPTIDE AND KETOAMIDE SCH571696
2OC8A:95-181; C:95-179STRUCTURE OF HEPATITIS C VIRAL NS3 PROTEASE DOMAIN COMPLEXED WITH NS4A PEPTIDE AND KETOAMIDE SCH503034
(-)
Hepatitis c virus. Organism_taxid: 11103. (9)
1CU1A:96-179,A:624-631; B:1096-1179,B:1624-1631CRYSTAL STRUCTURE OF AN ENZYME COMPLEX FROM HEPATITIS C VIRUS
1RGQB:98-186; A:98-182M9A HCV PROTEASE COMPLEX WITH PENTAPEPTIDE KETO-AMIDE INHIBITOR
2A4GA:95-181; C:95-179HEPATITIS C PROTEASE NS3-4A SERINE PROTEASE WITH KETOAMIDE INHIBITOR SCH225724 BOUND
2A4QA:95-181; C:95-179HCV NS3 PROTEASE WITH NS4A PEPTIDE AND A COVALENTLY BOUND MACROCYCLIC KETOAMIDE COMPOUND.
2A4RA:95-181; C:95-179HCV NS3 PROTEASE DOMAIN WITH A KETOAMIDE INHIBITOR COVALENTLY BOUND.
2GVFA:95-181; C:95-179HCV NS3-4A PROTEASE DOMAIN COMPLEXED WITH A MACROCYCLIC KETOAMIDE INHIBITOR, SCH419021
2OC1A:95-181; C:95-179STRUCTURE OF THE HCV NS3/4A PROTEASE INHIBITOR CVS4819
3KEEA:95-180; B:95-180; C:95-180; D:95-180HCV NS3/NS4A COMPLEXED WITH NON-COVALENT MACROCYCLIC COMPOUND TMC435
3KF2A:95-181; B:95-181THE HCV NS3/NS4A PROTEASE APO STRUCTURE
(-)
Hepatitis c virus. Organism_taxid: 11103. Strain: 1b. (1)
2K1QA:95-179NMR STRUCTURE OF HEPATITIS C VIRUS NS3 SERINE PROTEASE COMPLEXED WITH THE NON-COVALENTLY BOUND PHENETHYLAMIDE INHIBITOR
(-)
Hepatitis c virus. Organism_taxid: 11103. Strain: bk. (1)
1BT7A:95-179THE SOLUTION NMR STRUCTURE OF THE N-TERMINAL PROTEASE DOMAIN OF THE HEPATITIS C VIRUS (HCV) NS3-PROTEIN, FROM BK STRAIN, 20 STRUCTURES
(-)
Hepatitis c virus. Organism_taxid: 11103. Strain: h strain. (1)
2F9UA:95-183; C:95-179HCV NS3 PROTEASE DOMAIN WITH NS4A PEPTIDE AND A KETOAMIDE INHIBITOR WITH A P2 NORBORANE
(-)
Hepatitis c virus. Organism_taxid: 11103. Strain: h strain. (1)
2XCFA:95-180; B:95-180CRYSTAL STRUCTURE OF HCV NS3 PROTEASE WITH A BORONATE INHIBITOR
(-)
Hepatitis c virus. Organism_taxid: 11103. Strain: h. (3)
1A1RA:121-205; B:121-205HCV NS3 PROTEASE DOMAIN:NS4A PEPTIDE COMPLEX
2F9VA:95-181; C:95-179HCV NS3 PROTEASE DOMAIN WITH NS4A PEPTIDE AND A KETOAMIDE INHIBITOR WITH P1 AND P2 CYCLOPROPYLALANNINES
2OINB:1121-1207; A:121-205CRYSTAL STRUCTURE OF HCV NS3-4A R155K MUNTANT
(-)
Hepatitis c virus. Organism_taxid: 11103. Strain: h. (1)
2XCNA:95-180; B:95-180CRYSTAL STRUCTURE OF HCV NS3 PROTEASE WITH A BORONATE INHIBITOR
(-)
Hepatitis c virus. Organism_taxid: 11103. Strain: h1a. (1)
2FM2A:95-181; C:95-179HCV NS3-4A PROTEASE DOMAIN COMPLEXED WITH A KETOAMIDE INHIBITOR, SCH446211
(-)
Hepatitis c virus. Organism_taxid: 11103. Strain: hcv-h strain. (1)
2P59B:1121-1207; A:121-205CRYSTAL STRUCTURE OF HEPATITIS C VIRUS NS3.4A PROTEASE
(-)
Hepatitis c virus. Strain: h. (1)
2QV1B:1121-1207; A:121-205CRYSTAL STRUCTURE OF HCV NS3-4A V36M MUTANT
(-)
Homo sapiens (Yes) (3)
1HAOH:28-120,H:233-246; H:16-27,H:121-232COMPLEX OF HUMAN ALPHA-THROMBIN WITH A 15MER OLIGONUCLEOTIDE GGTTGGTGTGGTTGG (BASED ON NMR MODEL OF DNA)
1HAPH:28-120,H:233-246; H:16-27,H:121-232COMPLEX OF HUMAN ALPHA-THROMBIN WITH A 15MER OLIGONUCLEOTIDE GGTTGGTGTGGTTGG (BASED ON X-RAY MODEL OF DNA)
1HUTH:28-120,H:233-246; H:16-27,H:121-232THE STRUCTURE OF ALPHA-THROMBIN INHIBITED BY A 15-MER SINGLE-STRANDED DNA APTAMER
(-)
Homo sapiens. Organism_taxid: 9606. (3)
3DFJA:57-152,A:276-292; A:45-56,A:153-275CRYSTAL STRUCTURE OF HUMAN PROSTASIN
3DFLA:57-152,A:276-289; A:45-56,A:153-275CRYSTAL STRUCTURE OF HUMAN PROSTASIN COMPLEXED TO 4-GUANIDINOBENZOIC ACID
3E6PH:28-120,H:233-245; H:16-27,H:121-232CRYSTAL STRUCTURE OF HUMAN MEIZOTHROMBIN DESF1
(-)
Homo sapiens. Organism_taxid: 9606. (10)
1W0ZU:28-120,U:233-244; U:16-27,U:121-232UROKINASE TYPE PLASMINOGEN ACTIVATOR
1W10U:28-120,U:233-244; U:16-27,U:121-232UROKINASE TYPE PLASMINOGEN ACTIVATOR
1W11U:28-120,U:233-244; U:16-27,U:121-232UROKINASE TYPE PLASMINOGEN ACTIVATOR
1W12U:28-120,U:233-244; U:16-27,U:121-232UROKINASE TYPE PLASMINOGEN ACTIVATOR
1W13U:28-120,U:233-244; U:16-27,U:121-232UROKINASE TYPE PLASMINOGEN ACTIVATOR
1W14U:28-120,U:233-244; U:16-27,U:121-232UROKINASE TYPE PLASMINOGEN ACTIVATOR
2BVSH:28-120,H:233-246; H:16-27,H:121-232HUMAN THROMBIN COMPLEXED WITH FRAGMENT-BASED SMALL MOLECULES OCCUPYING THE S1 POCKET
2BVXH:28-120,H:233-246; H:16-27,H:121-232DESIGN AND DISCOVERY OF NOVEL, POTENT THROMBIN INHIBITORS WITH A SOLUBILIZING CATIONIC P1-P2-LINKER
2BXTH:28-120,H:233-246; H:16-27,H:121-232DESIGN AND DISCOVERY OF NOVEL, POTENT THROMBIN INHIBITORS WITH A SOLUBILIZING CATIONIC P1-P2-LINKER
2BXUH:28-120,H:233-246; H:16-27,H:121-232DESIGN AND DISCOVERY OF NOVEL, POTENT THROMBIN INHIBITORS WITH A SOLUBILIZING CATIONIC P1-P2-LINKER
(-)
Homo sapiens. Organism_taxid: 9606. Homo sapiens. Organism_taxid: 9606. (1)
3F6UH:28-120,H:233-244; H:16-27,H:121-232CRYSTAL STRUCTURE OF HUMAN ACTIVATED PROTEIN C (APC) COMPLEXED WITH PPACK
(-)
Horse (Equus caballus) (1)
1GVZA:28-120,A:233-245; A:16-27,A:121-232PROSTATE SPECIFIC ANTIGEN (PSA) FROM STALLION SEMINAL PLASMA
(-)
House mouse (Mus musculus) (6)
1AO5A:28-120,A:233-245; A:16-27,A:121-232; B:16-27,B:121-232; B:28-120,B:233-245MOUSE GLANDULAR KALLIKREIN-13 (PRORENIN CONVERTING ENZYME)
1NPMA:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-242; B:28-120,B:233-242NEUROPSIN, A SERINE PROTEASE EXPRESSED IN THE LIMBIC SYSTEM OF MOUSE BRAIN
1SGFG:28-120,G:233-245; Z:28-120,Z:233-245; A:28-120,A:233-246; X:28-120,X:233-244; G:16-27,G:121-232; Z:16-27,Z:121-232; A:25-27,A:121-232; X:26-27,X:121-232CRYSTAL STRUCTURE OF 7S NGF: A COMPLEX OF NERVE GROWTH FACTOR WITH FOUR BINDING PROTEINS (SERINE PROTEINASES)
2OCVB:28-120,B:233-245; B:16-27,B:121-232STRUCTURAL BASIS OF NA+ ACTIVATION MIMICRY IN MURINE THROMBIN
2PUXB:28-120,B:233-245; B:16-27,B:121-232CRYSTAL STRUCTURE OF MURINE THROMBIN IN COMPLEX WITH THE EXTRACELLULAR FRAGMENT OF MURINE PAR3
2PV9B:28-120,B:233-245; B:16-27,B:121-232CRYSTAL STRUCTURE OF MURINE THROMBIN IN COMPLEX WITH THE EXTRACELLULAR FRAGMENT OF MURINE PAR4
(-)
Human (Homo sapiens) (615)
1A0LA:28-120,A:233-245; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-245; C:28-120,C:233-245; D:28-120,D:233-245HUMAN BETA-TRYPTASE: A RING-LIKE TETRAMER WITH ACTIVE SITES FACING A CENTRAL PORE
1A2CH:28-120,H:233-246; H:16-27,H:121-232STRUCTURE OF THROMBIN INHIBITED BY AERUGINOSIN298-A FROM A BLUE-GREEN ALGA
1A3BH:28-120,H:233-244; H:16-27,H:121-232COMPLEX OF HUMAN ALPHA-THROMBIN WITH THE BIFUNCTIONAL BORONATE INHIBITOR BOROLOG1
1A3EH:28-120,H:233-244; H:16-27,H:121-232COMPLEX OF HUMAN ALPHA-THROMBIN WITH THE BIFUNCTIONAL BORONATE INHIBITOR BOROLOG2
1A46H:28-120,H:233-245; H:16-27,H:121-232THROMBIN COMPLEXED WITH HIRUGEN AND A BETA-STRAND MIMETIC INHIBITOR
1A4WH:28-120,H:233-239; H:16-27,H:121-232CRYSTAL STRUCTURES OF THROMBIN WITH THIAZOLE-CONTAINING INHIBITORS: PROBES OF THE S1' BINDING SITE
1A5GH:28-120,H:233-245; H:16-27,H:121-232HUMAN THROMBIN COMPLEXED WITH NOVEL SYNTHETIC PEPTIDE MIMETIC INHIBITOR AND HIRUGEN
1A5HA:28-120,A:233-242; A:16-27,A:121-232; B:16-27,B:121-232; B:28-120,B:233-242CATALYTIC DOMAIN OF HUMAN TWO-CHAIN TISSUE PLASMINOGEN ACTIVATOR COMPLEX OF A BIS-BENZAMIDINE
1A61H:28-120,H:233-245; H:16-27,H:121-232THROMBIN COMPLEXED WITH A BETA-MIMETIC THIAZOLE-CONTAINING INHIBITOR
1A7SA:1-12,A:108-207; A:13-107,A:208-221ATOMIC RESOLUTION STRUCTURE OF HBP
1ABIH:28-120,H:233-246; H:16-27,H:121-232STRUCTURE OF THE HIRULOG 3-THROMBIN COMPLEX AND NATURE OF THE S' SUBSITES OF SUBSTRATES AND INHIBITORS
1ABJH:28-120,H:233-246; H:16-27,H:121-232STRUCTURE OF THE HIRULOG 3-THROMBIN COMPLEX AND NATURE OF THE S' SUBSITES OF SUBSTRATES AND INHIBITORS
1AD8H:28-120,H:233-244; H:16-27,H:121-232COMPLEX OF THROMBIN WITH AND INHIBITOR CONTAINING A NOVEL P1 MOIETY
1AE5A:1-12,A:108-207; A:13-107,A:208-221HUMAN HEPARIN BINDING PROTEIN
1AE8H:28-120,H:233-246; H:16-27,H:121-232HUMAN ALPHA-THROMBIN INHIBITION BY EOC-D-PHE-PRO-AZALYS-ONP
1AFEH:28-120,H:233-246; H:16-27,H:121-232HUMAN ALPHA-THROMBIN INHIBITION BY CBZ-PRO-AZALYS-ONP
1AHTH:28-120,H:233-245; H:16-27,H:121-232CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND P-AMIDINOPHENYLPYRUVATE AT 1.6 ANGSTROMS RESOLUTION
1AI8H:28-120,H:233-243; H:16-27,H:121-232HUMAN ALPHA-THROMBIN TERNARY COMPLEX WITH THE EXOSITE INHIBITOR HIRUGEN AND ACTIVE SITE INHIBITOR PHCH2OCO-D-DPA-PRO-BOROMPG
1AIXH:28-120,H:233-243; H:16-27,H:121-232HUMAN ALPHA-THROMBIN TERNARY COMPLEX WITH EXOSITE INHIBITOR HIRUGEN AND ACTIVE SITE INHIBITOR PHCH2OCO-D-DPA-PRO-BOROVAL
1AU8A:16-27,A:121-232; A:28-120,A:233-244HUMAN CATHEPSIN G
1AUTC:28-120,C:233-243; C:16-27,C:121-232HUMAN ACTIVATED PROTEIN C
1AWFH:28-120,H:233-246; H:16-27,H:121-232NOVEL COVALENT THROMBIN INHIBITOR FROM PLANT EXTRACT
1AWHB:28-120,B:233-246; B:16-27,B:121-232; D:16-27,D:121-232; D:28-120,D:233-246NOVEL COVALENT THROMBIN INHIBITOR FROM PLANT EXTRACT
1AY6H:28-120,H:233-245; H:16-27,H:121-232THROMBIN INHIBITOR FROM THEONALLA, CYCLOTHEANAMIDE-BASED MACROCYCLIC TRIPEPTIDE MOTIF
1B0FA:16-27,A:121-232; A:28-120,A:233-243CRYSTAL STRUCTURE OF HUMAN NEUTROPHIL ELASTASE WITH MDL 101, 146
1B5GH:28-120,H:233-245; H:16-27,H:121-232HUMAN THROMBIN COMPLEXED WITH NOVEL SYNTHETIC PEPTIDE MIMETIC INHIBITOR AND HIRUGEN
1B7XB:28-120,B:233-242; B:16-27,B:121-232STRUCTURE OF HUMAN ALPHA-THROMBIN Y225I MUTANT BOUND TO D-PHE-PRO-ARG-CHLOROMETHYLKETONE
1BA8B:28-120,B:233-246; B:16-27,B:121-232THROMBIN INHIBITOR WITH A RIGID TRIPEPTIDYL ALDEHYDES
1BB0B:28-120,B:233-244; B:16-27,B:121-232THROMBIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES
1BCUH:28-120,H:233-244; H:16-27,H:121-232ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND PROFLAVIN
1BDAA:28-120,A:233-242; A:16-27,A:121-232; B:16-27,B:121-232; B:28-120,B:233-242CATALYTIC DOMAIN OF HUMAN SINGLE CHAIN TISSUE PLASMINOGEN ACTIVATOR IN COMPLEX WITH DANSYL-EGR-CMK (DANSYL-GLU-GLY-ARG CHLOROMETHYL KETONE)
1BHXF:150-247; B:16-147X-RAY STRUCTURE OF THE COMPLEX OF HUMAN ALPHA THROMBIN WITH THE INHIBITOR SDZ 229-357
1BIOA:28-122,A:233-243; A:16-27,A:123-232HUMAN COMPLEMENT FACTOR D IN COMPLEX WITH ISATOIC ANHYDRIDE INHIBITOR
1BMLA:574-664,A:779-790; A:562-573,A:665-778; B:562-573,B:665-778; B:574-664,B:779-790COMPLEX OF THE CATALYTIC DOMAIN OF HUMAN PLASMIN AND STREPTOKINASE
1BMMH:28-120,H:233-246; H:16-27,H:121-232HUMAN ALPHA-THROMBIN COMPLEXED WITH [S-(R*,R*)]-4-[(AMINOIMINOMETHYL) AMINO]-N-[[1-[3-HYDROXY-2-[(2-NAPHTHALENYLSULFONYL)AMINO]-1-OXOPROPYL]-2-PYRROLIDINYL] METHYL]BUTANAMIDE (BMS-186282)
1BMNH:28-120,H:233-245; H:16-27,H:121-232HUMAN ALPHA-THROMBIN COMPLEXED WITH [S-(R*,R*)]-1-(AMINOIMINOMETHYL)-N-[[1-[N-[(2-NAPHTHALENYLSULFONYL)-L-SERYL]-PYRROLIDINYL]METHYL]-3-PIPERIDENECARBOXAMIDE (BMS-189090)
1BUIA:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; B:28-120,B:233-244STRUCTURE OF THE TERNARY MICROPLASMIN-STAPHYLOKINASE-MICROPLASMIN COMPLEX: A PROTEINASE-COFACTOR-SUBSTRATE COMPLEX IN ACTION
1C1UH:28-120,H:239-252; H:16-27,H:121-238RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1VH:28-120,H:239-252; H:16-27,H:121-238RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1WH:28-120,H:239-252; H:16-27,H:121-238RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C4U2:28-120,2:233-246; 2:16-27,2:121-232SELECTIVE NON ELECTROPHILIC THROMBIN INHIBITORS WITH CYCLOHEXYL MOIETIES.
1C4V2:28-120,2:233-246; 2:16-27,2:121-232SELECTIVE NON ELECTROPHILIC THROMBIN INHIBITORS WITH CYCLOHEXYL MOIETIES.
1C4Y2:28-120,2:233-245; 2:16-27,2:121-232SELECTIVE NON-ELECTROPHILIC THROMBIN INHIBITORS
1C5LH:28-120,H:233-245; H:16-27,H:121-232STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5MD:16-27,D:121-232; D:28-120,D:233-250STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5NH:28-120,H:233-245; H:16-27,H:121-232STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5OH:28-120,H:233-245; H:16-27,H:121-232STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5WB:28-120,B:233-245; B:16-27,B:121-232STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5XB:28-120,B:233-245; B:16-27,B:121-232STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5YB:28-120,B:233-245; B:16-27,B:121-232STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5ZB:28-120,B:233-242; B:16-27,B:121-232STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1CA8B:28-120,B:233-243; B:16-27,B:121-232THROMBIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES
1CGHA:16-27,A:121-232; A:28-120,A:233-244HUMAN CATHEPSIN G
1CVWH:16-27,H:121-232; H:28-120,H:233-246CRYSTAL STRUCTURE OF ACTIVE SITE-INHIBITED HUMAN COAGULATION FACTOR VIIA (DES-GLA)
1D3DB:49-153,B:281-292; B:37-48,B:154-280CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZOTHIOPHENE INHIBITOR 4
1D3PB:49-153,B:281-292; B:37-48,B:154-280CRYSTAL STRUCTURE OF HUMAN APLHA-THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 3
1D3QB:49-153,B:281-292; B:37-48,B:154-280CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 2
1D3TB:49-153,B:281-292; B:37-48,B:154-280CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 1
1D4PB:49-153,B:281-292; B:37-48,B:154-280CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH 5-AMIDINOINDOLE-4-BENZYLPIPERIDINE INHIBITOR
1D6WA:28-120,A:233-243; A:16-27,A:121-232STRUCTURE OF THROMBIN COMPLEXED WITH SELECTIVE NON-ELECTROPHILIC INHIBITORS HAVING CYCLOHEXYL MOIETIES AT P1
1D9IA:28-120,A:233-244; A:16-27,A:121-232STRUCTURE OF THROMBIN COMPLEXED WITH SELECTIVE NON-ELECTOPHILIC INHIBITORS HAVING CYCLOHEXYL MOIETIES AT P1
1DANH:16-27,H:121-232; H:28-120,H:233-246COMPLEX OF ACTIVE SITE INHIBITED HUMAN BLOOD COAGULATION FACTOR VIIA WITH HUMAN RECOMBINANT SOLUBLE TISSUE FACTOR
1DDJA:574-664,A:779-791; A:562-573,A:665-778; B:562-573,B:665-778; C:562-573,C:665-778; D:562-573,D:665-778; B:574-664,B:779-791; C:574-664,C:779-791; D:574-664,D:779-791CRYSTAL STRUCTURE OF HUMAN PLASMINOGEN CATALYTIC DOMAIN
1DE7H:28-120,H:233-243; H:16-27,H:121-232; K:16-27,K:121-232; K:28-120,K:233-245INTERACTION OF FACTOR XIII ACTIVATION PEPTIDE WITH ALPHA-THROMBIN: CRYSTAL STRUCTURE OF THE ENZYME-SUBSTRATE COMPLEX
1DFPA:28-122,A:233-243; B:28-122,B:233-243; A:16-27,A:123-232; B:16-27,B:123-232FACTOR D INHIBITED BY DIISOPROPYL FLUOROPHOSPHATE
1DICA:28-122,A:233-243; A:16-27,A:123-232STRUCTURE OF 3,4-DICHLOROISOCOUMARIN-INHIBITED FACTOR D
1DITH:28-120,H:233-246; H:16-27,H:121-232COMPLEX OF A DIVALENT INHIBITOR WITH THROMBIN
1DLEA:1-120,A:233-248; B:1-120,B:233-248; B:121-229; A:121-229FACTOR B SERINE PROTEASE DOMAIN
1DM4B:28-120,B:233-246; B:16-27,B:121-232SER195ALA MUTANT OF HUMAN THROMBIN COMPLEXED WITH FIBRINOPEPTIDE A (7-16)
1DOJA:28-120,A:233-245; A:16-27,A:121-232CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN*RWJ-51438 COMPLEX AT 1.7 A
1DSTA:28-122,A:233-243; A:16-27,A:123-232MUTANT OF FACTOR D WITH ENHANCED CATALYTIC ACTIVITY
1DSUA:28-122,A:233-243; B:28-122,B:233-242; A:16-27,A:123-232; B:16-27,B:123-232HUMAN FACTOR D, COMPLEMENT ACTIVATING ENZYME
1DVAH:16-27,H:121-232; I:16-27,I:121-232; H:28-120,H:233-246; I:28-120,I:233-246CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE PEPTIDE EXOSITE INHIBITOR E-76 AND COAGULATION FACTOR VIIA
1DWBH:28-120,H:233-244; H:16-27,H:121-232CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS
1DWCH:28-120,H:233-245; H:16-27,H:121-232CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS
1DWDH:28-120,H:233-245; H:16-27,H:121-232CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS
1DWEH:28-120,H:233-245; H:16-27,H:121-232CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS
1DX5M:28-120,M:233-246; M:16-27,M:121-232; N:16-27,N:121-232; O:16-27,O:121-232; P:16-27,P:121-232; N:28-120,N:233-246; O:28-120,O:233-246; P:28-120,P:233-246CRYSTAL STRUCTURE OF THE THROMBIN-THROMBOMODULIN COMPLEX
1E0FE:28-120,E:233-244; D:16-27,D:121-232; E:16-27,E:121-232; F:16-27,F:121-232; D:28-120,D:233-245; F:28-120,F:233-246CRYSTAL STRUCTURE OF THE HUMAN ALPHA-THROMBIN-HAEMADIN COMPLEX: AN EXOSITE II-BINDING INHIBITOR
1EAWA:28-120,A:233-244; C:28-120,C:233-244; A:16-27,A:121-232; C:16-27,C:121-232CRYSTAL STRUCTURE OF THE MTSP1 (MATRIPTASE)-BPTI (APROTININ) COMPLEX
1EAXA:28-120,A:233-244; A:16-27,A:121-232CRYSTAL STRUCTURE OF MTSP1 (MATRIPTASE)
1EB1H:28-120,H:233-245; H:16-27,H:121-232COMPLEX STRUCTURE OF HUMAN THROMBIN WITH N-METHYL-ARGININE INHIBITOR
1EJNA:28-120,A:233-244; A:16-27,A:121-232UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN INHIBITOR COMPLEX
1ELVA:423-436,A:534-655; A:437-532,A:656-664CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN COMPLEMENT C1S PROTEASE
1EOJA:28-120,A:233-243; A:16-27,A:121-232DESIGN OF P1' AND P3' RESIDUES OF TRIVALENT THROMBIN INHIBITORS AND THEIR CRYSTAL STRUCTURES
1EOLA:28-120,A:233-243; A:16-27,A:121-232DESIGN OF P1' AND P3' RESIDUES OF TRIVALENT THROMBIN INHIBITORS AND THEIR CRYSTAL STRUCTURES
1EZQA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR128515
1EZXC:42-245CRYSTAL STRUCTURE OF A SERPIN:PROTEASE COMPLEX
1F0RA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208815
1F0SA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208707
1F5KU:28-120,U:233-244; U:16-27,U:121-232UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-BENZAMIDINE COMPLEX
1F5LA:28-120,A:233-242; A:16-27,A:121-232UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-AMILORIDE COMPLEX
1F92A:28-120,A:233-244; A:16-27,A:121-232UROKINASE PLASMINOGEN ACTIVATOR B CHAIN-UKI-1D COMPLEX
1FAKH:16-27,H:121-232; H:28-120,H:233-246HUMAN TISSUE FACTOR COMPLEXED WITH COAGULATION FACTOR VIIA INHIBITED WITH A BPTI-MUTANT
1FAXA:16-27,A:121-232; A:28-120,A:233-245COAGULATION FACTOR XA INHIBITOR COMPLEX
1FDPA:28-122,A:233-242; B:28-122,B:233-240; C:28-122,C:233-240; D:28-122,D:233-240; A:17-27,A:123-232; B:22-27,B:123-232; D:22-27,D:123-232; C:22-27,C:123-232PROENZYME OF HUMAN COMPLEMENT FACTOR D, RECOMBINANT PROFACTOR D
1FJSA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF THE INHIBITOR ZK-807834 (CI-1031) COMPLEXED WITH FACTOR XA
1FPCH:28-120,H:233-243; H:16-27,H:121-232ACTIVE SITE MIMETIC INHIBITION OF THROMBIN
1FPHH:28-120,H:233-247; H:16-27,H:121-232THE INTERACTION OF THROMBIN WITH FIBRINOGEN: A STRUCTURAL BASIS FOR ITS SPECIFICITY
1FQ3A:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-244; B:28-120,B:233-244CRYSTAL STRUCTURE OF HUMAN GRANZYME B
1FUJA:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; A:28-120,A:233-243; B:28-120,B:233-243; C:28-120,C:233-243; D:28-120,D:233-243PR3 (MYELOBLASTIN)
1FV9A:13-118,A:235-244; A:1-12,A:119-234CRYSTAL STRUCTURE OF HUMAN MICROUROKINASE IN COMPLEX WITH 2-AMINO-5-HYDROXY-BENZIMIDAZOLE
1FXYA:16-27,A:121-232; A:28-120,A:233-246COAGULATION FACTOR XA-TRYPSIN CHIMERA INHIBITED WITH D-PHE-PRO-ARG-CHLOROMETHYLKETONE
1FY1A:1-12,A:108-207; A:13-107,A:208-221[R23S,F25E]HBP, A MUTANT OF HUMAN HEPARIN BINDING PROTEIN (CAP37)
1FY3A:1-12,A:108-207; A:13-107,A:208-221[G175Q]HBP, A MUTANT OF HUMAN HEPARIN BINDING PROTEIN (CAP37)
1G2LA:16-27,A:122-237; A:28-121,A:238-250FACTOR XA INHIBITOR COMPLEX
1G2MA:16-27,A:121-232; A:28-120,A:233-245FACTOR XA INHIBITOR COMPLEX
1G30B:28-120,B:233-245; B:16-27,B:121-232THROMBIN INHIBITOR COMPLEX
1G32B:28-120,B:233-245; B:16-27,B:121-232THROMBIN INHIBITOR COMPLEX
1G37A:28-120,A:233-243; A:16-27,A:121-232CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN COMPLEXED WITH BCH-10556 AND EXOSITE-DIRECTED PEPTIDE
1GHVH:28-120,H:233-244; H:16-27,H:121-232A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GHWH:28-120,H:233-242; H:16-27,H:121-232A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GHXH:28-120,H:233-244; H:16-27,H:121-232A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GHYH:28-120,H:233-244; H:16-27,H:121-232A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI7B:28-120,B:233-242; B:16-27,B:121-232A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI8B:28-120,B:233-242; B:16-27,B:121-232A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI9B:28-120,B:233-242; B:16-27,B:121-232A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GJ4H:28-120,H:233-245; H:16-27,H:121-232SELECTIVITY AT S1, H2O DISPLACEMENT, UPA, TPA, SER190/ALA190 PROTEASE, STRUCTURE-BASED DRUG DESIGN
1GJ5H:28-120,H:233-244; H:16-27,H:121-232SELECTIVITY AT S1, H2O DISPLACEMENT, UPA, TPA, SER190/ALA190 PROTEASE, STRUCTURE-BASED DRUG DESIGN
1GJ7B:28-120,B:233-243; B:16-27,B:121-232ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1GJ8B:28-120,B:233-242; B:16-27,B:121-232ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1GJ9B:28-120,B:233-243; B:16-27,B:121-232ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1GJAB:28-120,B:233-242; B:16-27,B:121-232ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1GJBB:28-120,B:233-243; B:16-27,B:121-232ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1GJCB:28-120,B:233-243; B:16-27,B:121-232ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1GJDB:28-120,B:233-242; B:16-27,B:121-232ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1GPZA:560-675; B:560-675; B:461-558,B:676-681; A:461-558,A:676-681; A:442-460; B:442-460THE CRYSTAL STRUCTURE OF THE ZYMOGEN CATALYTIC DOMAIN OF COMPLEMENT PROTEASE C1R
1GVLA:16-27,A:121-232; A:28-120,A:233-244HUMAN PROKALLIKREIN 6 (HK6)/ PROZYME/ PROPROTEASE M/ PRONEUROSIN
1H1BA:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-243; B:28-120,B:233-243CRYSTAL STRUCTURE OF HUMAN NEUTROPHIL ELASTASE COMPLEXED WITH AN INHIBITOR (GW475151)
1H4WA:16-27,A:121-232; A:28-120,A:233-245STRUCTURE OF HUMAN TRYPSIN IV (BRAIN TRYPSIN)
1H8DH:28-120,H:233-245; H:16-27,H:121-232X-RAY STRUCTURE OF THE HUMAN ALPHA-THROMBIN COMPLEX WITH A TRIPEPTIDE PHOSPHONATE INHIBITOR.
1H8IH:28-120,H:233-245; H:16-27,H:121-232X-RAY CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN WITH A TRIPEPTIDE PHOSPHONATE INHIBITOR.
1HAGE:28-120,E:233-247; E:16-27,E:121-232THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2, HIRUGEN-AND PPACK-THROMBIN: CHANGES ACCOMPANYING ACTIVATION AND EXOSITE BINDING TO THROMBIN
1HAHH:28-120,H:233-246; H:16-27,H:121-232THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2, HIRUGEN-AND PPACK-THROMBIN: CHANGES ACCOMPANYING ACTIVATION AND EXOSITE BINDING TO THROMBIN
1HAIH:28-120,H:233-246; H:16-27,H:121-232THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2, HIRUGEN-AND PPACK-THROMBIN: CHANGES ACCOMPANYING ACTIVATION AND EXOSITE BINDING TO THROMBIN
1HBTH:28-120,H:233-244; H:16-27,H:121-232HUMAN ALPHA-THROMBIN COMPLEXED WITH A PEPTIDYL PYRIDINIUM METHYL KETONE CONTAINING BIVALENT INHIBITOR
1HCGA:16-27,A:121-232; A:28-120,A:233-251STRUCTURE OF HUMAN DES(1-45) FACTOR XA AT 2.2 ANGSTROMS RESOLUTION
1HDTH:28-120,H:233-247; H:16-27,H:121-232STRUCTURE OF A RETRO-BINDING PEPTIDE INHIBITOR COMPLEXED WITH HUMAN ALPHA-THROMBIN
1HFDA:28-122,A:233-243; A:16-27,A:123-232HUMAN COMPLEMENT FACTOR D IN A P21 CRYSTAL FORM
1HGTH:28-120,H:233-246; H:16-27,H:121-232STRUCTURE OF THE HIRUGEN AND HIRULOG 1 COMPLEXES OF ALPHA-THROMBIN
1HLTH:28-120,H:233-243; H:16-27,H:121-232; K:16-27,K:121-232; K:28-120,K:233-243THE STRUCTURE OF A NONADECAPEPTIDE OF THE FIFTH EGF DOMAIN OF THROMBOMODULIN COMPLEXED WITH THROMBIN
1HNEE:16-27,E:121-232; E:28-120,E:233-243STRUCTURE OF HUMAN NEUTROPHIL ELASTASE IN COMPLEX WITH A PEPTIDE CHLOROMETHYL KETONE INHIBITOR AT 1.84-ANGSTROMS RESOLUTION
1HXEH:28-120,H:233-243; H:16-27,H:121-232SERINE PROTEASE
1HXFH:28-120,H:233-243; H:16-27,H:121-232HUMAN THROMBIN COMPLEX WITH HIRUDIN VARIANT
1IAUA:16-27,A:121-232; A:28-120,A:233-244HUMAN GRANZYME B IN COMPLEX WITH AC-IEPD-CHO
1IHSH:28-120,H:233-246; H:16-27,H:121-232CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN ALPHA-THROMBIN AND NON-HYDROLYZABLE BIFUNCTIONAL INHIBITORS, HIRUTONIN-2 AND HIRUTONIN-6
1IHTH:28-120,H:233-246; H:16-27,H:121-232CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN ALPHA-THROMBIN AND NON-HYDROLYZABLE BIFUNCTIONAL INHIBITORS, HIRUTONIN-2 AND HIRUTONIN-6
1IOEA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55532
1IQEA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55590
1IQFA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55165
1IQGA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55159
1IQHA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55143
1IQIA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55125
1IQJA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55124
1IQKA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55113
1IQLA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M54476
1IQMA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M54471
1IQNA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55192
1J9CH:16-27,H:121-232; H:28-120,H:233-246CRYSTAL STRUCTURE OF TISSUE FACTOR-FACTOR VIIA COMPLEX
1JBUH:20-27,H:121-232; H:28-120,H:233-246COAGULATION FACTOR VII ZYMOGEN (EGF2/PROTEASE) IN COMPLEX WITH INHIBITORY EXOSITE PEPTIDE A-183
1JMOH:28-120,H:233-245; H:16-27,H:121-232CRYSTAL STRUCTURE OF THE HEPARIN COFACTOR II-S195A THROMBIN COMPLEX
1JOUB:28-120,B:233-245; B:16-27,B:121-232; D:16-27,D:121-232; F:16-27,F:121-232; D:28-120,D:233-245; F:28-120,F:233-245CRYSTAL STRUCTURE OF NATIVE S195A THROMBIN WITH AN UNOCCUPIED ACTIVE SITE
1JWTA:49-153,A:275-287; A:16-48,A:154-274CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH A NOVEL BICYCLIC LACTAM INHIBITOR
1K21H:28-120,H:233-243; H:16-27,H:121-232HUMAN THROMBIN-INHIBITOR COMPLEX
1K22H:28-120,H:233-245; H:16-27,H:121-232HUMAN THROMBIN-INHIBITOR COMPLEX
1KLIH:16-27,H:121-232; H:28-120,H:233-246COFACTOR-AND SUBSTRATE-ASSISTED ACTIVATION OF FACTOR VIIA
1KLJH:16-27,H:121-232; H:28-120,H:233-246CRYSTAL STRUCTURE OF UNINHIBITED FACTOR VIIA
1KLTA:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF PMSF-TREATED HUMAN CHYMASE AT 1.9 ANGSTROMS RESOLUTION
1KSNA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH FXV673
1KTSB:28-120,B:233-245; B:16-27,B:121-232THROMBIN INHIBITOR COMPLEX
1KTTB:28-120,B:233-245; B:16-27,B:121-232THROMBIN INHIBITOR COMPLEX
1KYE  [entry was replaced by entry 3LIW without any CATH domain information]
1KYNA:16-27,A:121-232; B:316-327,B:421-532; B:328-420,B:533-544; A:28-120,A:233-243CATHEPSIN-G
1L2EA:16-27,A:121-232; A:28-120,A:233-243HUMAN KALLIKREIN 6 (HK6) ACTIVE FORM WITH BENZAMIDINE INHIBITOR
1L4DA:574-664,A:779-790; A:562-573,A:665-778CRYSTAL STRUCTURE OF MICROPLASMINOGEN-STREPTOKINASE ALPHA DOMAIN COMPLEX
1L4ZA:574-664,A:779-790; A:562-573,A:665-778X-RAY CRYSTAL STRUCTURE OF THE COMPLEX OF MICROPLASMINOGEN WITH ALPHA DOMAIN OF STREPTOKINASE IN THE PRESENCE CADMIUM IONS
1LCYA:6-109,A:204-210; A:110-202CRYSTAL STRUCTURE OF THE MITOCHONDRIAL SERINE PROTEASE HTRA2
1LHCH:28-120,H:233-244; H:16-27,H:121-232HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROARG-OH
1LHDH:28-120,H:233-244; H:16-27,H:121-232HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROLYS-OH
1LHEH:28-120,H:233-244; H:16-27,H:121-232HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BORO-N-BUTYL-AMIDINO-GLYCINE-OH
1LHFH:28-120,H:233-244; H:16-27,H:121-232HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BORO-HOMOLYS-OH
1LHGH:28-120,H:233-244; H:16-27,H:121-232HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROORNITHINE-OH
1LMWB:28-120,B:233-245; B:16-27,B:121-232; D:16-27,D:121-232; D:28-120,D:233-245LMW U-PA STRUCTURE COMPLEXED WITH EGRCMK (GLU-GLY-ARG CHLOROMETHYL KETONE)
1LO6A:16-27,A:121-232; A:28-120,A:233-243HUMAN KALLIKREIN 6 (HK6) ACTIVE FORM WITH BENZAMIDINE INHIBITOR AT 1.56 A RESOLUTION
1LPGB:16-27,B:121-232; B:28-120,B:233-244CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 79.
1LPKB:16-27,B:121-232; B:28-120,B:233-244CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 125.
1LPZB:16-27,B:121-232; B:28-120,B:233-244CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 41.
1LQDB:16-27,B:121-232; B:28-120,B:233-244CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 45.
1LTOA:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244HUMAN ALPHA1-TRYPTASE
1MD7A:449-460,A:560-675; A:461-558,A:676-683MONOMERIC STRUCTURE OF THE ZYMOGEN OF COMPLEMENT PROTEASE C1R
1MD8A:447-460,A:560-675; A:461-558,A:676-683MONOMERIC STRUCTURE OF THE ACTIVE CATALYTIC DOMAIN OF COMPLEMENT PROTEASE C1R
1MH0A:28-120,A:233-243; A:16-27,A:121-232; B:16-27,B:121-232; B:28-120,B:233-243CRYSTAL STRUCTURE OF THE ANTICOAGULANT SLOW FORM OF THROMBIN
1MQ5A:16-27,A:121-232; A:28-120,A:233-243CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO-2-[[(4-CHLOROPHENYL) AMINO]CARBONYL]PHENYL]-4-[(4-METHYL-1-PIPERAZINYL)METHYL]-2-THIOPHENECARBOXAMIDE COMPLEXED WITH HUMAN FACTOR XA
1MQ6A:16-27,A:121-232; A:28-120,A:233-243CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO-2-[[(5-CHLORO-2-PYRIDINYL) AMINO]CARBONYL]-6-METHOXYPHENYL]-4-[[(4,5-DIHYDRO-2-OXAZOLYL) METHYLAMINO]METHYL]-2-THIOPHENECARBOXAMIDE COMPLEXED WITH HUMAN FACTOR XA
1MU6B:28-120,B:233-244; B:16-27,B:121-232CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH L-378,622
1MU8B:28-120,B:233-244; B:16-27,B:121-232THROMBIN-HIRUGEN_L-378,650
1MUEB:28-120,B:233-244; B:16-27,B:121-232THROMBIN-HIRUGEN-L405,426
1MZAA:28-120,A:233-245; A:16-27,A:121-232CRYSTAL STRUCTURE OF HUMAN PRO-GRANZYME K
1MZDA:28-120,A:233-245; A:16-27,A:121-232CRYSTAL STRUCTURE OF HUMAN PRO-GRANZYME K
1NFUA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR132747
1NFWA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR209685
1NFXA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208944
1NFYA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR200095
1NM6A:28-120,A:233-244; A:16-27,A:121-232THROMBIN IN COMPLEX WITH SELECTIVE MACROCYCLIC INHIBITOR AT 1.8A
1NN6A:18-27,A:123-228; A:28-122,A:229-240HUMAN PRO-CHYMASE
1NO9H:28-120,H:233-245; H:16-27,H:121-232DESIGN OF WEAKLY BASIC THROMBIN INHIBITORS INCORPORATING NOVEL P1 BINDING FUNCTIONS: MOLECULAR AND X-RAY CRYSTALLOGRAPHIC STUDIES.
1NRNH:28-120,H:233-242; H:16-27,H:121-232CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1NROH:28-120,H:233-244; H:16-27,H:121-232CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1NRPH:28-120,H:233-245; H:16-27,H:121-232CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1NRQH:28-120,H:233-238; H:16-27,H:121-232CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1NRRH:28-120,H:233-244; H:16-27,H:121-232CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1NRSH:28-120,H:233-245; H:16-27,H:121-232CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1NT1A:28-120,A:233-244; A:16-27,A:121-232THROMBIN IN COMPLEX WITH SELECTIVE MACROCYCLIC INHIBITOR
1NU7B:28-120,B:233-245; B:16-27,B:121-232; F:16-27,F:121-232; F:28-120,F:233-245STAPHYLOCOAGULASE-THROMBIN COMPLEX
1NU9D:28-120,D:233-245; A:16-27,A:121-232; D:16-27,D:121-232; A:28-120,A:233-246STAPHYLOCOAGULASE-PRETHROMBIN-2 COMPLEX
1NY22:28-120,2:233-245; 2:16-27,2:121-232HUMAN ALPHA THROMBIN INHIBITED BY RPPGF AND HIRUGEN
1NZQH:28-120,H:233-244; H:16-27,H:121-232D-PHE-PRO-ARG-TYPE THROMBIN INHIBITOR
1O0DH:28-120,H:233-244; H:16-27,H:121-232HUMAN THROMBIN COMPLEXED WITH A D-PHE-PRO-ARG-TYPE INHIBITOR AND A C-TERMINAL HIRUDIN DERIVED EXO-SITE INHIBITOR
1O2GH:28-120,H:233-245; H:16-27,H:121-232ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3PB:28-120,B:233-243; B:16-27,B:121-232ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O5AB:28-120; B:16-27,B:121-243DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
1O5BB:28-120; B:16-27,B:121-242DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
1O5CB:28-120; B:16-27,B:121-243DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
1O5DH:16-27,H:121-232; H:28-120,H:233-246DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
1O5EH:16-27,H:121-230; H:28-120,H:231-255DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
1O5FH:16-27,H:121-230; H:28-120,H:231-255DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
1O5GH:28-120,H:233-245; H:16-27,H:121-232DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
1OOKB:28-120,B:233-245; B:16-27,B:121-232CRYSTAL STRUCTURE OF THE COMPLEX OF PLATELET RECEPTOR GPIB-ALPHA AND HUMAN ALPHA-THROMBIN
1OP8A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; E:16-27,E:121-232; F:16-27,F:121-232; A:28-120,A:233-246; B:28-120,B:233-246; C:28-120,C:233-246; D:28-120,D:233-246; E:28-120,E:233-246; F:28-120,F:233-246CRYSTAL STRUCTURE OF HUMAN GRANZYME A
1OPHB:16-27,B:121-232; B:28-120,B:233-245NON-COVALENT COMPLEX BETWEEN ALPHA-1-PI-PITTSBURGH AND S195A TRYPSIN
1ORFA:16-27,A:121-232; A:28-120,A:233A-244THE OLIGOMERIC STRUCTURE OF HUMAN GRANZYME A REVEALS THE MOLECULAR DETERMINANTS OF SUBSTRATE SPECIFICITY
1OWDA:13-118,A:235-244; A:1-12,A:119-234SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1OWEA:13-131,A:249-258; A:1-12,A:132-248SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1OWHA:13-131,A:249-258; A:1-12,A:132-248SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1OWIA:13-118,A:235-244; A:1-12,A:119-234SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1OWJA:13-118,A:235-244; A:1-12,A:119-234SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1OWKA:13-118,A:235-244; A:1-12,A:119-234SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1OYTH:28-120,H:233-244; H:16-27,H:121-232COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH A DESIGNED FLUORINATED INHIBITOR
1P0SH:16-27,H:121-232; H:28-120,H:233-245CRYSTAL STRUCTURE OF BLOOD COAGULATION FACTOR XA IN COMPLEX WITH ECOTIN M84R
1P57B:16-27,B:121-230; B:28-120,B:231-254EXTRACELLULAR DOMAIN OF HUMAN HEPSIN
1P8VC:13-117,C:245-257; C:1-12,C:118-244CRYSTAL STRUCTURE OF THE COMPLEX OF PLATELET RECEPTOR GPIB-ALPHA AND ALPHA-THROMBIN AT 2.6A
1PJPA:16-27,A:121-232; A:28-120,A:233-245THE 2.2 A CRYSTAL STRUCTURE OF HUMAN CHYMASE IN COMPLEX WITH SUCCINYL-ALA-ALA-PRO-PHE-CHLOROMETHYLKETONE
1PPBH:28-120,H:233-247; H:16-27,H:121-232THE REFINED 1.9 ANGSTROMS CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN: INTERACTION WITH D-PHE-PRO-ARG CHLOROMETHYLKETONE AND SIGNIFICANCE OF THE TYR-PRO-PRO-TRP INSERTION SEGMENT
1PPFE:16-27,E:121-232; E:28-120,E:233-243X-RAY CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN LEUKOCYTE ELASTASE (PMN ELASTASE) AND THE THIRD DOMAIN OF THE TURKEY OVOMUCOID INHIBITOR
1Q3XA:459-550,A:675-682; B:459-550,B:675-682; A:445-458,A:552-674; B:445-458,B:552-674CRYSTAL STRUCTURE OF THE CATALYTIC REGION OF HUMAN MASP-2
1QBVH:28-120,H:233-244; H:16-27,H:121-232CRYSTAL STRUCTURE OF THROMBIN COMPLEXED WITH AN GUANIDINE-MIMETIC INHIBITOR
1QFKH:153-164,H:261-381; H:165-260,H:382-395STRUCTURE OF HUMAN FACTOR VIIA AND ITS IMPLICATIONS FOR THE TRIGGERING OF BLOOD COAGULATION
1QHRB:28-120,B:233-246; B:16-27,B:121-232NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
1QJ1B:28-120,B:233-246; B:16-27,B:121-232NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
1QJ6B:28-120,B:233-246; B:16-27,B:121-232NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
1QJ7B:28-120,B:233-246; B:16-27,B:121-232NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
1QRZA:574-664,A:779-791; A:562-573,A:665-778; B:562-573,B:665-778; C:562-573,C:665-778; D:562-573,D:665-778; B:574-664,B:779-791; C:574-664,C:779-791; D:574-664,D:779-791CATALYTIC DOMAIN OF PLASMINOGEN
1QURH:28-120,H:233-245; H:16-27,H:121-232HUMAN ALPHA-THROMBIN IN COMPLEX WITH BIVALENT, BENZAMIDINE-BASED SYNTHETIC INHIBITOR
1RD3B:28-120,B:233-244; B:16-27,B:121-232; D:16-27,D:121-232; D:28-120,D:233-2442.5A STRUCTURE OF ANTICOAGULANT THROMBIN VARIANT E217K
1RFNA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR IXA IN COMPLEX WITH P-AMINO BENZAMIDINE
1RIWC:185-286; B:37-183THROMBIN IN COMPLEX WITH NATURAL PRODUCT INHIBITOR OSCILLARIN
1RJXB:574-664,B:779-790; B:562-573,B:665-778HUMAN PLASMINOGEN CATALYTIC DOMAIN, K698M MUTANT
1RRKA:452-570; A:571-739CRYSTAL STRUCTURE ANALYSIS OF THE BB SEGMENT OF FACTOR B
1RS0A:452-570; A:571-739CRYSTAL STRUCTURE ANALYSIS OF THE BB SEGMENT OF FACTOR B COMPLEXED WITH DI-ISOPROPYL-PHOSPHATE (DIP)
1RTFB:28-120,B:233-242; B:16-27,B:121-232COMPLEX OF BENZAMIDINE WITH THE CATALYTIC DOMAIN OF HUMAN TWO CHAIN TISSUE PLASMINOGEN ACTIVATOR [(TC)-T-PA]
1RTKA:452-570; A:571-739CRYSTAL STRUCTURE ANALYSIS OF THE BB SEGMENT OF FACTOR B COMPLEXED WITH 4-GUANIDINOBENZOIC ACID
1SB1H:28-120,H:233-244; H:16-27,H:121-232NOVEL NON-COVALENT THROMBIN INHIBITORS INCORPORATING P1 4,5,6,7-TETRAHYDROBENZOTHIAZOLE ARGININE SIDE CHAIN MIMETICS
1SC8U:28-120,U:233-244; U:16-27,U:121-232UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-J435 COMPLEX
1SFQB:28-120,B:233-245; B:16-27,B:121-232; E:16-27,E:121-232; E:28-120,E:233-245FAST FORM OF THROMBIN MUTANT R(77A)A BOUND TO PPACK
1SG8B:28-120,B:233-245; B:16-27,B:121-232; E:16-27,E:121-232; E:28-120,E:233-245CRYSTAL STRUCTURE OF THE PROCOAGULANT FAST FORM OF THROMBIN
1SGIB:28-120,B:233-243; B:16-27,B:121-232; E:16-27,E:121-232; E:28-120,E:233-243CRYSTAL STRUCTURE OF THE ANTICOAGULANT SLOW FORM OF THROMBIN
1SHHE:28-120,E:233-244; B:16-27,B:121-232; E:16-27,E:121-232; B:28-120,B:233-245SLOW FORM OF THROMBIN BOUND WITH PPACK
1SHYA:506-596,A:712-722; A:495-505,A:597-711THE CRYSTAL STRUCTURE OF HGF BETA-CHAIN IN COMPLEX WITH THE SEMA DOMAIN OF THE MET RECEPTOR.
1SI5H:506-596,H:712-728; H:495-505,H:597-711PROTEASE-LIKE DOMAIN FROM 2-CHAIN HEPATOCYTE GROWTH FACTOR
1SL3A:28-120,A:233-244; A:16-27,A:121-232CRYSTAL STRUCTUE OF THROMBIN IN COMPLEX WITH A POTENT P1 HETEROCYCLE-ARYL BASED INHIBITOR
1SPJA:28-120,A:233-245; A:16-27,A:121-232STRUCTURE OF MATURE HUMAN TISSUE KALLIKREIN (HUMAN KALLIKREIN 1 OR KLK1) AT 1.70 ANGSTROM RESOLUTION WITH VACANT ACTIVE SITE
1SQAA:13-131,A:249-258; A:1-12,A:132-248SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1SQOA:13-131,A:249-258; A:1-12,A:132-248SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1SQTA:13-118,A:235-244; A:1-12,A:119-234SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1SR5C:28-120,C:233-243; C:16-27,C:121-232ANTITHROMBIN-ANHYDROTHROMBIN-HEPARIN TERNARY COMPLEX STRUCTURE
1T31A:16-27,A:121-232; A:28-120,A:233-245A DUAL INHIBITOR OF THE LEUKOCYTE PROTEASES CATHEPSIN G AND CHYMASE WITH THERAPEUTIC EFFICACY IN ANIMALS MODELS OF INFLAMMATION
1T32A:16-27,A:121-232; A:28-120,A:233-244A DUAL INHIBITOR OF THE LEUKOCYTE PROTEASES CATHEPSIN G AND CHYMASE WITH THERAPEUTIC EFFICACY IN ANIMALS MODELS OF INFLAMMATION
1T4UH:49-153,H:275-287; H:37-48,H:154-274CRYSTAL STRUCTURE ANALYSIS OF A NOVEL OXYGUANIDINE BOUND TO THROMBIN
1T4VH:49-153,H:275-287; H:37-48,H:154-274CRYSTAL STRUCTURE ANALYSIS OF A NOVEL OXYGUANIDINE BOUND TO THROMBIN
1TA2A:28-120,A:233-244; A:16-27,A:121-232CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH COMPOUND 1
1TA6A:28-120,A:233-244; A:16-27,A:121-232CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH COMPOUND 14B
1TB6H:28-120,H:233-245; H:16-27,H:121-2322.5A CRYSTAL STRUCTURE OF THE ANTITHROMBIN-THROMBIN-HEPARIN TERNARY COMPLEX
1TBZH:28-120,H:233-246; H:16-27,H:121-232HUMAN THROMBIN WITH ACTIVE SITE N-METHYL-D PHENYLALANYL-N-[5-(AMINOIMINOMETHYL)AMINO]-1-{{BENZOTHIAZOLYL)CARBONYL] BUTYL]-L-PROLINAMIDE TRIFLUROACETATE AND EXOSITE-HIRUGEN
1THPB:28-120,B:233-244; B:16-27,B:121-232STRUCTURE OF HUMAN ALPHA-THROMBIN Y225P MUTANT BOUND TO D-PHE-PRO-ARG-CHLOROMETHYLKETONE
1THRH:28-120,H:233-246; H:16-27,H:121-232STRUCTURES OF THROMBIN COMPLEXES WITH A DESIGNED AND A NATURAL EXOSITE INHIBITOR
1THSH:28-120,H:233-246; H:16-27,H:121-232STRUCTURES OF THROMBIN COMPLEXES WITH A DESIGNED AND A NATURAL EXOSITE INHIBITOR
1TMBH:28-120,H:233-246; H:16-27,H:121-232MOLECULAR BASIS FOR THE INHIBITION OF HUMAN ALPHA-THROMBIN BY THE MACROCYCLIC PEPTIDE CYCLOTHEONAMIDE A
1TMTH:28-120,H:233-245; H:16-27,H:121-232CHANGES IN INTERACTIONS IN COMPLEXES OF HIRUDIN DERIVATIVES AND HUMAN ALPHA-THROMBIN DUE TO DIFFERENT CRYSTAL FORMS
1TMUH:28-120,H:233-245; H:16-27,H:121-232CHANGES IN INTERACTIONS IN COMPLEXES OF HIRUDIN DERIVATIVES AND HUMAN ALPHA-THROMBIN DUE TO DIFFERENT CRYSTAL FORMS
1TOMH:28-120,H:233-245; H:16-27,H:121-232ALPHA-THROMBIN COMPLEXED WITH HIRUGEN
1TQ0B:28-120,B:233-243; D:16-27,D:121-232; B:16-27,B:121-232; D:28-120,D:233-243CRYSTAL STRUCTURE OF THE POTENT ANTICOAGULANT THROMBIN MUTANT W215A/E217A IN FREE FORM
1TQ7B:28-120,B:233-243; B:16-27,B:121-232CRYSTAL STRUCTURE OF THE ANTICOAGULANT THROMBIN MUTANT W215A/E217A BOUND TO PPACK
1TRNA:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-246; B:28-120,B:233-246CRYSTAL STRUCTURE OF HUMAN TRYPSIN 1: UNEXPECTED PHOSPHORYLATION OF TYROSINE 151
1TWXB:28-120,B:233-246; B:16-27,B:121-232CRYSTAL STRUCTURE OF THE THROMBIN MUTANT D221A/D222K
1U6QA:13-118,A:235-244; A:1-12,A:119-234SUBSTITUTED 2-NAPHTHAMADINE INHIBITORS OF UROKINASE
1UMAH:28-120,H:233-246; H:16-27,H:121-232ALPHA-THROMBIN (HIRUGEN) COMPLEXED WITH NA-(N,N-DIMETHYLCARBAMOYL)-ALPHA-AZALYSINE
1UVSH:28-120,H:233-237; H:16-27,H:121-232BOVINE THROMBIN--BM51.1011 COMPLEX
1V3XA:16-27,A:121-232; A:28-120,A:233-243FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-[6-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO(5,4-C)PYRIDIN-2-YL] CARBONYL-2-CARBAMOYL-4-(6-CHLORONAPHTH-2-YLSULPHONYL)PIPERAZINE
1VJ9U:28-120,U:233-244; U:16-27,U:121-232UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-JT464 COMPLEX
1VJAU:28-120,U:233-244; U:16-27,U:121-232UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-JT463 COMPLEX
1VR1H:28-120,H:233-241; H:16-27,H:121-232SPECIFITY FOR PLASMINOGEN ACTIVATOR INHIBITOR-1
1VZQH:28-120,H:233-255; H:16-27,H:121-232COMPLEX OF THROMBIN WITH DESIGNED INHIBITOR 7165
1W0YH:16-27,H:121-232; H:28-120,H:233-246TF7A_3771 COMPLEX
1W2KH:16-27,H:121-232; H:28-120,H:233-246TF7A_4380 COMPLEX
1W7GH:28-120,H:233-247; H:16-27,H:121-232ALPHA-THROMBIN COMPLEX WITH SULFATED HIRUDIN (RESIDUES 54-65) AND L-ARGININE TEMPLATE INHIBITOR CS107
1W7XH:16-27,H:121-232; H:28-120,H:233-246FACTOR7 - 413 COMPLEX
1W8BH:16-27,H:121-232; H:28-120,H:233-246FACTOR7 - 413 COMPLEX
1WAYB:28-120,B:233-246; B:16-27,B:121-232ACTIVE SITE THROMBIN INHIBITORS
1WBGB:28-120,B:233-246; B:16-27,B:121-232ACTIVE SITE THROMBIN INHIBITORS
1WQVH:16-27,H:121-232; H:28-120,H:233-246HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH PROPYLSULFONAMIDE-D-THR-MET-P-AMINOBENZAMIDINE
1WSSH:16-27,H:121-232; H:28-120,H:233-246HUMAN FACTOR VIIA-TISSUE FACTOR IN COMPLEX WITH PEPTIDE-MIMETIC INHIBITOR THAT HAS TWO CHARGED GROUPS IN P2 AND P4
1WTGH:16-27,H:121-232; H:28-120,H:233-246HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-BIPHENYLALANINE-GLN-P-AMINOBENZAMIDINE
1WU1A:16-27,A:121-232; A:28-120,A:233-243FACTOR XA IN COMPLEX WITH THE INHIBITOR 4-[(5-CHLOROINDOL-2-YL) SULFONYL]-2-(2-METHYLPROPYL)-1-[[5-(PYRIDIN-4-YL) PYRIMIDIN-2-YL]CARBONYL]PIPERAZINE
1WUNH:16-27,H:121-232; H:28-120,H:233-246HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-TRP-GLN-P-AMINOBENZAMIDINE
1WV7H:16-27,H:121-232; H:28-120,H:233-246HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-5-PROPOXY-TRP-GLN-P-AMINOBENZAMIDINE
1XKAC:16-27,C:121-232; C:28-120,C:233-245FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S)-(3'-AMIDINO-3-BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID
1XKBC:16-27,C:121-232; C:28-120,C:233-245; D:28-120,D:233-244; D:16-27,D:121-232FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S)-(3'-AMIDINO-3-BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID
1XM1A:28-120,A:233-245; A:16-27,A:121-232NONBASIC THROMBIN INHIBITOR COMPLEX
1XMNB:28-120,B:233-246; F:16-27,F:121-232; H:16-27,H:121-232; D:16-27,D:121-232; B:16-27,B:121-232; D:28-120,D:233-246; F:28-120,F:233-246; H:28-120,H:233-246CRYSTAL STRUCTURE OF THROMBIN BOUND TO HEPARIN
1XX9B:28-121,B:234-245; A:28-121,A:234-244; B:16-27,B:122-233; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE FXIA CATALYTIC DOMAIN IN COMPLEX WITH ECOTINM84R
1XXDA:28-121,A:234-245; B:28-121,B:234-245; A:16-27,A:122-233; B:16-27,B:122-233CRYSTAL STRUCTURE OF THE FXIA CATALYTIC DOMAIN IN COMPLEX WITH MUTATED ECOTIN
1XXFA:28-121,A:234-244; B:28-121,B:234-244; A:16-27,A:122-233; B:16-27,B:122-233CRYSTAL STRUCTURE OF THE FXIA CATALYTIC DOMAIN IN COMPLEX WITH ECOTIN MUTANT (ECOTINP)
1YBWA:408-419,A:520-633; B:408-419,B:520-633; A:420-519,A:634-645; B:420-519,B:634-645PROTEASE DOMAIN OF HGFA WITH NO INHIBITOR
1YC0A:408-419,A:520-633; A:420-519,A:634-646SHORT FORM HGFA WITH FIRST KUNITZ DOMAIN FROM HAI-1
1YGCH:16-27,H:121-232; H:28-120,H:233-246SHORT FACTOR VIIA WITH A SMALL MOLECULE INHIBITOR
1YPEH:28-120,H:233-244; H:16-27,H:121-232THROMBIN INHIBITOR COMPLEX
1YPGH:28-120,H:233-244; H:16-27,H:121-232THROMBIN INHIBITOR COMPLEX
1YPJH:28-120,H:233-244; H:16-27,H:121-232THROMBIN INHIBITOR COMPLEX
1YPKH:28-120,H:233-244; H:16-27,H:121-232THROMBIN INHIBITOR COMPLEX
1YPLH:28-120,H:233-244; H:16-27,H:121-232X-RAY CRYSTAL STRUCTURE OF THROMBIN INHIBITED BY SYNTHETIC CYANOPEPTIDE ANALOGUE RA-1008
1YPMH:28-120,H:233-244; H:16-27,H:121-232X-RAY CRYSTAL STRUCTURE OF THROMBIN INHIBITED BY SYNTHETIC CYANOPEPTIDE ANALOGUE RA-1014
1Z6EA:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3'-AMINO-1,2-BENZISOXAZOL-5'-YL)-N-(4-(2'-((DIMETHYLAMINO)METHYL)-1H-IMIDAZOL-1-YL)-2-FLUOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE (RAZAXABAN; DPC906; BMS-561389)
1Z6JH:16-27,H:121-232; H:28-120,H:233-246CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF FACTOR VIIA/TISSUE FACTOR/PYRAZINONE INHIBITOR
1Z71A:28-120,A:233-244; A:16-27,A:121-232THROMBIN AND P2 PYRIDINE N-OXIDE INHIBITOR COMPLEX STRUCTURE
1Z8GA:163-174,A:276-392; A:175-275,A:393-417CRYSTAL STRUCTURE OF THE EXTRACELLULAR REGION OF THE TRANSMEMBRANE SERINE PROTEASE HEPSIN WITH COVALENTLY BOUND PREFERRED SUBSTRATE.
1Z8IB:28-120,B:233-245; B:16-27,B:121-232CRYSTAL STRUCTURE OF THE THROMBIN MUTANT G193A BOUND TO PPACK
1Z8JB:28-120,B:233-245; B:16-27,B:121-232CRYSTAL STRUCTURE OF THE THROMBIN MUTANT G193P BOUND TO PPACK
1ZGIA:28-120,A:233-244; A:16-27,A:121-232THROMBIN IN COMPLEX WITH AN OXAZOLOPYRIDINE INHIBITOR 21
1ZGVA:28-120,A:233-244; A:16-27,A:121-232THROMBIN IN COMPLEX WITH AN OXAZOLOPYRIDINE INHIBITOR 2
1ZHMA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE COAGULATION FACTOR XIA IN COMPLEX WITH BENZAMIDINE (S434A-T475A-K437 MUTANT)
1ZHPA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH BENZAMIDINE (S434A-T475A-K505 MUTANT)
1ZHRA:28-121,A:234-245; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH BENZAMIDINE (S434A-T475A-C482S-K437A MUTANT)
1ZJDA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH KUNITZ PROTEASE INHIBITOR DOMAIN OF PROTEASE NEXIN II
1ZLRA:28-121,A:234-244; A:16-27,A:122-233FACTOR XI CATALYTIC DOMAIN COMPLEXED WITH 2-GUANIDINO-1-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)ETHYL NICOTINATE
1ZMJA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FACTOR XI IN COMPLEX WITH 4-(GUANIDINOMETHYL)-PHENYLBORONIC ACID
1ZMLA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FACTOR XI IN COMPLEX WITH (R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)PHENETHYL)GUANIDINE
1ZMNA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH (R)-1-(4-(4-(HYDROXYMETHYL)-1,3, 2-DIOXABOROLAN-2-YL)PHENYL)GUANIDINE
1ZOMA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH A PEPTIDOMIMETIC INHIBITOR
1ZPBA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH 4-METHYL-PENTANOIC ACID {1-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYLCARBAMOYL]-2-METHYL-PROPYL}-AMIDE
1ZPCA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH 2-[2-(3-CHLORO-PHENYL)-2-HYDROXY-ACETYLAMINO]-N-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYL]-3-METHYL-BUTYRAMIDE
1ZPZA:28-121,A:234-244; A:16-27,A:122-233FACTOR XI CATALYTIC DOMAIN COMPLEXED WITH N-((R)-1-(4-BROMOPHENYL)ETHYL)UREA-ASN-VAL-ARG-ALPHA-KETOTHIAZOLE
1ZRBA:28-120,A:233-244; A:16-27,A:121-232THROMBIN IN COMPLEX WITH AN AZAFLUORENYL INHIBITOR 23B
1ZRKA:28-121,A:234-244; A:16-27,A:122-233FACTOR XI COMPLEXED WITH 3-HYDROXYPROPYL 3-(7-AMIDINONAPHTHALENE-1-CARBOXAMIDO)BENZENESULFONATE
1ZSJA:28-121,A:234-245; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH N-(7-CARBAMIMIDOYL-NAPHTHALEN-1-YL)-3-HYDROXY-2-METHYL-BENZAMIDE
1ZSKA:28-121,A:234-245; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH 6-CARBAMIMIDOYL-4-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-NAPHTHALENE-2-CARBOXYLIC ACID METHYL ESTER
1ZSLA:28-121,A:234-244; A:16-27,A:122-233FACTOR XI COMPLEXED WITH A PYRIMIDINONE INHIBITOR
1ZTJA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH 2-(5-BENZYLAMINO-2-METHYLSULFANYL-6-OXO-6H-PYRIMIDIN-1-YL)-N-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYL]-ACETAMIDE
1ZTKA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH 2-(5-AMINO-6-OXO-2-M-TOLYL-6H-PYRIMIDIN-1-YL)-N-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYL]-ACETAMIDE
1ZTLA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH N-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYL]-2-{6-OXO-5-[(QUINOLIN-8-YLMETHYL)-AMINO]-2-M-TOLYL-6H-PYRIMIDIN-1-YL}-ACETAMIDE
2A0QB:28-120,B:233-244; B:16-27,B:121-232; D:16-27,D:121-232; D:28-120,D:233-244STRUCTURE OF THROMBIN IN 400 MM POTASSIUM CHLORIDE
2A2QH:16-27,H:121-232; H:28-120,H:233-246COMPLEX OF ACTIVE-SITE INHIBITED HUMAN COAGULATION FACTOR VIIA WITH HUMAN SOLUBLE TISSUE FACTOR IN THE PRESENCE OF CA2+, MG2+, NA+, AND ZN2+
2A2XH:28-120,H:233-245; H:16-27,H:121-232ORALLY ACTIVE THROMBIN INHIBITORS IN COMPLEX WITH THROMBIN INH12
2A45B:28-120,B:233-246; B:16-27,B:121-232; E:16-27,E:121-232; E:28-120,E:233-246CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THROMBIN AND THE CENTRAL "E" REGION OF FIBRIN
2AEIH:16-27,H:121-232; H:28-120,H:233-246CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF FACTOR VIIA/TISSUE FACTOR AND 2-[[6-[3-(AMINOIMINOMETHYL)PHENOXY]-3,5-DIFLURO-4-[(1-METHYL-3-PHENYLPROPYL)AMINO]-2-PYRIDINYL]OXY]-BENZOIC ACID
2AERH:16-27,H:121-232; H:28-120,H:233-246CRYSTAL STRUCTURE OF BENZAMIDINE-FACTOR VIIA/SOLUBLE TISSUE FACTOR COMPLEX.
2AFQD:28-120,D:233-244; D:16-27,D:121-232; B:16-27,B:121-232; B:28-120,B:233-2461.9 ANGSTROM CRYSTAL STRUCTURE OF WILD-TYPE HUMAN THROMBIN IN THE SODIUM FREE STATE
2ANKH:28-120,H:233-245; H:16-27,H:121-232ORALLY ACTIVE THROMBIN INHIBITORS IN COMPLEX WITH THROMBIN AND AN EXOSITE DECAPEPTIDE
2ANMH:28-120,H:233-244; H:16-27,H:121-232TERNARY COMPLEX OF AN ORALLY ACTIVE THROMBIN INHIBITOR WITH HUMAN THROMBIN AND A C-TERMINAL HIRUDIN DERIVED EXO-SIT INHIBITOR
2ANWA:28-120,A:234-245; A:16-27,A:121-233EXPRESSION, CRYSTALLIZATION AND THREE-DIMENSIONAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PLASMA KALLIKREIN: IMPLICATIONS FOR STRUCTURE-BASED DESIGN OF PROTEASE INHIBITORS
2ANYA:28-120,A:234-245; A:16-27,A:121-233EXPRESSION, CRYSTALLIZATION AND THE THREE-DIMENSIONAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PLASMA KALLIKREIN: IMPLICATIONS FOR STRUCTURE-BASED DESIGN OF PROTEASE INHIBITORS
2ASUB:484-492,B:587-699; B:493-586,B:700-708CRYSTAL STRUCTURE OF THE BETA-CHAIN OF HGFL/MSP
2B5TB:28-120,B:233-245; B:16-27,B:121-232; D:16-27,D:121-232; D:28-120,D:233-2452.1 ANGSTROM STRUCTURE OF A NONPRODUCTIVE COMPLEX BETWEEN ANTITHROMBIN, SYNTHETIC HEPARIN MIMETIC SR123781 AND TWO S195A THROMBIN MOLECULES
2B7DH:16-27,H:121-232; H:28-120,H:233-246FACTOR VIIA INHIBITORS: CHEMICAL OPTIMIZATION, PRECLINICAL PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY IN A BABOON THROMBOSIS MODEL
2B8OH:16-27,H:121-232; H:28-120,H:233-246CRYSTAL STRUCTURE OF GLU-GLY-ARG-CHLOROMETHYL KETONE-FACTOR VIIA/SOLUBLE TISSUE FACTOR COMPLEX
2BDGA:16-27,A:121-234; B:16-27,B:121-234; A:28-120,A:235-244; B:28-120,B:235-244HUMAN KALLIKREIN 4 COMPLEX WITH NICKEL AND P-AMINOBENZAMIDINE
2BDHA:16-27,A:121-234; B:16-27,B:121-234; C:16-27,C:121-234; D:16-27,D:121-234; A:28-120,A:235-244; B:28-120,B:235-244; C:28-120,C:235-244; D:28-120,D:235-244HUMAN KALLIKREIN 4 COMPLEX WITH ZINC AND P-AMINOBENZAMIDINE
2BDIA:16-27,A:121-234; B:16-27,B:121-234; C:16-27,C:121-234; D:16-27,D:121-234; E:16-27,E:121-234; F:16-27,F:121-234; G:16-27,G:121-234; H:16-27,H:121-234; I:16-27,I:121-234; J:16-27,J:121-234; K:16-27,K:121-234; L:16-27,L:121-234; M:16-27,M:121-234; N:16-27,N:121-234; O:16-27,O:121-234; P:16-27,P:121-234; A:28-120,A:235-244; B:28-120,B:235-244; C:28-120,C:235-244; D:28-120,D:235-244; E:28-120,E:235-244; F:28-120,F:235-244; G:28-120,G:235-244; H:28-120,H:235-244; I:28-120,I:235-244; J:28-120,J:235-244; K:28-120,K:235-244; L:28-120,L:235-244; M:28-120,M:235-244; N:28-120,N:235-244; O:28-120,O:235-244; P:28-120,P:235-244HUMAN KALLIKREIN 4 COMPLEX WITH COBALT AND P-AMINOBENZAMIDINE
2BDYA:49-153,A:275-286; A:37-48,A:154-274THROMBIN IN COMPLEX WITH INHIBITOR
2BM2A:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244HUMAN BETA-II TRYPTASE IN COMPLEX WITH 4-(3-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL-(5-PHENETHYL- PYRIDIN-3-YL)-METHANONE
2BMGB:16-27,B:121-232; B:28-120,B:233-244CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 50
2BOHB:16-27,B:121-232; B:28-120,B:233-245CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH COMPOUND "1"
2BOKA:16-27,A:121-232; A:28-120,A:233-244FACTOR XA - CATION
2BQ6B:16-27,B:121-232; B:28-120,B:233-244CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 21
2BQ7B:16-27,B:121-232; B:28-120,B:233-244CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 43
2BQWB:16-27,B:121-232; B:28-120,B:233-244CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH COMPOUND 45
2BVRH:28-120,H:233-243; H:16-27,H:121-232HUMAN THROMBIN COMPLEXED WITH FRAGMENT-BASED SMALL MOLECULES OCCUPYING THE S1 POCKET
2BZ6H:16-27,H:121-232; H:28-120,H:233-246ORALLY AVAILABLE FACTOR7A INHIBITOR
2C8WB:28-120,B:233-246; B:16-27,B:121-232THROMBIN INHIBITORS
2C8XB:28-120,B:233-246; B:16-27,B:121-232THROMBIN INHIBITORS
2C8YB:28-120,B:233-246; B:16-27,B:121-232THROMBIN INHIBITORS
2C8ZB:28-120,B:233-246; B:16-27,B:121-232THROMBIN INHIBITORS
2C90B:28-120,B:233-246; B:16-27,B:121-232THROMBIN INHIBITORS
2C93B:28-120,B:233-246; B:16-27,B:121-232THROMBIN INHIBITORS
2CF8H:28-120,H:233-244; H:16-27,H:121-232COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH AN INHIBITOR
2CF9H:28-120,H:233-244; H:16-27,H:121-232COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH AN INHIBITOR
2CJIA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2CN0H:28-120,H:233-244; H:16-27,H:121-232COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH A DESIGNED INHIBITOR
2D1JA:16-27,A:121-232; A:28-120,A:233-243FACTOR XA IN COMPLEX WITH THE INHIBITOR 2-[[4-[(5-CHLOROINDOL-2-YL)SULFONYL]PIPERAZIN-1-YL] CARBONYL]THIENO[3,2-B]PYRIDINE N-OXIDE
2D26C:28-120,C:233-245; C:20-27,C:121-232ACTIVE SITE DISTORTION IS SUFFICIENT FOR PROTEINASE INHIBIT SECOND CRYSTAL STRUCTURE OF COVALENT SERPIN-PROTEINASE COMPLEX
2EC9H:16-27,H:121-232; H:28-120,H:233-246CRYSTAL STRUCTURE ANALYSIS OF HUMAN FACTOR VIIA , SOULUBLE TISSUE FACTOR COMPLEXED WITH BCX-3607
2EI6A:16-27,A:121-232; A:28-120,A:233-243FACTOR XA IN COMPLEX WITH THE INHIBITOR (-)-CIS-N1-[(5-CHLOROINDOL-2-YL)CARBONYL]-N2-[(5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDIN-2-YL)CARBONYL]-1,2-CYCLOHEXANEDIAMINE
2EI7A:16-27,A:121-232; A:28-120,A:233-243FACTOR XA IN COMPLEX WITH THE INHIBITOR TRANS-N1-[(5-CHLOROINDOL-2-YL)CARBONYL]-N2-[(5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDIN-2-YL)CARBONYL]-1,2-CYCLOHEXANEDIAMINE
2EI8A:16-27,A:121-232; A:28-120,A:233-243FACTOR XA IN COMPLEX WITH THE INHIBITOR (1S,2R,4S)-N1-[(5-CHLOROINDOL-2-YL)CARBONYL]-4-(N,N-DIMETHYLCARBAMOYL)-N2-[(5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDIN-2-YL) CARBONYL]-1,2-CYCLOHEXANEDIAMINE
2F9BH:16-27,H:121-232; H:28-120,H:233-246DISCOVERY OF NOVEL HETEROCYCLIC FACTOR VIIA INHIBITORS
2F9NA:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT K192Q/D216G IN COMPLEX WITH LEUPEPTIN
2F9OC:28-120,C:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; D:28-120,D:233-244; A:28-120,A:233-243; B:28-120,B:233-243CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT D216G
2F9PA:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-243CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT D216G IN COMPLEX WITH LEUPEPTIN
2FDAA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN COAGULATION FACTOR XIA IN COMPLEX WITH ALPHA-KETOTHIAZOLE ARGININE DERIVED LIGAND
2FEQH:28-120,H:233-245; H:16-27,H:121-232ORALLY ACTIVE THROMBIN INHIBITORS
2FESH:28-120,H:233-245; H:16-27,H:121-232ORALLY ACTIVE THROMBIN INHIBITORS
2FIRH:16-27,H:121-232; H:28-120,H:233-246CRYSTAL STRUCTURE OF DFPR-VIIA/STF
2FLBH:16-27,H:121-232; H:28-120,H:233-246DISCOVERY OF A NOVEL HYDROXY PYRAZOLE BASED FACTOR IXA INHIBITOR
2FLRH:16-27,H:121-232; H:28-120,H:233-246NOVEL 5-AZAINDOLE FACTOR VIIA INHIBITORS
2FPZA:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244HUMAN TRYPTASE WITH 2-AMINO BENZIMIDAZOLE
2FS8A:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244HUMAN BETA-TRYPTASE II WITH INHIBITOR CRA-29382
2FS9A:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244HUMAN BETA TRYPTASE II WITH INHIBITOR CRA-28427
2FWWA:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244HUMAN BETA-TRYPTASE II COMPLEXED WITH 4-PIPERIDINEBUTYRATE TO MAKE ACYLENZYME
2FXRA:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244HUMAN BETA TRYPTASE II COMPLEXED WITH ACTIVATED KETONE INHIBITOR CRA-29382
2FZZA:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3-AMINO-1,2-BENZISOXAZOL-5-YL)-6-(2'-(((3R)-3-HYDROXY-1-PYRROLIDINYL) METHYL)-4-BIPHENYLYL)-3-(TRIFLUOROMETHYL)-1,4,5,6-TETRAHYDRO-7H-PYRAZOLO[3,4-C]PYRIDIN-7-ONE
2G00A:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR 3-(6-(2'-((DIMETHYLAMINO)METHYL)-4-BIPHENYLYL)-7-OXO-3-(TRIFLUOROMETHYL)-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-1-YL)BENZAMIDE
2GD4B:16-27,B:121-232; H:16-27,H:121-232; B:28-120,B:233-249; H:28-120,H:233-244CRYSTAL STRUCTURE OF THE ANTITHROMBIN-S195A FACTOR XA-PENTASACCHARIDE COMPLEX
2GDDA:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244HUMAN BETA II TRYPTASE WITH INHIBITOR CRA-27592
2GDEH:28-120,H:233-244; H:16-27,H:121-232THROMBIN IN COMPLEX WITH INHIBITOR
2GP9B:28-120,B:233-245; B:16-27,B:121-232CRYSTAL STRUCTURE OF THE SLOW FORM OF THROMBIN IN A SELF-INHIBITED CONFORMATION
2GV6A:28-120,A:233-244; A:16-27,A:121-232CRYSTAL STRUCTURE OF MATRIPTASE WITH INHIBITOR CJ-730
2GV7A:28-120,A:233-244; A:16-27,A:121-232STRUCTURE OF MATRIPTASE IN COMPLEX WITH INHIBITOR CJ-672
2H9EH:16-27,H:121-232; H:28-120,H:233-243CRYSTAL STRUCTURE OF FXA/SELECTIDE/NAPC2 TERNARY COMPLEX
2H9TH:28-120,H:233-246; H:16-27,H:121-232CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN IN COMPLEX WITH SURAMIN
2HGTH:28-120,H:233-246; H:16-27,H:121-232STRUCTURE OF THE HIRUGEN AND HIRULOG 1 COMPLEXES OF ALPHA-THROMBIN
2HNTF:152-244; C:16-72; E:80-142CRYSTALLOGRAPHIC STRUCTURE OF HUMAN GAMMA-THROMBIN
2HPPH:28-120,H:233-245; H:16-27,H:121-232STRUCTURES OF THE NONCOVALENT COMPLEXES OF HUMAN AND BOVINE PROTHROMBIN FRAGMENT 2 WITH HUMAN PPACK-THROMBIN
2HPQH:28-120,H:233-245; H:16-27,H:121-232STRUCTURES OF THE NONCOVALENT COMPLEXES OF HUMAN AND BOVINE PROTHROMBIN FRAGMENT 2 WITH HUMAN PPACK-THROMBIN
2HVXA:16-27,A:121-232; A:28-120,A:233-245DISCOVERY OF POTENT, ORALLY ACTIVE, NONPEPTIDE INHIBITORS OF HUMAN MAST CELL CHYMASE BY USING STRUCTURE-BASED DRUG DESIGN
2HWLB:28-120,B:233-245; B:16-27,B:121-232; D:16-27,D:121-232; D:28-120,D:233-245CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH FIBRINOGEN GAMMA' PEPTIDE
2J2UA:16-27,A:121-232; A:28-120,A:233-243CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2J34A:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2J38A:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2J4IA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2J94A:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2J95A:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2JH0D:28-120,D:233-246; D:16-27,D:121-232HUMAN THROMBIN HIRUGEN INHIBITOR COMPLEX
2JH5D:28-120,D:233-246; D:16-27,D:121-232HUMAN THROMBIN HIRUGEN INHIBITOR COMPLEX
2JH6D:28-120,D:233-246; D:16-27,D:121-232HUMAN THROMBIN HIRUGEN INHIBITOR COMPLEX
2JKHA:16-27,A:121-232; A:28-120,A:233-244FACTOR XA - CATION INHIBITOR COMPLEX
2NWNA:28-120,A:233-243; A:16-27,A:121-232NEW PHARMACOPHORE FOR SERINE PROTEASE INHIBITION REVEALED BY CRYSTAL STRUCTURE OF HUMAN UROKINASE-TYPE PLASMINOGEN ACTIVATOR COMPLEXED WITH A CYCLIC PEPTIDYL INHIBITOR, UPAIN-1
2O8TA:28-120,A:233-242; A:16-27,A:121-232CRYSTAL STRUCTURE AND BINDING EPITOPES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (C122A/N145Q) IN COMPLEX WITH INHIBITORS
2O8UA:28-120,A:233-242; A:16-27,A:121-232CRYSTAL STRUCTURE AND BINDING EPITOPES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (C122A/N145Q/S195A) IN COMPLEX WITH INHIBITORS
2O8WA:28-120,A:233-242; A:16-27,A:121-232CRYSTAL STRUCTURE AND BINDING EPITOPES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (C122A/N145Q/S195A) IN COMPLEX WITH INHIBITORS
2OD3B:28-120,B:233-244; B:16-27,B:121-232HUMAN THROMBIN CHIMERA WITH HUMAN RESIDUES 184A, 186, 186A, 186B, 186C AND 222 REPLACED BY MURINE THROMBIN EQUIVALENTS.
2OQ5A:28-120,A:233-244; A:16-27,A:121-232CRYSTAL STRUCTURE OF DESC1, A NEW MEMBER OF THE TYPE II TRANSMEMBRANE SERINE PROTEINASES FAMILY
2P16A:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR APIXABAN (BMS-562247) AKA 1-(4-METHOXYPHENYL)-7-OXO-6-(4-(2-OXO-1-PIPERIDINYL)PHENYL)-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3, 4-C]PYRIDINE-3-CARBOXAMIDE
2P3FH:16-27,H:121-232; H:28-120,H:233-245CRYSTAL STRUCTURE OF THE FACTOR XA/NAP5 COMPLEX
2P3TB:16-27,B:121-232; B:28-120,B:233-243CRYSTAL STRUCTURE OF HUMAN FACTOR XA COMPLEXED WITH 3-CHLORO-4-(2-METHYLAMINO-IMIDAZOL-1-YLMETHYL)-THIOPHENE-2-CARBOXYLIC ACID [4-CHLORO-2-(5-CHLORO-PYRIDIN-2-YLCARBAMOYL)-6-METHOXY-PHENYL]-AMIDE
2P3UB:16-27,B:121-232; B:28-120,B:233-243CRYSTAL STRUCTURE OF HUMAN FACTOR XA COMPLEXED WITH 3-CHLORO-N-(4-CHLORO-2-{[(5-CHLOROPYRIDIN-2-YL) AMINO]CARBONYL}-6-METHOXYPHENYL)-4-[(1-METHYL-1H-IMIDAZOL-2-YL)METHYL]THIOPHENE-2-CARBOXAMIDE {PFIZER 320663}
2P93A:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR 5-CHLORO-N-(2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO)ETHYL)THIOPHENE-2-CARBOXAMIDE
2P94A:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR 3-CHLORO-N-((1R,2S)-2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO)CYCLOHEXYL)-1H-INDOLE-6-CARBOXAMIDE
2P95A:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR 5-CHLORO-N-((1R,2S)-2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO) CYCLOPENTYL) THIOPHENE-2-CARBOXAMIDE
2PGBB:28-120,B:233-245; B:16-27,B:121-232INHIBITOR-FREE HUMAN THROMBIN MUTANT C191A-C220A
2PGQB:28-120,B:233-245; B:16-27,B:121-232HUMAN THROMBIN MUTANT C191A-C220A IN COMPLEX WITH THE INHIBITOR PPACK
2PHBA:16-27,A:121-232; A:28-120,A:233-244AN ORALLY EFFICACIOUS FACTOR XA INHIBITOR
2PKSC:185-286; B:37-183THROMBIN IN COMPLEX WITH INHIBITOR
2PR3A:16-27,A:121-232; A:28-120,A:233-244FACTOR XA INHIBITOR
2PSXA:16-27,A:121-234; A:28-120,A:235-246CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 5 IN COMPLEX WITH LEUPEPTIN
2PSYA:16-27,A:121-234; A:28-120,A:235-246CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 5 IN COMPLEX WITH LEUPEPTIN AND ZINC
2PUQH:153-164,H:261-381; H:165-260,H:382-395CRYSTAL STRUCTURE OF ACTIVE SITE INHIBITED COAGULATION FACTOR VIIA IN COMPLEX WITH SOLUBLE TISSUE FACTOR
2PW8H:28-120,H:233-245; H:16-27,H:121-232CRYSTAL STRUCTURE OF SULFO-HIRUDIN COMPLEXED TO THROMBIN
2Q1JA:16-27,A:121-232; A:28-120,A:233-244THE DISCOVERY OF GLYCINE AND RELATED AMINO ACID-BASED FACTOR XA INHIBITORS
2QXGA:16-27,A:121-234; B:16-27,B:121-234; A:28-120,A:235-246; B:28-120,B:235-246CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 7 IN COMPLEX WITH ALA-ALA-PHE-CHLOROMETHYLKETONE
2QXHA:16-27,A:121-234; A:28-120,A:235-246CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 7 IN COMPLEX WITH SUC-ALA-ALA-PRO-PHE-CHLOROMETHYLKETONE
2QXIA:16-27,A:121-234; A:28-120,A:235-246HIGH RESOLUTION STRUCTURE OF HUMAN KALLIKREIN 7 IN COMPLEX WITH SUC-ALA-ALA-PRO-PHE-CHLOROMETHYLKETONE
2QXJA:16-27,A:121-234; A:28-120,A:235-246CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 7 IN COMPLEX WITH SUC-ALA-ALA-PRO-PHE-CHLOROMETHYLKETONE AND COPPER
2QY0B:447-458,B:559-674; D:447-458,D:559-674; D:459-558,D:675-686; B:459-558,B:675-686ACTIVE DIMERIC STRUCTURE OF THE CATALYTIC DOMAIN OF C1R REVEALS ENZYME-PRODUCT LIKE CONTACTS
2R0KA:16-27,A:121-230; A:28-120,A:231-243PROTEASE DOMAIN OF HGFA WITH INHIBITOR FAB58
2R2MB:49-153,B:275-287; B:37-48,B:154-2742-(2-CHLORO-6-FLUOROPHENYL)ACETAMIDES AS POTENT THROMBIN INHIBITORS
2R2WU:28-120,U:233-244; U:16-27,U:121-232UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-GPPE COMPLEX
2R9PA:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; A:28-120,A:233-245; B:28-120,B:233-245; C:28-120,C:233-245; D:28-120,D:233-245HUMAN MESOTRYPSIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR(BPTI)
2RA0A:16-27,A:121-232; A:28-120,A:233-244X-RAY STRUCTURE OF FXA IN COMPLEX WITH 7-FLUOROINDAZOLE
2RA3A:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-246; B:28-120,B:233-246HUMAN CATIONIC TRYPSIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
2RG3A:16-27,A:121-232; A:28-120,A:233-243COVALENT COMPLEX STRUCTURE OF ELASTASE
2THFB:28-120,B:233-244; B:16-27,B:121-232STRUCTURE OF HUMAN ALPHA-THROMBIN Y225F MUTANT BOUND TO D-PHE-PRO-ARG-CHLOROMETHYLKETONE
2UUFB:28-120,B:233-246; B:16-27,B:121-232THROMBIN-HIRUGEN BINARY COMPLEX AT 1.26A RESOLUTION
2UUJB:28-120,B:233-246; B:16-27,B:121-232THROMBIN-HIRUGEN-GW473178 TERNARY COMPLEX AT 1.32A RESOLUTION
2UUKB:28-120,B:233-246; B:16-27,B:121-232THROMBIN-HIRUGEN-GW420128 TERNARY COMPLEX AT 1.39A RESOLUTION
2UWLA:16-27,A:121-232; A:28-120,A:233-244SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND FACTOR XA
2UWOA:16-27,A:121-232; A:28-120,A:233-244SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND FACTOR XA
2UWPA:16-27,A:121-232; A:28-120,A:233-245FACTOR XA INHIBITOR COMPLEX
2V3HH:28-120,H:233-244; H:16-27,H:121-232THROMBIN WITH 3-CYCLE NO F
2V3OH:28-120,H:233-244; H:16-27,H:121-232THROMBIN WITH 3-CYCLE WITH F
2VH0A:16-27,A:121-232; A:28-120,A:233-244STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: BIARYL PYRROLIDIN-2-ONES INCORPORATING BASIC HETEROCYCLIC MOTIFS
2VH6A:16-27,A:121-232; A:28-120,A:233-244STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH BIARYL P4 MOTIFS
2VINA:28-120,A:233-245; A:16-27,A:121-232FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2VIOA:28-120,A:233-245; A:16-27,A:121-232FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2VIPA:28-120,A:233-245; A:16-27,A:121-232FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2VIQA:28-120,A:233-245; A:16-27,A:121-232FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2VIVA:28-120,A:233-245; A:16-27,A:121-232FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2VIWA:28-120,A:233-245; A:16-27,A:121-232FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2VNTA:22-128,A:245-254; A:10-21,A:129-244; B:10-21,B:129-244; D:10-21,D:129-244; E:10-21,E:129-244; C:8-21,C:129-244; F:8-21,F:129-244; B:22-128,B:245-254; C:22-128,C:245-254; D:22-128,D:245-254; E:22-128,E:245-254; F:22-128,F:245-254UROKINASE-TYPE PLASMINOGEN ACTIVATOR INHIBITOR COMPLEX WITH A 1-(7-SULPHOAMIDOISOQUINOLINYL)GUANIDINE
2VVCA:16-27,A:121-232; A:28-120,A:233-243; B:28-120,B:233-243; B:16-27,B:121-232AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VVUA:16-27,A:121-232; A:28-120,A:233-244AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VVVA:16-27,A:121-232; A:28-120,A:233-244AMINOPYRROLIDINE-RELATED TRIAZOLE FACTOR XA INHIBITOR
2VWLA:16-27,A:121-232; A:28-120,A:233-245AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VWMA:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-243; B:28-120,B:233-243AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VWNA:16-27,A:121-232; A:28-120,A:233-245AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VWOA:16-27,A:121-232; A:28-120,A:233-245AMINOPYRROLIDINE FACTOR XA INHIBITOR
2W26A:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH BAY59-7939
2W3IA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 4,4-DISUBSTITUTED PYRROLIDINE-1,2-DICARBOXAMIDE INHIBITOR 2
2W3KA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 4,4-DISUBSTITUTED PYRROLIDINE-1,2-DICARBOXAMIDE INHIBITOR 1
2WPHS:16-27,S:121-232; S:28-120,S:233-245FACTOR IXA SUPERACTIVE TRIPLE MUTANT
2WPIS:16-27,S:121-232; S:28-120,S:233-245FACTOR IXA SUPERACTIVE DOUBLE MUTANT
2WPJS:16-27,S:121-232; S:28-120,S:233-245FACTOR IXA SUPERACTIVE TRIPLE MUTANT, NACL-SOAKED
2WPKS:16-27,S:121-232; S:28-120,S:233-245FACTOR IXA SUPERACTIVE TRIPLE MUTANT, ETHYLENE GLYCOL-SOAKED
2WPLS:16-27,S:121-232; S:28-120,S:233-245FACTOR IXA SUPERACTIVE TRIPLE MUTANT, EDTA-SOAKED
2WPMS:16-27,S:121-232; S:28-120,S:233-245FACTOR IXA SUPERACTIVE MUTANT, EGR-CMK INHIBITED
2WUBC:16-27,C:121-230; A:16-27,A:121-230; A:28-120,A:231-244; C:28-120,C:231-244CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC NON-INHIBITORY ANTIBODY FAB40.DELTATRP
2WUCA:16-27,A:121-230; A:28-120,A:231-244CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC NON-INHIBITORY ANTIBODY FAB40.DELTATRP AND AC-KQLR-CHLOROMETHYLKETONE
2XBVA:16-27,A:121-232; A:28-120,A:233-245FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XBWA:16-27,A:121-232; A:28-120,A:233-245FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XBXA:16-27,A:121-232; A:28-120,A:233-245FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XBYA:16-27,A:121-232; A:28-120,A:233-245FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XC0A:16-27,A:121-232; A:28-120,A:233-245FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XC4A:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XC5A:16-27,A:121-232; A:28-120,A:233-245FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2Z7FE:16-27,E:121-232; E:28-120,E:233-243CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN NEUTROPHIL ELASTASE WITH 1/2SLPI
2ZA5A:28-124,A:247-258; A:16-27,A:125-246; B:16-27,B:125-246; C:16-27,C:125-246; D:16-27,D:125-246; B:28-124,B:247-258; C:28-124,C:247-258; D:28-124,D:247-258CRYSTAL STRUCTURE OF HUMAN TRYPTASE WITH POTENT NON-PEPTIDE INHIBITOR
2ZC9H:28-120,H:233-246; H:16-27,H:121-232THROMBIN IN COMPLEX WITH INHIBITOR
2ZCHP:28-120,P:233-245; P:16-27,P:121-232CRYSTAL STRUCTURE OF HUMAN PROSTATE SPECIFIC ANTIGEN COMPLEXED WITH AN ACTIVATING ANTIBODY
2ZCKP:28-120,P:234-246; P:16-27,P:121-233CRYSTAL STRUCTURE OF A TERNARY COMPLEX BETWEEN PSA, A SUBSTRAT-ACYL INTERMEDIATE AND AN ACTIVATING ANTIBODY
2ZCLP:28-120,P:233-245; P:16-27,P:121-232CRYSTAL STRUCTURE OF HUMAN PROSTATE SPECIFIC ANTIGEN COMPLEXED WITH AN ACTIVATING ANTIBODY
2ZDAH:28-120,H:233-246; H:16-27,H:121-232EXPLORING THROMBIN S1 POCKET
2ZDVH:28-120,H:233-246; H:16-27,H:121-232EXPLORING THROMBIN S1 POCKET
2ZEBA:13-109,A:232-243; A:1-12,A:110-231; B:1-12,B:110-231; C:1-12,C:110-231; D:1-12,D:110-231; B:13-109,B:232-243; C:13-109,C:232-243; D:13-109,D:232-243POTENT, NONPEPTIDE INHIBITORS OF HUMAN MAST CELL TRYPTASE
2ZECA:28-124,A:247-258; A:16-27,A:125-246; B:16-27,B:125-246; C:16-27,C:125-246; D:16-27,D:125-246; B:28-124,B:247-258; C:28-124,C:247-258; D:28-124,D:247-258POTENT, NONPEPTIDE INHIBITORS OF HUMAN MAST CELL TRYPTASE
2ZF0H:28-120,H:233-246; H:16-27,H:121-232EXPLORING THROMBIN S1 POCKET
2ZFFH:28-120,H:233-246; H:16-27,H:121-232EXPLORING THROMBIN S1-POCKET
2ZFPH:28-120,H:233-246; H:16-27,H:121-232THROMBIN INIBITION
2ZFQH:28-120,H:233-246; H:16-27,H:121-232EXPLORING THROMBIN S3 POCKET
2ZFRH:28-120,H:233-246; H:16-27,H:121-232EXPLORING THROMBIN S3 POCKET
2ZG0H:28-120,H:233-245; H:16-27,H:121-232EXPLORING THROMBIN S3 POCKET
2ZGBH:28-120,H:233-246; H:16-27,H:121-232THROMBIN INHIBITION
2ZGCA:13-104,A:219-231; A:1-12,A:105-218CRYSTAL STRUCTURE OF ACTIVE HUMAN GRANZYME M
2ZGHA:13-104,A:219-231; A:1-12,A:105-218CRYSTAL STRUCTURE OF ACTIVE GRANZYME M BOUND TO ITS PRODUCT
2ZGJA:13-104,A:219-231; A:1-12,A:105-218CRYSTAL STRUCTURE OF D86N-GZMM COMPLEXED WITH ITS OPTIMAL SYNTHESIZED SUBSTRATE
2ZGXH:28-120,H:233-246; H:16-27,H:121-232THROMBIN INHIBITION
2ZHEH:28-120,H:233-246; H:16-27,H:121-232EXPLORING THROMBIN S3 POCKET
2ZHFH:28-120,H:233-245; H:16-27,H:121-232EXPLORING THROMBIN S3 POCKET
2ZHQH:28-120,H:233-246; H:16-27,H:121-232THROMBIN INHIBITION
2ZHWH:28-120,H:233-245; H:16-27,H:121-232EXPLORING THROMBIN S3 POCKET
2ZI2H:28-120,H:233-245; H:16-27,H:121-232THROMBIN INHIBITION
2ZIQH:28-120,H:233-246; H:16-27,H:121-232THROMBIN INHIBITION
2ZKSA:13-104,A:219-231; A:1-12,A:105-218STRUCTURAL INSIGHTS INTO THE PROTEOLYTIC MACHINERY OF APOPTOSIS-INDUCING GRANZYME M
2ZNKH:28-120,H:233-246; H:16-27,H:121-232THROMBIN INHIBITION
2ZO3H:28-120,H:233-246; H:16-27,H:121-232BISPHENYLIC THROMBIN INHIBITORS
2ZP0H:16-27,H:121-232; H:28-120,H:233-246HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH BENZYLSULFONAMIDE-D-ILE-GLN-P-AMINOBENZAMIDINE
2ZWLH:16-27,H:121-232; H:28-120,H:233-246HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH HIGHLY SELECTIVE PEPTIDE INHIBITOR
2ZZUH:16-27,H:121-232; H:28-120,H:233-246HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-5-(3-CARBOXYBENZYLOXY)-TRP-GLN-P-AMINOBENZAMIDINE
3B9FH:28-120,H:233-245; H:16-27,H:121-2321.6 A STRUCTURE OF THE PCI-THROMBIN-HEPARIN COMPLEX
3BEFB:28-120,B:233-245; B:16-27,B:121-232; E:16-27,E:121-232; E:28-120,E:233-245CRYSTAL STRUCTURE OF THROMBIN BOUND TO THE EXTRACELLULAR FRAGMENT OF PAR1
3BEIB:28-120,B:233-245; B:16-27,B:121-232CRYSTAL STRUCTURE OF THE SLOW FORM OF THROMBIN IN A SELF_INHIBITED CONFORMATION
3BF6H:28-120,H:233-246; H:16-27,H:121-232THROMBIN:SURAMIN COMPLEX
3BG8A:382-480,A:596-607; A:370-381,A:481-595CRYSTAL STRUCTURE OF FACTOR XIA IN COMPLEX WITH CLAVATADINE A
3BIUH:28-120,H:233-244; H:16-27,H:121-232HUMAN THROMBIN-IN COMPLEX WITH UB-THR10
3BIVH:28-120,H:233-244; H:16-27,H:121-232HUMAN THROMBIN-IN COMPLEX WITH UB-THR11
3BN9A:28-120,A:233-244; B:28-120,B:233-244; A:16-27,A:121-232; B:16-27,B:121-232CRYSTAL STRUCTURE OF MT-SP1 IN COMPLEX WITH FAB INHIBITOR E2
3BSQB:16-27,B:117-227; A:16-27,A:117-227; C:16-27,C:117-227; A:28-116,A:228-238; C:28-116,C:228-238; B:28-116,B:228-237CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 7 PRODUCED AS A SECRETION PROTEIN IN E.COLI
3C1KA:28-120,A:233-244; A:16-27,A:121-232CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH INHIBITOR 15
3C27B:49-153,B:275-287; B:37-48,B:154-274CYANOFLUOROPHENYLACETAMIDES AS ORALLY EFFICACIOUS THROMBIN INHIBITORS
3CENA:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR N-(2-(((5-CHLORO-2-PYRIDINYL) AMINO)SULFONYL)PHENYL)-4-(2-OXO-1(2H)-PYRIDINYL)BENZAMIDE
3CS7A:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(4-METHOXYPHENYL)-6-(4-(1-(PYRROLIDIN-1-YLMETHYL)CYCLOPROPYL)PHENYL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE
3D49H:28-120,H:233-245; H:16-27,H:121-232THROMBIN INHIBITION
3DA9B:49-153,B:275-288; B:37-48,B:154-274CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH INHIBITOR
3DD2H:28-120,H:233-245; H:16-27,H:121-232CRYSTAL STRUCTURE OF AN RNA APTAMER BOUND TO HUMAN THROMBIN
3DHKH:28-120,H:233-246; H:16-27,H:121-232BISPHENYLIC THROMBIN INHIBITORS
3DT0H:28-120,H:233-246; H:16-27,H:121-232UNDERSTANDING THROMBIN INHIBITION
3DUXH:28-120,H:233-246; H:16-27,H:121-232UNDERSTANDING THROMBIN INHIBITION
3E0NB:28-120,B:233-252; B:16-27,B:121-232THE X-RAY STRUCTURE OF HUMAN PROSTASIN IN COMPLEX WITH DFFR-CHLOROMETHYL KETONE INHIBITOR
3E0PB:28-120,B:233-247; B:16-27,B:121-232THE X-RAY STRUCTURE OF HUMAN PROSTASIN IN COMPLEX WITH A COVALENT BENZOXAZOLE INHIBITOR
3E16B:28-120,B:233-248; B:16-27,B:121-232X-RAY STRUCTURE OF HUMAN PROSTASIN IN COMPLEX WITH BENZOXAZOLE WARHEAD PEPTIDOMIMIC, LYSINE IN P3
3E1XB:28-120,B:233-248; B:16-27,B:121-232THE CRYSTAL STRUCTURE OF APO PROSTASIN AT 1.7 ANGSTROMS RESOLUTION
3EE0B:28-120,B:233-245; B:16-27,B:121-232CRYSTAL STRUCTURE OF THE W215A/E217A MUTANT OF HUMAN THROMBIN (SPACE GROUP P2(1)2(1)2(1))
3EGKH:28-120,H:233-246; H:16-27,H:121-232KNOBLE INHIBITOR
3ELAH:153-164,H:261-381; H:165-260,H:382-395CRYSTAL STRUCTURE OF ACTIVE SITE INHIBITED COAGULATION FACTOR VIIA MUTANT IN COMPLEX WITH SOLUBLE TISSUE FACTOR
3ENSB:16-27,B:121-232; B:28-120,B:233-248; D:28-120,D:233-248; D:16-27,D:121-232CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH METHYL (2Z)-3-[(3-CHLORO-1H-INDOL-7-YL)AMINO]-2-CYANO-3-{[(3S)-2-OXO-1-(2-OXO-2-PYRROLIDIN-1-YLETHYL)AZEPAN-3-YL]AMINO}ACRYLATE
3EQ0H:28-120,H:233-243; H:16-27,H:121-232THROMBIN INHIBITOR
3F68H:28-120,H:233-246; H:16-27,H:121-232THROMBIN INHIBITION
3FFGA:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR (R)-6-(2'-((3-HYDROXYPYRROLIDIN-1-YL)METHYL)BIPHENYL-4-YL)-1-(3-(5-OXO-4, 5-DIHYDRO-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE
3FVFB:28-120,B:233-249; B:16-27,B:121-232THE CRYSTAL STRUCTURE OF PROSTASIN COMPLEXED WITH CAMOSTAT AT 1.6 ANGSTROMS RESOLUTION
3GICB:28-120,B:233-243; B:16-27,B:121-232STRUCTURE OF THROMBIN MUTANT DELTA(146-149E) IN THE FREE FORM
3GISF:28-120,F:233-244; F:16-27,F:121-232; B:16-27,B:121-232; D:16-27,D:121-232; B:28-120,B:233-245; D:28-120,D:233-245CRYSTAL STRUCTURE OF NA-FREE THROMBIN IN COMPLEX WITH THROMBOMODULIN
3GOVB:461-570,B:687-699; B:449-460,B:571-686CRYSTAL STRUCTURE OF THE CATALYTIC REGION OF HUMAN MASP-1
3GYLB:28-120,B:233-248; B:16-27,B:121-232STRUCTURE OF PROSTASIN AT 1.3 ANGSTROMS RESOLUTION IN COMPLEX WITH A CALCIUM ION.
3GYMA:28-120,A:233-242; A:16-27,A:121-232; B:16-27,B:121-232; B:28-120,B:233-242STRUCTURE OF PROSTASIN IN COMPLEX WITH APROTININ
3HATH:28-120,H:233-246; H:16-27,H:121-232ACTIVE SITE MIMETIC INHIBITION OF THROMBIN
3HKJE:28-120,E:233-246; E:16-27,E:121-232; B:16-27,B:121-232; B:28-120,B:233-247CRYSTAL STRUCTURE OF HUMAN THROMBIN MUTANT W215A/E217A IN COMPLEX WITH THE EXTRACELLULAR FRAGMENT OF HUMAN PAR1
3HPTD:16-27,D:121-232; B:16-27,B:121-232; B:28-120,B:233-248; D:28-120,D:233-248CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH (S)-2-CYANO-1-(2-METHYLBENZOFURAN-5-YL)-3-(2-OXO-1-(2-OXO-2-(PYRROLIDIN-1-YL)ETHYL) AZEPAN-3-YL)GUANIDINE
3IG6D:28-120,D:233-243; B:16-27,B:121-232; D:16-27,D:121-232; B:28-120,B:233-242LOW MOLECULAR WEIGTH HUMAN UROKINASE TYPE PLASMINOGEN ACTIVATOR 2-[6-(3'-AMINOMETHYL-BIPHENYL-3-YLOXY)-4-(3-DIMETHYLAMINO-PYRROLIDIN-1-YL)-3,5-DIFLUORO-PYRIDIN-2-YLOXY]-4-DIMETHYLAMINO-BENZOIC ACID COMPLEX
3JZ1B:28-120,B:233-246; B:16-27,B:121-232CRYSTAL STRUCTURE OF HUMAN THROMBIN MUTANT N143P IN E:NA+ FORM
3JZ2B:28-120,B:233-245; B:16-27,B:121-232CRYSTAL STRUCTURE OF HUMAN THROMBIN MUTANT N143P IN E* FORM
3K2UA:16-27,A:121-230; A:28-120,A:231-243CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC INHIBITORY ANTIBODY FAB40
3K9XB:16-27,B:121-232; D:16-27,D:121-232; B:28-120,B:233-248; D:28-120,D:233-248X-RAY CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH (S)-N-((2-METHYLBENZOFURAN-5-YLAMINO)(2-OXO-1-(2-OXO-2- (PYRROLIDIN-1-YL) ETHYL)AZEPAN-3- YLAMINO)METHYLENE)NICOTINAMIDE
3KCGH:16-27,H:121-232; H:28-120,H:233-245CRYSTAL STRUCTURE OF THE ANTITHROMBIN-FACTOR IXA-PENTASACCHARIDE COMPLEX
3KGPA:28-120,A:233-242; A:16-27,A:121-232CRYSTAL STRUCTURES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR IN COMPLEX WITH 4-(AMINOMETHYL) BENZOIC ACID AND 4-(AMINOMETHYL-PHENYL)-METHANOL
3KHVA:28-120,A:233-243; A:16-27,A:121-232CRYSTAL STRUCTURES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR IN COMPLEX WITH 4-(AMINOMETHYL) BENZOIC ACID AND 4-(AMINOMETHYL-PHENYL)-METHANOL
3KIDU:28-120,U:233-243; U:16-27,U:121-232THE CRYSTAL STRUCTURES OF 2-AMINOBENZOTHIAZOLE-BASED INHIBITORS IN COMPLEXES WITH UROKINASE-TYPE PLASMINOGEN ACTIVATOR
3KL6A:16-27,A:121-232; A:28-120,A:233-242DISCOVERY OF TETRAHYDROPYRIMIDIN-2(1H)-ONE DERIVATIVE TAK-442: A POTENT, SELECTIVE AND ORALLY ACTIVE FACTOR XA INHIBITOR
3KQBA:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR N-(3-FLUORO-2'-(METHYLSULFONYL)BIPHENYL-4-YL)-1-(3-(5-OXO-4,5-DIHYDRO-1H- 1,2,4-TRIAZOL-3-YL)PHENYL)-3-(TRIFLUOROMETHYL)-1H- PYRAZOLE-5-CARBOXAMIDE
3KQCA:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR 6-(2'- (METHYLSULFONYL) BIPHENYL-4-YL)-1-(3-(5-OXO-4,5-DIHYDRO-1H- 1,2,4-TRIAZOL-3-YL) PHENYL)-3-(TRIFLUOROMETHYL)-5,6- DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE
3KQDA:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3-(5-OXO-4,5- DIHYDRO-1H-1, 2,4-TRIAZOL-3-YL)PHENYL)-6-(2'-(PYRROLIDIN-1- YLMETHYL)BIPHENYL-4-YL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO- 1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE
3KQEA:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR 3-METHYL-1-(3-(5- OXO-4,5-DIHYDRO-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-6-(2'- (PYRROLIDIN-1-YLMETHYL) BIPHENYL-4-YL)-5,6-DIHYDRO-1H- PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE
3LC3A:16-27,A:121-232; C:16-27,C:121-232; A:28-120,A:233-245; C:28-120,C:233-245BENZOTHIOPHENE INHIBITORS OF FACTOR IXA
3LC5A:16-27,A:121-232; A:28-120,A:233-245SELECTIVE BENZOTHIOPHINE INHIBITORS OF FACTOR IXA
4HTCH:28-120,H:233-245; H:16-27,H:121-232THE REFINED STRUCTURE OF THE HIRUDIN-THROMBIN COMPLEX
4THNH:28-120,H:233-246; H:16-27,H:121-232THE CRYSTAL STRUCTURE OF ALPHA-THROMBIN-HIRUNORM IV COMPLEX REVEALS A NOVEL SPECIFICITY SITE RECOGNITION MODE.
5GDSH:28-120,H:233-246; H:16-27,H:121-232HIRUNORMS ARE TRUE HIRUDIN MIMETICS. THE CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN:HIRUNORM V COMPLEX
7KMEH:28-120,H:233-246; H:16-27,H:121-232CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN INHIBITED WITH SEL2711.
8KME2:28-120,2:233-244; 2:16-27,2:121-232CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN INHIBITED WITH SEL2770.
(-)
Human coronavirus 229e. Organism_taxid: 11137. Strain: 229e. (1)
1P9SA:1-98; B:1-98; A:99-196; B:99-196CORONAVIRUS MAIN PROTEINASE (3CLPRO) STRUCTURE: BASIS FOR DESIGN OF ANTI-SARS DRUGS
(-)
Human coxsackievirus b3. Organism_taxid: 12072. (4)
2ZTXA:1-14,A:84-180; A:15-83COMPLEX STRUCTURE OF CVB3 3C PROTEASE WITH EPDTC
2ZTYA:1-14,A:84-180; A:15-83CRYSTAL STRUCTURE OF 3C PROTEASE FROM CVB3 IN SPACE GROUP C2
2ZTZA:1-14,A:84-180; A:15-83; B:15-83; B:1-14,B:84-180CRYSTAL STRUCTURE OF 3C PROTEASE FROM CVB3 IN SPACE GROUP P21
2ZU1A:1-14,A:84-180; B:1-14,B:84-180; A:15-83; B:15-83CRYSTAL STRUCTURE OF CVB3 3C PROTEASE MUTANT C147A
(-)
Human coxsackievirus b3. Organism_taxid: 12072. Strain: b3. (2)
2VB0A:1-14,A:84-183; A:15-83CRYSTAL STRUCTURE OF COXSACKIEVIRUS B3 PROTEINASE 3C
2ZU3A:1-14,A:84-180; A:15-83COMPLEX STRUCTURE OF CVB3 3C PROTEASE WITH TG-0204998
(-)
Human coxsackievirus b4. Organism_taxid: 12073. (1)
1Z8RA:51-1482A CYSTEINE PROTEINASE FROM HUMAN COXSACKIEVIRUS B4 (STRAIN JVB / BENSCHOTEN / NEW YORK / 51)
(-)
Human hepatitis a virus hu/northern africa/mbb/1978. Organism_taxid: 12100. Strain: mbb. (2)
2A4OA:1-100,A:204-212; A:101-203DUAL MODES OF MODIFICATION OF HEPATITIS A VIRUS 3C PROTEASE BY A SERINE DERIVED BETA-LACTONE: SELECTIVE CRYTSTALLIZATION AND HIGH RESOLUTION STRUCTURE OF THE HIS102 ADDUCT
2CXVA:1-100,A:204-212; A:101-203DUAL MODES OF MODIFICATION OF HEPATITIS A VIRUS 3C PROTEASE BY A SERINE-DERIVED BETALACTONE: SELECTIVE CRYSTALLIZATION AND HIGH-RESOLUTION STRUCTURE OF THE HIS-102 ADDUCT
(-)
Human poliovirus 1 mahoney. Organism_taxid: 12081. Strain: mahoney. (1)
1L1NA:1-14,A:84-180; B:3-14,B:84-180; A:15-83; B:15-83POLIOVIRUS 3C PROTEINASE
(-)
Human rhinovirus 14. Organism_taxid: 12131. (1)
2B0FA:1-14,A:84-182; A:15-83NMR STRUCTURE OF THE HUMAN RHINOVIRUS 3C PROTEASE (SEROTYPE 14) WITH COVALENTLY BOUND ACE-LEALFQ-ETHYLPROPIONATE INHIBITOR
(-)
Human rhinovirus 14. Organism_taxid: 12131. Strain: serotype 14. (1)
2IN2A:1-14,A:84-182; A:15-83NMR STRUCTURE OF THE APO HUMAN RHINOVIRUS 3C PROTEASE (SEROTYPE 14)
(-)
Human rhinovirus 2. Organism_taxid: 12130 (1)
1CQQA:1-14,A:84-180; A:15-83TYPE 2 RHINOVIRUS 3C PROTEASE WITH AG7088 INHIBITOR
(-)
Human rhinovirus 2. Organism_taxid: 12130. (1)
2HRVA:45-139; B:45-139; A:1-44; B:1-442A CYSTEINE PROTEINASE FROM HUMAN RHINOVIRUS 2
(-)
Human sars coronavirus. (1)
2CGG  [entry was replaced by entry 2VJ1 without any CATH domain information]
(-)
Lysobacter enzymogenes. Organism_taxid: 69 (1)
2ALPA:120-230; A:16-119,A:231-243REFINED STRUCTURE OF ALPHA-LYTIC PROTEASE AT 1.7 ANGSTROMS RESOLUTION. ANALYSIS OF HYDROGEN BONDING AND SOLVENT STRUCTURE
(-)
Lysobacter enzymogenes. Organism_taxid: 69. (9)
1P01A:116-230; A:16-115,A:231-242SERINE PROTEASE MECHANISM. STRUCTURE OF AN INHIBITORY COMPLEX OF ALPHA-LYTIC PROTEASE AND A TIGHTLY BOUND PEPTIDE BORONIC ACID
1P02A:116-230; A:16-115,A:231-242STRUCTURE ANALYSIS OF SPECIFICITY. ALPHA-LYTIC PROTEASE COMPLEXES WITH ANALOGUES OF REACTION INTERMEDIATES
1P03A:116-230; A:16-115,A:231-242STRUCTURE ANALYSIS OF SPECIFICITY. ALPHA-LYTIC PROTEASE COMPLEXES WITH ANALOGUES OF REACTION INTERMEDIATES
1P04A:116-230; A:16-115,A:231-242STRUCTURE ANALYSIS OF SPECIFICITY. ALPHA-LYTIC PROTEASE COMPLEXES WITH ANALOGUES OF REACTION INTERMEDIATES
1P05A:116-230; A:16-115,A:231-242STRUCTURE ANALYSIS OF SPECIFICITY. ALPHA-LYTIC PROTEASE COMPLEXES WITH ANALOGUES OF REACTION INTERMEDIATES
1P06A:116-230; A:16-115,A:231-242STRUCTURE ANALYSIS OF SPECIFICITY. ALPHA-LYTIC PROTEASE COMPLEXES WITH ANALOGUES OF REACTION INTERMEDIATES
1SSXA:120-230; A:16-119,A:231-2430.83A RESOLUTION CRYSTAL STRUCTURE OF ALPHA-LYTIC PROTEASE AT PH 8
2H5CA:120-230; A:16-119,A:231-2430.82A RESOLUTION CRYSTAL STRUCTURE OF ALPHA-LYTIC PROTEASE AT PH 5
2H5DA:120-230; A:16-119,A:231-2430.9A RESOLUTION CRYSTAL STRUCTURE OF ALPHA-LYTIC PROTEASE COMPLEXED WITH A TRANSITION STATE ANALOGUE, MEOSUC-ALA-ALA-PRO-VAL BORONIC ACID
(-)
Lysobacter enzymogenes. Organism_taxid: 69. (15)
1P09A:116-230; A:16-115,A:231-242STRUCTURAL PLASTICITY AS A DETERMINANT OF ENZYME SPECIFICITY. CREATING BROADLY SPECIFIC PROTEASES
1P10A:116-230; A:16-115,A:231-242STRUCTURAL PLASTICITY AS A DETERMINANT OF ENZYME SPECIFICITY. CREATING BROADLY SPECIFIC PROTEASES
1P11E:116-230; E:16-115,E:231-242CRYSTAL STRUCTURES OF ALPHA-LYTIC PROTEASE COMPLEXES WITH IRREVERSIBLY BOUND PHOSPHONATE ESTERS
1P12E:116-230; E:16-115,E:231-242CRYSTAL STRUCTURES OF ALPHA-LYTIC PROTEASE COMPLEXES WITH IRREVERSIBLY BOUND PHOSPHONATE ESTERS
1QQ4A:77-183; A:3-76,A:184-196CRYSTAL STRUCTURE OF AN ALPHA-LYTIC PROTEASE MUTANT WITH ACCELERATED FOLDING KINETICS, R102H/G134S
1QRWA:77-183; A:3-76,A:184-196CRYSTAL STRUCTURE OF AN ALPHA-LYTIC PROTEASE MUTANT WITH ACCELERATED FOLDING KINETICS, R102H/G134S, PH 8
1QRXA:77-183; A:3-76,A:184-196CRYSTAL STRUCTURE OF WILD-TYPE ALPHA-LYTIC PROTEASE AT 1.6 A, PH 5.14
2LPRA:116-230; A:16-115,A:231-242STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS
2ULLA:120-230; A:16-119,A:231-243MULTIPLE CONFORMATION STRUCTURE OF ALPHA-LYTIC PROTEASE AT 120 K
3LPRA:116-230; A:16-115,A:231-242STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS
5LPRA:116-230; A:16-115,A:231-242STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS
6LPRA:116-230; A:16-115,A:231-242STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS
7LPRA:116-230; A:16-115,A:231-242STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS
8LPRA:116-230; A:16-115,A:231-242STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS
9LPRA:116-230; A:16-115,A:231-242STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS
(-)
Lysobacter enzymogenes. Organism_taxid: 69. Cell_line: b834. (1)
3PROA:77-183; B:77-183; A:3-76,A:184-196; B:3-76,B:184-196ALPHA-LYTIC PROTEASE COMPLEXED WITH C-TERMINAL TRUNCATED PRO REGION
(-)
Lysobacter enzymogenes. Organism_taxid: 69. Strain: 495. (14)
1BOQA:77-183; A:3-76,A:184-196PRO REGION C-TERMINUS: PROTEASE ACTIVE SITE INTERACTIONS ARE CRITICAL IN CATALYZING THE FOLDING OF ALPHA-LYTIC PROTEASE
1GBAA:120-230; A:16-119,A:231-243ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY ALA
1GBBA:120-230; A:16-119,A:231-243ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-ALANINE BORONIC ACID
1GBCA:120-230; A:16-119,A:231-243ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-LEUCINE BORONIC ACID
1GBDA:120-230; A:16-119,A:231-243ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-PHENYLALANINE BORONIC ACID
1GBEA:120-230; A:16-119,A:231-243ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY LEU
1GBFA:120-230; A:16-119,A:231-243ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY LEU COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-ALANINE BORONIC ACID
1GBHA:120-230; A:16-119,A:231-243ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY LEU COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-LEUCINE BORONIC ACID
1GBIA:120-230; A:16-119,A:231-243ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY LEU COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-PHENYLALANINE BORONIC ACID
1GBJA:120-230; A:16-119,A:231-243ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA
1GBKA:120-230; A:16-119,A:231-243ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-ALANINE BORONIC ACID
1GBLA:120-230; A:16-119,A:231-243ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-LEUCINE BORONIC ACID
1GBMA:120-230; A:16-119,A:231-243ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-PHENYLALANINE BORONIC ACID
1TALA:120-230; A:16-119,A:231-236ALPHA-LYTIC PROTEASE AT 120 K (SINGLE STRUCTURE MODEL)
(-)
Mold (Fusarium oxysporum) (1)
2VU8E:16-27,E:121-232; E:28-120,E:233-242CRYSTAL STRUCTURE OF AN INSECT INHIBITOR WITH A FUNGAL TRYPSIN
(-)
Mouse (Mus musculus) (6)
3EDXB:28-120,B:233-245; B:16-27,B:121-232; D:16-27,D:121-232; F:16-27,F:121-232; D:28-120,D:233-245; F:28-120,F:233-245CRYSTAL STRUCTURE OF THE W215A/E217A MUTANT OF MURINE THROMBIN
3FZZA:21-32,A:128-235; A:33-127,A:236-247; B:33-127,B:236-247; B:21-32,B:128-235STRUCTURE OF GRC
3G01A:21-32,A:128-235; B:21-32,B:128-235; A:33-127,A:236-247; B:33-127,B:236-247STRUCTURE OF GRC MUTANT E192R/E193G
3HK3B:28-120,B:233-245; B:16-27,B:121-232CRYSTAL STRUCTURE OF MURINE THROMBIN MUTANT W215A/E217A (ONE MOLECULE IN THE ASYMMETRIC UNIT)
3HK6B:28-120,B:233-245; B:16-27,B:121-232; D:16-27,D:121-232; D:28-120,D:233-245CRYSTAL STRUCTURE OF MURINE THROMBIN MUTANT W215A/E217A (TWO MOLECULES IN THE ASYMMETRIC UNIT)
3HKIB:28-120,B:233-245; E:16-27,E:121-232; B:16-27,B:121-232; E:28-120,E:233-245CRYSTAL STRUCTURE OF MURINE THROMBIN MUTANT W215A/E217A IN COMPLEX WITH THE EXTRACELLULAR FRAGMENT OF HUMAN PAR1
(-)
Mycobacterium tuberculosis h37rv. Organism_taxid: 83332. Strain: h37rv. (1)
1Y8TB:103-226; A:102-226; C:104-227; C:6-103; A:6-101; B:6-102CRYSTAL STRUCTURE OF RV0983 FROM MYCOBACTERIUM TUBERCULOSIS-PROTEOLYTICALLY ACTIVE FORM
(-)
Mycobacterium tuberculosis. Organism_taxid: 1773. Mycobacterium tuberculosis. Organism_taxid: 1773. (1)
2Z9IA:102-226; B:102-226; C:103-226; C:6-102; A:6-101; B:4-101CRYSTAL STRUCTURE OF RV0983 FROM MYCOBACTERIUM TUBERCULOSIS-PROTEOLYTICALLY ACTIVE FORM
(-)
Narrow-clawed crayfish (Pontastacus leptodactylus) (1)
2F91A:16-27,A:121-233; A:28-120,A:234-2441.2A RESOLUTION STRUCTURE OF A CRAYFISH TRYPSIN COMPLEXED WITH A PEPTIDE INHIBITOR, SGTI
(-)
Nocardiopsis alba. Organism_taxid: 53437. Strain: toa-1. (1)
2OUAA:120-230; B:120-230; A:15A-119,A:231-244; B:15A-119,B:231-244CRYSTAL STRUCTURE OF NOCARDIOPSIS PROTEASE (NAPASE)
(-)
Norway rat (Rattus norvegicus) (18)
1BRBE:16-27,E:121-232; E:28-120,E:233-245CRYSTAL STRUCTURES OF RAT ANIONIC TRYPSIN COMPLEXED WITH THE PROTEIN INHIBITORS APPI AND BPTI
1BRCE:16-27,E:121-232; E:28-120,E:233-245RELOCATING A NEGATIVE CHARGE IN THE BINDING POCKET OF TRYPSIN
1CO7E:16-27,E:121-232; E:28-120,E:233-245R117H MUTANT RAT ANIONIC TRYPSIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
1F5RA:14-27,A:121-232; A:28-120,A:233-244RAT TRYPSINOGEN MUTANT COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR
1F7ZA:16-27,A:121-232; A:28-120,A:233-244RAT TRYPSINOGEN K15A COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR
1FI8A:16-27,A:121-232; B:16-27,B:121-232; B:28-120,B:233-243; A:28-120,A:233-243RAT GRANZYME B [N66Q] COMPLEXED TO ECOTIN [81-84 IEPD]
1J14A:16-27,A:121-232; A:28-120,A:233-245BENZAMIDINE IN COMPLEX WITH RAT TRYPSIN MUTANT X99RT
1J15A:16-27,A:121-232; A:28-120,A:233-245BENZAMIDINE IN COMPLEX WITH RAT TRYPSIN MUTANT X99/175/190RT
1J16A:16-27,A:121-232; A:28-120,A:233-245BENZAMIDINE IN COMPLEX WITH RAT TRYPSIN MUTANT X99/175/190RT
1J17T:16-27,T:121-232; T:28-120,T:233-245FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH RAT TRYPSIN MUTANT X99/175/190RT
1KDQB:151-245; A:17-146CRYSTAL STRUCTURE ANALYSIS OF THE MUTANT S189D RAT CHYMOTRYPSIN
1YKTA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN/BPTI COMPLEX MUTANT
1YLCA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN/BPTI COMPLEX MUTANT
1YLDA:16-27,A:121-232; A:28-120,A:233-245TRYPSIN/BPTI COMPLEX MUTANT
2TRMA:16-27,A:121-232; A:28-120,A:233-245THE THREE-DIMENSIONAL STRUCTURE OF ASN102 MUTANT OF TRYPSIN. ROLE OF ASP102 IN SERINE PROTEASE CATALYSIS
3TGIE:16-27,E:121-232; E:28-120,E:233-245WILD-TYPE RAT ANIONIC TRYPSIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
3TGJE:16-27,E:121-232; E:28-120,E:233-244S195A TRYPSINOGEN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
3TGKE:15-27,E:121-232; E:28-120,E:233-244TRYPSINOGEN MUTANT D194N AND DELETION OF ILE 16-VAL 17 COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
(-)
Organism_taxid (lysobacter enzymogenes) (1)
4PROA:77-183; B:77-183; A:3-76,A:184-196; B:3-76,B:184-196ALPHA-LYTIC PROTEASE COMPLEXED WITH PRO REGION
(-)
Pig (Sus scrofa) (115)
1AKSA:16-145; B:146-245CRYSTAL STRUCTURE OF THE FIRST ACTIVE AUTOLYSATE FORM OF THE PORCINE ALPHA TRYPSIN
1AN1E:16-27,E:121-232; E:28-120,E:233-244LEECH-DERIVED TRYPTASE INHIBITOR/TRYPSIN COMPLEX
1AVWA:16-27,A:121-232; A:28-120,A:233-245COMPLEX PORCINE PANCREATIC TRYPSIN/SOYBEAN TRYPSIN INHIBITOR, ORTHORHOMBIC CRYSTAL FORM
1AVXA:16-27,A:121-232; A:28-120,A:233-245COMPLEX PORCINE PANCREATIC TRYPSIN/SOYBEAN TRYPSIN INHIBITOR, TETRAGONAL CRYSTAL FORM
1B0EA:28-120,A:233-245; A:16-27,A:121-232CRYSTAL STRUCTURE OF PORCINE PANCREATIC ELASTASE WITH MDL 101,146
1BMAA:28-126,A:243-255; A:16-27,A:127-242BENZYL METHYL AMINIMIDE INHIBITOR COMPLEXED TO PORCINE PANCREATIC ELASTASE
1BRUP:28-120,P:233-245; P:16-27,P:121-232STRUCTURE OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH THE ELASTASE INHIBITOR GR143783
1BTUA:28-120,A:233-245; A:16-27,A:121-232PORCINE PANCREATIC ELASTASE COMPLEXED WITH (3S, 4R)-1-TOLUENESULPHONYL-3-ETHYL-AZETIDIN-2-ONE-4-CARBOXYLIC ACID
1C1MA:28-120,A:233-245; A:16-27,A:121-232PORCINE ELASTASE UNDER XENON PRESSURE (8 BAR)
1C9PA:16-27,A:121-232; A:28-120,A:233-244COMPLEX OF BDELLASTASIN WITH PORCINE TRYPSIN
1EAIA:28-120,A:233-245; A:16-27,A:121-232; B:16-27,B:121-232; B:28-120,B:233-245COMPLEX OF ASCARIS CHYMOTRPSIN/ELASTASE INHIBITOR WITH PORCINE ELASTASE
1EASA:28-120,A:233-245; A:16-27,A:121-232NONPEPTIDIC INHIBITORS OF HUMAN LEUKOCYTE ELASTASE. 3. DESIGN, SYNTHESIS, X-RAY CRYSTALLOGRAPHIC ANALYSIS, AND STRUCTURE-ACTIVITY RELATIONSHIPS FOR A SERIES OF ORALLY ACTIVE 3-AMINO-6-PHENYLPYRIDIN-2-ONE TRIFLUOROMETHYL KETONES
1EATA:28-120,A:233-245; A:16-27,A:121-232NONPEPTIDIC INHIBITORS OF HUMAN LEUKOCYTE ELASTASE. 5. DESIGN, SYNTHESIS, AND X-RAY CRYSTALLOGRAPHY OF A SERIES OF ORALLY ACTIVE 5-AMINO-PYRIMIDIN-6-ONE-CONTAINING TRIFLUOROMETHYLKETONES
1EAUA:28-120,A:233-245; A:16-27,A:121-232NONPEPTIDIC INHIBITORS OF HUMAN LEUKOCYTE ELASTASE. 6. DESIGN OF A POTENT, INTRATRACHEALLY ACTIVE, PYRIDONE-BASED TRIFLUOROMETHYL KETONE
1EJAA:16-27,A:121-232; A:28-120,A:233-245STRUCTURE OF PORCINE TRYPSIN COMPLEXED WITH BDELLASTASIN, AN ANTISTASIN-TYPE INHIBITOR
1ELAA:28-126,A:243-255; A:16-27,A:127-242ANALOGOUS INHIBITORS OF ELASTASE DO NOT ALWAYS BIND ANALOGOUSLY
1ELBA:28-126,A:243-255; A:16-27,A:127-242ANALOGOUS INHIBITORS OF ELASTASE DO NOT ALWAYS BIND ANALOGOUSLY
1ELCA:28-126,A:243-255; A:16-27,A:127-242ANALOGOUS INHIBITORS OF ELASTASE DO NOT ALWAYS BIND ANALOGOUSLY
1ELDE:28-126,E:243-255; E:16-27,E:127-242STRUCTURAL ANALYSIS OF THE ACTIVE SITE OF PORCINE PANCREATIC ELASTASE BASED ON THE X-RAY CRYSTAL STRUCTURES OF COMPLEXES WITH TRIFLUOROACETYL-DIPEPTIDE-ANILIDE INHIBITORS
1ELEE:28-126,E:243-255; E:16-27,E:127-242STRUCTURAL ANALYSIS OF THE ACTIVE SITE OF PORCINE PANCREATIC ELASTASE BASED ON THE X-RAY CRYSTAL STRUCTURES OF COMPLEXES WITH TRIFLUOROACETYL-DIPEPTIDE-ANILIDE INHIBITORS
1ELFA:28-126,A:243-255; A:16-27,A:127-242NATURE OF THE INACTIVATION OF ELASTASE BY N-PEPTIDYL-O-AROYL HYDROXYLAMINE AS A FUNCTION OF PH
1ELGA:28-126,A:243-255; A:16-27,A:127-242NATURE OF THE INACTIVATION OF ELASTASE BY N-PEPTIDYL-O-AROYL HYDROXYLAMINE AS A FUNCTION OF PH
1EPTC:146-245; B:61-145; A:16-60REFINED 1.8 ANGSTROMS RESOLUTION CRYSTAL STRUCTURE OF PORCINE EPSILON-TRYPSIN
1ESAA:28-126,A:243-255; A:16-27,A:127-242DIRECT STRUCTURE OBSERVATION OF AN ACYL-ENZYME INTERMEDIATE IN THE HYDROLYSIS OF AN ESTER SUBSTRATE BY ELASTASE
1ESBA:28-126,A:243-255; A:16-27,A:127-242DIRECT STRUCTURE OBSERVATION OF AN ACYL-ENZYME INTERMEDIATE IN THE HYDROLYSIS OF AN ESTER SUBSTRATE BY ELASTASE
1ESTA:28-120,A:233-245; A:16-27,A:121-232THE ATOMIC STRUCTURE OF CRYSTALLINE PORCINE PANCREATIC ELASTASE AT 2.5 ANGSTROMS RESOLUTION. COMPARISONS WITH THE STRUCTURE OF ALPHA-CHYMOTRYPSIN
1FIZA:16-27,A:121-232; A:28-120,A:233-245THREE DIMENSIONAL STRUCTURE OF BETA-ACROSIN FROM BOAR SPERMATOZOA
1FLEE:28-120,E:233-245; E:16-27,E:121-232CRYSTAL STRUCTURE OF ELAFIN COMPLEXED WITH PORCINE PANCREATIC ELASTASE
1FMGA:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF PORCINE BETA TRYPSIN WITH 0.04% POLYDOCANOL
1FN6A:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF PORCINE BETA TRYPSIN WITH 0.1% POLYDOCANOL
1FNIA:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF PORCINE BETA TRYPSIN WITH 0.01% POLYDOCANOL
1FZZA:28-120,A:233-245; A:16-27,A:121-232THE CRYSTAL STRUCTURE OF THE COMPLEX OF NON-PEPTIDIC INHIBITOR ONO-6818 AND PORCINE PANCREATIC ELASTASE.
1GWAA:28-120,A:233-245; A:16-27,A:121-232TRIIODIDE DERIVATIVE OF PORCINE PANCREAS ELASTASE
1H9HE:16-27,E:121-232; E:28-120,E:233-245COMPLEX OF EETI-II WITH PORCINE TRYPSIN
1H9IE:16-27,E:121-232; E:28-120,E:233-245COMPLEX OF EETI-II MUTANT WITH PORCINE TRYPSIN
1H9LB:28-120,B:233-245; B:16-27,B:121-232PORCINE PANCREATIC ELASTASE COMPLEXED WITH ACETYL-VAL-GLU-PRO-ILE-COOH
1HAYB:28-120,B:233-245; B:16-27,B:121-232SNAPSHOTS OF SERINE PROTEASE CATALYSIS: (B) ACYL-ENZYME INTERMEDIATE BETWEEN PORCINE PANCREATIC ELASTASE AND HUMAN BETA-CASOMORPHIN-7 JUMPED TO PH 10 FOR 10 SECONDS
1HB0B:28-120,B:233-245; B:16-27,B:121-232SNAPSHOTS OF SERINE PROTEASE CATALYSIS: (D) ACYL-ENZYME INTERMEDIATE BETWEEN PORCINE PANCREATIC ELASTASE AND HUMAN BETA-CASOMORPHIN-7 JUMPED TO PH 10 FOR 2 MINUTES
1HIAA:16-95B; X:16-95B; B:96-246; Y:96-246KALLIKREIN COMPLEXED WITH HIRUSTASIN
1HV7A:28-126,A:243-255; A:16-27,A:127-242PORCINE PANCREATIC ELASTASE COMPLEXED WITH GW311616A
1L0ZA:13-111,A:228-240; A:1-12,A:112-227THE STRUCTURE OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH XENON AND BROMIDE, CRYOPROTECTED WITH DRY PARAFFIN OIL
1L1GA:13-111,A:228-240; A:1-12,A:112-227THE STRUCTURE OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH XENON AND BROMIDE, CRYOPROTECTED WITH GLYCEROL
1LDTT:16-27,T:121-232; T:28-120,T:233-245COMPLEX OF LEECH-DERIVED TRYPTASE INHIBITOR WITH PORCINE TRYPSIN
1LKAA:13-111,A:228-240; A:1-12,A:112-227PORCINE PANCREATIC ELASTASE/CA-COMPLEX
1LKBA:13-111,A:228-240; A:1-12,A:112-227PORCINE PANCREATIC ELASTASE/NA-COMPLEX
1LVYA:28-120,A:233-245; A:16-27,A:121-232PORCINE ELASTASE
1MCTA:16-27,A:121-232; A:28-120,A:233-245THE REFINED 1.6 ANGSTROMS RESOLUTION CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN PORCINE BETA-TRYPSIN AND MCTI-A, A TRYPSIN INHIBITOR OF SQUASH FAMILY
1MCVA:28-120,A:233-245; A:16-27,A:121-232CRYSTAL STRUCTURE ANALYSIS OF A HYBRID SQUASH INHIBITOR IN COMPLEX WITH PORCINE PANCREATIC ELASTASE
1MMJN:13-111,N:228-240; N:1-12,N:112-227PORCINE PANCREATIC ELASTASE COMPLEXED WITH A POTENT PEPTIDYL INHIBITOR, FR136706
1NESE:28-120,E:233-245; E:16-27,E:121-232STRUCTURE OF THE PRODUCT COMPLEX OF ACETYL-ALA-PRO-ALA WITH PORCINE PANCREATIC ELASTASE AT 1.65 ANGSTROMS RESOLUTION
1OKXA:28-126,A:243-255; A:16-27,A:127-242; B:16-27,B:127-242; B:28-126,B:243-255BINDING STRUCTURE OF ELASTASE INHIBITOR SCYPTOLIN A
1PFXC:16-27,C:121-232; C:28-120,C:233-245PORCINE FACTOR IXA
1PPHE:16-27,E:121-232; E:28-120,E:233-245GEOMETRY OF BINDING OF THE NALPHA-TOSYLATED PIPERIDIDES OF M-AMIDINO-, P-AMIDINO-AND P-GUANIDINO PHENYLALANINE TO THROMBIN AND TRYPSIN: X-RAY CRYSTAL STRUCTURES OF THEIR TRYPSIN COMPLEXES AND MODELING OF THEIR THROMBIN COMPLEXES
1QGFA:28-120,A:233-245; A:16-27,A:121-232PORCINE PANCREATIC ELASTASE COMPLEXED WITH (3R, 4S)N-PARA-TOLUENESULPHONYL-3-ETHYL-4-(CARBOXYLIC ACID)PYRROLIDIN-2-ONE
1QNJA:28-120,A:233-245; A:16-27,A:121-232THE STRUCTURE OF NATIVE PORCINE PANCREATIC ELASTASE AT ATOMIC RESOLUTION (1.1 A)
1QQUA:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF PORCINE BETA TRYPSIN WITH BOUND ACETATE ION
1QR3E:28-120,E:233-245; E:16-27,E:121-232STRUCTURE OF PORCINE PANCREATIC ELASTASE IN COMPLEX WITH FR901277, A NOVEL MACROCYCLIC INHIBITOR OF ELASTASES AT 1.6 ANGSTROM RESOLUTION
1S5SA:16-27,A:121-232; A:28-120,A:233-245PORCINE TRYPSIN COMPLEXED WITH GUANIDINE-3-PROPANOL INHIBITOR
1S6FA:16-27,A:121-232; A:28-120,A:233-245PORCINE TRYPSIN COVALENT COMPLEX WITH BORATE AND GUANIDINE-3 INHIBITOR
1S6HA:16-27,A:121-232; A:28-120,A:233-243PORCINE TRYPSIN COMPLEXED WITH GUANIDINE-3-PROPANOL INHIBITOR
1S81A:16-27,A:121-232; A:28-120,A:233-244PORCINE TRYPSIN WITH NO INHIBITOR BOUND
1S82A:16-27,A:121-232; A:28-120,A:233-245PORCINE TRYPSIN COMPLEXED WITH BORATE AND ETHYLENE GLYCOL
1S83A:16-27,A:121-232; A:28-120,A:233-245PORCINE TRYPSIN COMPLEXED WITH 4-AMINO PROPANOL
1S84A:16-27,A:121-232; A:28-120,A:233-245PORCINE TRYPSIN COVALENT COMPLEX WITH 4-AMINO BUTANOL, BORATE AND ETHYLENE GLYCOL
1S85A:16-27,A:121-232; A:28-120,A:233-245PORCINE TRYPSIN COMPLEXED WITH P-HYDROXYMETHYL BENZAMIDINE AND BORATE
1TFXA:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-245; B:28-120,B:233-245COMPLEX OF THE SECOND KUNITZ DOMAIN OF TISSUE FACTOR PATHWAY INHIBITOR WITH PORCINE TRYPSIN
1TX6A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; A:28-120,A:233-245; B:28-120,B:233-245; C:28-120,C:233-245; D:28-120,D:233-245TRYPSIN:BBI COMPLEX
1UHBA:16-145; B:146-245CRYSTAL STRUCTURE OF PORCINE ALPHA TRYPSIN BOUND WITH AUTO CATALYTICALY PRODUCED NATIVE PEPTIDE AT 2.15 A RESOLUTION
1UO6A:13-111,A:228-240; A:1-12,A:112-227PORCINE PANCREATIC ELASTASE/XE-COMPLEX
1UVOA:13-111,A:228-240; A:1-12,A:112-227STRUCTURE OF THE COMPLEX OF PORCINE PANCREATIC ELASTASE IN COMPLEX WITH CADMIUM REFINED AT 1.85 A RESOLUTION (CRYSTAL A)
1UVPA:13-111,A:228-240; A:1-12,A:112-227STRUCTURE OF THE COMPLEX OF PORCINE PANCREATIC ELASTASE IN COMPLEX WITH CADMIUM REFINED AT 1.85 A RESOLUTION (CRYSTAL B)
1V6DA:16-27,A:121-232; A:28-120,A:233-245THE CRYSTAL STRUCTURE OF THE TRYPSIN COMPLEX WITH SYNTHETIC HETEROCHIRAL PEPTIDE
1X7AC:16-27,C:121-232; C:28-120,C:233-245PORCINE FACTOR IXA COMPLEXED TO 1-{3-[AMINO(IMINO) METHYL]PHENYL}-N-[4-(1H-BENZIMIDAZOL-1-YL)-2-FLUOROPHENYL]-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE
1YF4A:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF TRYPSIN-VASOPRESSIN COMPLEX
1Z7KA:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF TRYPSIN- OVOMUCOID TURKEY EGG WHITE INHIBITOR COMPLEX
2A31A:16-27,A:121-232; A:28-120,A:233-245TRYPSIN IN COMPLEX WITH BORATE
2A32A:16-27,A:121-232; A:28-120,A:233-245TRYPSIN IN COMPLEX WITH BENZENE BORONIC ACID
2A7CA:13-111,A:228-240; A:1-12,A:112-227ON THE ROUTINE USE OF SOFT X-RAYS IN MACROMOLECULAR CRYSTALLOGRAPHY, PART III- THE OPTIMAL DATA COLLECTION WAVELENGTH
2A7JA:13-111,A:228-240; A:1-12,A:112-227ON THE ROUTINE USE OF SOFT X-RAYS IN MACROMOLECULAR CRYSTALLOGRAPHY, PART III- THE OPTIMAL DATA COLLECTION WAVELENGTH
2BD9A:28-120,A:233-245; A:16-27,A:121-232PORCINE PANCREATIC ELASTASE COMPLEXED WITH BETA-CASOMORPHIN-7 AND ARG-PHE AT PH 5.0 (50 MIN SOAK) AND IMMERSED IN PH 9 BUFFER FOR 28 SECONDS (2ND PH JUMP)
2BDBA:28-120,A:233-245; A:16-27,A:121-232PORCINE PANCREATIC ELASTASE COMPLEXED WITH ASN-PRO-ILE AND ALA-ALA AT PH 5.0
2BDCA:28-120,A:233-245; A:16-27,A:121-232PORCINE PANCREATIC ELASTASE COMPLEXED WITH ASN-PRO-ILE AT PH 5.0
2BLOA:28-120,A:233-245; A:16-27,A:121-232ELASTASE BEFORE A HIGH DOSE X-RAY "BURN"
2BLQA:28-120,A:233-245; A:16-27,A:121-232ELASTASE AFTER A HIGH DOSE X-RAY "BURN"
2CV3A:28-126,A:243-255; A:16-27,A:127-242CRYSTAL STRUCTURE OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH A MACROCLYCLIC PEPTIDE INHIBITOR
2DE8A:13-111,A:228-240; A:1-12,A:112-227CRYSTAL STRUCTURE OF PORCINE PANCREATIC ELASTASE WITH A UNIQUE CONFORMATION INDUCED BY TRIS
2DE9A:13-111,A:228-240; A:1-12,A:112-227CRYSTAL STRUCTURE OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH TRIS AFTER SOAKING A TRIS-FREE SOLUTION
2ESTE:28-120,E:233-245; E:16-27,E:121-232CRYSTALLOGRAPHIC STUDY OF THE BINDING OF A TRIFLUOROACETYL DIPEPTIDE ANILIDE INHIBITOR WITH ELASTASE
2FO9A:28-126,A:243-255; A:16-27,A:127-242STRUCTURE OF PORCINE PANCREATIC ELASTASE IN 95% ACETONE
2FOAA:28-126,A:243-255; A:16-27,A:127-242STRUCTURE OF PORCINE PANCREATIC ELASTASE IN 40/50/10 % BENZENE
2FOBA:28-126,A:243-255; A:16-27,A:127-242STRUCTURE OF PORCINE PANCREATIC ELASTASE IN 40/50/10 CYCLOHEXANE
2FOCA:28-126,A:243-255; A:16-27,A:127-242STRUCTURE OF PORCINE PANCREATIC ELASTASE IN 55% DIMETHYLFORMAMIDE
2FODA:28-126,A:243-255; A:16-27,A:127-242STRUCTURE OF PORCINE PANCREATIC ELASTASE IN 80% ETHANOL
2FOEA:28-126,A:243-255; A:16-27,A:127-242STRUCTURE OF PORCINE PANCREATIC ELASTASE IN 80% HEXANE
2FOFA:28-126,A:243-255; A:16-27,A:127-242STRUCTURE OF PORCINE PANCREATIC ELASTASE IN 80% ISOPROPANOL
2FOGA:28-126,A:243-255; A:16-27,A:127-242STRUCTURE OF PORCINE PANCREATIC ELASTASE IN 40% TRIFLUOROETHANOL
2FOHA:28-126,A:243-255; A:16-27,A:127-242STRUCTURE OF PORCINE PANCREATIC ELASTASE IN 40% TRIFLUOROETHANOL
2G4TA:13-111,A:228-240; A:1-12,A:112-227ANOMALOUS SUBSTRUCTURE OF PORCINE PANCREATIC ELASTASE (NA)
2G4UA:13-111,A:228-240; A:1-12,A:112-227ANOMALOUS SUBSTRUCTURE OF PORCINE PANCREATIC ELASTAASE (CA)
2IOTA:28-120,A:233-245; A:16-27,A:121-232CLAVULANIC ACID BOUND TO ELASTASE
2KAIA:16-95B; B:95Y-246REFINED 2.5 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF THE COMPLEX FORMED BY PORCINE KALLIKREIN A AND THE BOVINE PANCREATIC TRYPSIN INHIBITOR. CRYSTALLIZATION, PATTERSON SEARCH, STRUCTURE DETERMINATION, REFINEMENT, STRUCTURE AND COMPARISON WITH ITS COMPONENTS AND WITH THE BOVINE TRYPSIN-PANCREATIC TRYPSIN INHIBITOR COMPLEX
2OQUA:13-111,A:228-240; A:1-12,A:112-227HIGH PRESSURE CRYOCOOLING OF CAPILLARY SAMPLE CRYOPROTECTION AND DIFFRACTION PHASING AT LONG WAVELENGTHS
2PKAA:16-95B; X:16-95B; B:95Y-246; Y:95Y-246REFINED 2 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF PORCINE PANCREATIC KALLIKREIN A, A SPECIFIC TRYPSIN-LIKE SERINE PROTEINASE. CRYSTALLIZATION, STRUCTURE DETERMINATION, CRYSTALLOGRAPHIC REFINEMENT, STRUCTURE AND ITS COMPARISON WITH BOVINE TRYPSIN
2V0BA:13-111,A:228-240; A:1-12,A:112-227SAD STRUCTURE SOLUTION PORCINE PANCREATIC ELASTASE FROM A SELENATE DERIVATIVE
2V35A:28-120,A:233-245; A:16-27,A:121-232PORCINE PANCREATIC ELASTASE IN COMPLEX WITH INHIBITOR JM54
3E3TA:13-111,A:228-240; A:1-12,A:112-227STRUCTURE OF PORCINE PANCREATIC ELASTASE WITH THE MAGIC TRIANGLE I3C
3ESTA:28-120,A:233-245; A:16-27,A:121-232STRUCTURE OF NATIVE PORCINE PANCREATIC ELASTASE AT 1.65 ANGSTROMS RESOLUTION
3HGNA:28-120,A:233-245; A:16-27,A:121-232STRUCTURE OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH A POTENT PEPTIDYL INHIBITOR FR130180 DETERMINED BY NEUTRON CRYSTALLOGRAPHY
3HGPA:28-120,A:233-245; A:16-27,A:121-232STRUCTURE OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH A POTENT PEPTIDYL INHIBITOR FR130180 DETERMINED BY HIGH RESOLUTION CRYSTALLOGRAPHY
4ESTE:28-120,E:233-245; E:16-27,E:121-232CRYSTAL STRUCTURE OF THE COVALENT COMPLEX FORMED BY A PEPTIDYL ALPHA, ALPHA-DIFLUORO-BETA-KETO AMIDE WITH PORCINE PANCREATIC ELASTASE AT 1.78-ANGSTROMS RESOLUTION
5ESTE:28-120,E:233-245; E:16-27,E:121-232CRYSTALLOGRAPHIC ANALYSIS OF THE INHIBITION OF PORCINE PANCREATIC ELASTASE BY A PEPTIDYL BORONIC ACID: STRUCTURE OF A REACTION INTERMEDIATE
6ESTA:28-120,A:233-245; A:16-27,A:121-232INTERACTION OF THE PEPTIDE CF3-LEU-ALA-NH-C6H4-CF3(TFLA) WITH PORCINE PANCREATIC ELASTASE. X-RAY STUDIES AT 1.8 ANGSTROMS
7ESTE:28-120,E:233-245; E:16-27,E:121-232INTERACTION OF THE PEPTIDE CF3-LEU-ALA-NH-C6H4-CF3(TFLA) WITH PORCINE PANCREATIC ELASTASE. X-RAY STUDIES AT 1.8 ANGSTROMS
8ESTE:28-120,E:233-245; E:16-27,E:121-232REACTION OF PORCINE PANCREATIC ELASTASE WITH 7-SUBSTITUTED 3-ALKOXY-4-CHLOROISOCOUMARINS: DESIGN OF POTENT INHIBITORS USING THE CRYSTAL STRUCTURE OF THE COMPLEX FORMED WITH 4-CHLORO-3-ETHOXY-7-GUANIDINO-ISOCOUMARIN
9ESTA:28-120,A:233-245; A:16-27,A:121-232STRUCTURAL STUDY OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH 7-AMINO-3-(2-BROMOETHOXY)-4-CHLOROISOCOUMARIN AS A NONREACTIVATABLE DOUBLY COVALENT ENZYME-INHIBITOR COMPLEX
(-)
Prrsv (Porcine respiratory and reproductive syndrome virus) (2)
3FANA:81-154CRYSTAL STRUCTURE OF CHYMOTRYPSIN-LIKE PROTEASE/PROTEINASE (3CLSP/NSP4) OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV)
3FAOA:81-154CRYSTAL STRUCTURE OF S118A MUTANT 3CLSP OF PRRSV
(-)
Pseudonaja textilis textilis. Organism_taxid: 169397. (1)
3D65E:16-27,E:121-232; E:28-120,E:233-244CRYSTAL STRUCTURE OF TEXTILININ-1, A KUNITZ-TYPE SERINE PROTEASE INHIBITOR FROM THE AUSTRALIAN COMMON BROWN SNAKE VENOM, IN COMPLEX WITH TRYPSIN
(-)
Rat (Rattus norvegicus) (2)
1QL9A:16-27,A:121-232; A:28-120,A:233-245FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH RAT TRYPSIN MUTANT X99RT
2JETC:151-243; B:19-146CRYSTAL STRUCTURE OF A TRYPSIN-LIKE MUTANT (S189D, A226G) CHYMOTRYPSIN.
(-)
Red fire ant (Solenopsis invicta) (1)
1EQ9A:28-120,A:233-244; B:328-420,B:533-544; A:16-27,A:121-232; B:316-327,B:421-532CRYSTAL STRUCTURE OF FIRE ANT CHYMOTRYPSIN COMPLEXED TO PMSF
(-)
Rice (Oryza sativa) (1)
2QN5T:19-30,T:121-232; T:31-120,T:233-244CRYSTAL STRUCTURE AND FUNCTIONAL STUDY OF THE BOWMAN-BIRK INHIBITOR FROM RICE BRAN IN COMPLEX WITH BOVINE TRYPSIN
(-)
Sars coronavirus sin2774. Organism_taxid: 235410. (2)
2BX3A:2-14,A:100-197; A:15-99CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEINASE (P43212)
2BX4A:3-14,A:100-197; A:15-99CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEINASE (P21212)
(-)
Sars coronavirus. Organism_taxid: 227859 (2)
1Z1IA:1-14,A:100-197; A:15-99CRYSTAL STRUCTURE OF NATIVE SARS CLPRO
1Z1JA:1-14,A:100-197; B:1001-1014,B:1100-1197; A:15-99; B:1015-1099CRYSTAL STRUCTURE OF SARS 3CLPRO C145A MUTANT
(-)
Sars coronavirus. Organism_taxid: 227859. (2)
2Z3CA:1-14,A:100-197; A:15-99A MECHANISTIC VIEW OF ENZYME INHIBITION AND PEPTIDE HYDROLYSIS IN THE ACTIVE SITE OF THE SARS-COV 3C-LIKE PEPTIDASE
2Z3EA:1-14,A:100-197; A:15-99A MECHANISTIC VIEW OF ENZYME INHIBITION AND PEPTIDE HYDROLYSIS IN THE ACTIVE SITE OF THE SARS-COV 3C-LIKE PEPTIDASE
(-)
Sars coronavirus. Organism_taxid: 227859. (9)
2AMDB:-1-14,B:100-197; A:15-99; B:15-99; A:-3-14,A:100-197CRYSTAL STRUCTURE OF SARS_COV MPRO IN COMPLEX WITH AN INHIBITOR N9
2AMQB:1-14,B:100-197; A:3-14,A:100-197; A:15-99; B:15-99CRYSTAL STRUCTURE OF SARS_COV MPRO IN COMPLEX WITH AN INHIBITOR N3
2D2DB:1-14,B:100-197; A:3-14,A:100-197; A:15-99; B:15-99CRYSTAL STRUCTURE OF SARS-COV MPRO IN COMPLEX WITH AN INHIBITOR I2
2GT7A:1-14,A:100-197; B:15-99; A:15-99; B:1-14,B:100-197CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PEPTIDASE AT PH 6.0 IN THE SPACE GROUP P21
2GT8A:3-14,A:100-197; A:15-99CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PEPTIDASE (WITH AN ADDITIONAL ALA AT THE N-TERMINUS OF EACH PROTOMER) IN THE SPACE GROUP P43212
2GTBA:2-14,A:100-197; A:15-99CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PEPTIDASE (WITH AN ADDITIONAL ALA AT THE N-TERMINUS OF EACH PROTOMER) INHIBITED BY AN AZA-PEPTIDE EPOXIDE IN THE SPACE GROUP P43212
2GX4A:1-14,A:100-197; A:15-99CRYSTAL STRUCTURE OF SARS CORONAVIRUS 3CL PROTEASE INHIBITOR COMPLEX
2H2ZA:1-14,A:100-197; A:15-99CRYSTAL STRUCTURE OF SARS-COV MAIN PROTEASE WITH AUTHENTIC N AND C-TERMINI
2HOBA:1-14,A:100-197; A:15-99CRYSTAL STRUCTURE OF SARS-COV MAIN PROTEASE WITH AUTHENTIC N AND C-TERMINI IN COMPLEX WITH A MICHAEL ACCEPTOR N3
(-)
Sars coronavirus. Organism_taxid: 227859. Expression_system_vector_type: plasmid. (1)
2DUCA:1-14,A:100-197; B:1-14,B:100-197; A:15-99; B:15-99CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEINASE(3CLPRO)
(-)
Sars coronavirus. Organism_taxid: 227859. Strain: bj01. (1)
1WOFB:-1-14,B:100-197; A:-3-14,A:100-197; A:15-99; B:15-99CRYSTAL STRUCTURE OF SARS-COV MPRO IN COMPLEX WITH AN INHIBITOR N1
(-)
Sars coronavirus. Organism_taxid: 227859. Strain: sars. (11)
1UJ1A:3-14,A:100-197; A:15-99; B:15-99; B:3-14,B:100-197CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEINASE (3CLPRO)
1UK2A:3-14,A:100-197; A:15-99; B:15-99; B:3-14,B:100-197CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEINASE (3CLPRO) AT PH8.0
1UK3A:3-14,A:100-197; B:3-14,B:100-197; A:15-99; B:15-99CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEINASE (3CLPRO) AT PH7.6
1UK4A:3-14,A:100-197; B:3-14,B:100-197; A:15-99; B:15-99CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEINASE (3CLPRO) COMPLEXED WITH AN INHIBITOR
2A5AA:1-14,A:100-197; A:15-99CRYSTAL STRUCTURE OF UNBOUND SARS CORONAVIRUS MAIN PEPTIDASE IN THE SPACE GROUP C2
2A5IA:1-14,A:100-197; A:15-99CRYSTAL STRUCTURES OF SARS CORONAVIRUS MAIN PEPTIDASE INHIBITED BY AN AZA-PEPTIDE EPOXIDE IN THE SPACE GROUP C2
2A5KA:1-14,A:100-197; B:1-14,B:100-197; A:15-99; B:15-99CRYSTAL STRUCTURES OF SARS CORONAVIRUS MAIN PEPTIDASE INHIBITED BY AN AZA-PEPTIDE EPOXIDE IN SPACE GROUP P212121
2ALVA:2-14,A:100-197; A:15-99X-RAY STRUCTURAL ANALYSIS OF SARS CORONAVIRUS 3CL PROTEINASE IN COMPLEX WITH DESIGNED ANTI-VIRAL INHIBITORS
2GZ7A:1-14,A:100-197; A:15-99STRUCTURE-BASED DRUG DESIGN AND STRUCTURAL BIOLOGY STUDY OF NOVEL NONPEPTIDE INHIBITORS OF SARS-COV MAIN PROTEASE
2GZ8A:1-14,A:100-197; A:15-99STRUCTURE-BASED DRUG DESIGN AND STRUCTURAL BIOLOGY STUDY OF NOVEL NONPEPTIDE INHIBITORS OF SARS-COV MAIN PROTEASE
2GZ9A:1-14,A:100-197; A:15-99STRUCTURE-BASED DRUG DESIGN AND STRUCTURAL BIOLOGY STUDY OF NOVEL NONPEPTIDE INHIBITORS OF SARS-COV MAIN PROTEASE
(-)
Sars coronavirus. Organism_taxid: 227859. Strain: sin2774. (1)
2C3SA:1-14,A:100-197; A:15-99STRUCTURE OF SARS COV MAIN PROTEINASE AT 1.9 A (PH6.5)
(-)
Sars coronavirus. Organism_taxid: 227859. Strain: tor2. (1)
2OP9A:0-14,A:100-197; B:1-14,B:100-197; A:15-99; B:15-99SUBSTRATE SPECIFICITY PROFILING AND IDENTIFICATION OF A NEW CLASS OF INHIBITOR FOR THE MAJOR PROTEASE OF THE SARS CORONAVIRUS
(-)
Sars coronavirus. Organism_taxid: 227859. Strain: urbani. (1)
1Q2WB:3-14,B:100-197; A:3-14,A:100-197; A:15-99; B:15-99X-RAY CRYSTAL STRUCTURE OF THE SARS CORONAVIRUS MAIN PROTEASE
(-)
Sars-cov (Sars coronavirus) (1)
2Z3DA:1-14,A:100-197; A:15-99A MECHANISTIC VIEW OF ENZYME INHIBITION AND PEPTIDE HYDROLYSIS IN THE ACTIVE SITE OF THE SARS-COV 3C-LIKE PEPTIDASE
(-)
Semliki forest virus. Organism_taxid: 11033. (2)
1VCPA:183-267; B:183-267; C:183-267; A:119-182; B:119-182; C:119-182SEMLIKI FOREST VIRUS CAPSID PROTEIN (CRYSTAL FORM I)
1VCQA:183-267; B:183-267; A:119-182; B:119-182SEMLIKI FOREST VIRUS CAPSID PROTEIN (CRYSTAL FORM II)
(-)
Sheep (Ovis aries) (1)
1FIWA:16-27,A:121-232; A:28-120,A:233-245THREE-DIMENSIONAL STRUCTURE OF BETA-ACROSIN FROM RAM SPERMATOZOA
(-)
Sindbis virus. Organism_taxid: 11034 (1)
2SNVA:179-264; A:114-178THE REFINED STRUCTURE OF SINDBIS VIRUS CORE PROTEIN IN COMPARISON WITH OTHER CHYMOTRYPSIN-LIKE SERINE PROTEINASE STRUCTURES
(-)
Sindbis virus. Organism_taxid: 11034. (7)
1KXAA:179-264; A:114-178SINDBIS VIRUS CAPSID, (WILD-TYPE) RESIDUES 106-264, TETRAGONAL CRYSTAL FORM
1KXBA:179-264; A:114-178SINDBIS VIRUS CAPSID (S215A MUTANT), TETRAGONAL CRYSTAL FORM
1KXCA:179-264; A:114-178SINDBIS VIRUS CAPSID (N190K MUTANT), TETRAGONAL CRYSTAL FORM
1KXDA:179-264; A:114-178SINDBIS VIRUS CAPSID (N222L MUTANT), TETRAGONAL CRYSTAL FORM
1KXEA:179-264; A:114-178SINDBIS VIRUS CAPSID (Y180S, E183G DOUBLE MUTANT), TETRAGONAL CRYSTAL FORM
1KXFA:179-264; A:114-178SINDBIS VIRUS CAPSID, (WILD-TYPE) RESIDUES 1-264, TETRAGONAL CRYSTAL FORM (FORM II)
1SVPA:179-264; B:179-264; A:114-178; B:114-178SINDBIS VIRUS CAPSID PROTEIN
(-)
Sindbis virus. Organism_taxid: 11034. Strain: sa-ar 86. Cell_line: baby hamster kidney cells (bhk21). (1)
2SNWA:179-264; B:179-264; A:114-178; B:114-178SINDBIS VIRUS CAPSID PROTEIN, TYPE3 CRYSTAL FORM
(-)
Sindbis virus. Organism_taxid: 11034. Strain: sa-ar 86. Cell_line: bl21. (1)
1WYKA:179-264; B:179-264; C:179-264; D:179-264; A:114-178; B:114-178; C:114-178; D:114-178SINDBIS VIRUS CAPSID PROTEIN (114-264)
(-)
Southern copperhead (Agkistrodon contortrix contortrix) (2)
2AIPA:16-25,A:127-230; A:26-125,A:231-245CRYSTAL STRUCTURE OF NATIVE PROTEIN C ACTIVATOR FROM THE VENOM OF COPPERHEAD SNAKE AGKISTRODON CONTORTRIX CONTORTRIX
2AIQA:16-25,A:127-230; A:26-125,A:231-245CRYSTAL STRUCTURE OF BENZAMIDINE-INHIBITED PROTEIN C ACTIVATOR FROM THE VENOM OF COPPERHEAD SNAKE AGKISTRODON CONTORTRIX CONTORTRIX
(-)
Staphylococcus aureus. Organism_taxid: 1280. (3)
1DT2A:40-135,A:218-243; A:4-39,A:136-216CRYSTAL STRUCTURE OF EXFOLIATIVE TOXIN B
1DUAA:47-141,A:230-242; A:1-46,A:142-229CRYSTAL STRUCTURE OF EXFOLIATIVE TOXIN A
1DUEA:47-141,A:230-242; A:1-46,A:142-229CRYSTAL STRUCTURE OF EXFOLIATIVE TOXIN A S195A MUTANT
(-)
Staphylococcus aureus. Organism_taxid: 1280. Strain: ibs-sa417 (1)
1AGJA:47-141,A:230-242; B:47-141,B:230-242; A:1-46,A:142-229; B:1-46,B:142-229EPIDERMOLYTIC TOXIN A FROM STAPHYLOCOCCUS AUREUS
(-)
Staphylococcus aureus. Organism_taxid: 1280. Strain: mnev (1)
1EXFA:31-120,A:232-243; A:1B-30,A:121-231EXFOLIATIVE TOXIN A
(-)
Staphylococcus aureus. Organism_taxid: 1280. Strain: mu50. (1)
2O8LA:1-14,A:116-216; A:15-115STRUCTURE OF V8 PROTEASE FROM STAPHYLOCOCCUS AUREUS
(-)
Staphylococcus aureus. Organism_taxid: 1280. Strain: rn4220. (1)
1QTFA:40-135,A:218-243; A:1-39,A:136-216CRYSTAL STRUCTURE OF EXFOLIATIVE TOXIN B
(-)
Staphylococcus aureus. Organism_taxid: 1280. Strain: v8 (1)
1WCZA:1-14,A:116-216; A:15-115CRYSTAL STRUCTURE OF AN ALKALINE FORM OF V8 PROTEASE FROM STAPHYLOCOCCUS AUREUS
(-)
Stejneger's pit viper (Viridovipera stejnegeri) (1)
1BQYA:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-245; B:28-120,B:233-245PLASMINOGEN ACTIVATOR (TSV-PA) FROM SNAKE VENOM
(-)
Streptomyces fradiae. Organism_taxid: 1906. Strain: atcc 14544 (1)
2SFAA:79-178; A:1-78,A:179-191SERINE PROTEINASE FROM STREPTOMYCES FRADIAE ATCC 14544
(-)
Streptomyces griseus. Organism_taxid: 1911 (4)
1SGCA:116-230; A:16-115,A:231-242THE 1.8 ANGSTROMS STRUCTURE OF THE COMPLEX BETWEEN CHYMOSTATIN AND STREPTOMYCES GRISEUS PROTEASE A. A MODEL FOR SERINE PROTEASE CATALYTIC TETRAHEDRAL INTERMEDIATES
1SGTA:16-27,A:121-232; A:28-120,A:233-245REFINED CRYSTAL STRUCTURE OF STREPTOMYCES GRISEUS TRYPSIN AT 1.7 ANGSTROMS RESOLUTION
2QAAA:117-230; B:117-230; A:16-116,A:231-242; B:16-116,B:231-242CRYSTAL STRUCTURE OF THE SECOND TETRAHEDRAL INTERMEDIATES OF SGPB AT PH 7.3
2SGAA:116-230; A:16-115,A:231-242ELECTRON DENSITY CALCULATIONS AS AN EXTENSION OF PROTEIN STRUCTURE REFINEMENT. STREPTOMYCES GRISEUS PROTEASE AT 1.5 ANGSTROMS RESOLUTION
(-)
Streptomyces griseus. Organism_taxid: 1911. (5)
1DS2E:117-230; E:16-116,E:231-242CRYSTAL STRUCTURE OF SGPB:OMTKY3-COO-LEU18I
2GKVE:117-230; E:16-116,E:231-242CRYSTAL STRUCTURE OF THE SGPB:P14'-ALA32 OMTKY3-DEL(1-5) COMPLEX
2NU0E:117-230; E:16-116,E:231-242MOLECULAR STRUCTURES OF THE COMPLEXES OF SGPB WITH OMTKY3 AROMATIC P1 VARIANTS TRP18I, HIS18I, PHE18I, AND TYR18I
2NU1E:117-230; E:16-116,E:231-242MOLECULAR STRUCTURES OF THE COMPLEXES OF SGPB WITH OMTKY3 AROMATIC P1 VARIANTS TRP18I, HIS18I, PHE18I AND TYR18I
2QA9E:117-230; E:16-116,E:231-242CRYSTAL STRUCTURE OF THE SECOND TETRAHEDRAL INTERMEDIATES OF SGPB AT PH 4.2
(-)
Streptomyces griseus. Organism_taxid: 1911. (12)
1HPGA:116-230; A:16-115,A:231-242A GLUTAMIC ACID SPECIFIC SERINE PROTEASE UTILIZES A NOVEL HISTIDINE TRIAD IN SUBSTRATE BINDING
1OS8A:16-27,A:121-232; A:28-120,A:233-245RECOMBINANT STREPTOMYCES GRISEUS TRYPSIN
1OSSA:16-27,A:121-232; A:28-120,A:233-245T190P STREPTOMYCES GRISEUS TRYPSIN IN COMPLEX WITH BENZAMIDINE
2FMJA:16-27,A:121-232; A:28-120,A:233-245220-LOOP MUTANT OF STREPTOMYCES GRISEUS TRYPSIN
3BEUA:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-245; B:28-120,B:233-245NA+-DEPENDENT ALLOSTERY MEDIATES COAGULATION FACTOR PROTEASE ACTIVE SITE SELECTIVITY
3I77A:16-27,A:121-232; A:28-120,A:233-24535/99/170-LOOPS OF FXA IN SGT
3I78A:16-27,A:121-232; A:28-120,A:233-24535/99/170/186/220-LOOPS OF FXA IN SGT
3SGAE:116-230; E:16-115,E:231-242STRUCTURES OF PRODUCT AND INHIBITOR COMPLEXES OF STREPTOMYCES GRISEUS PROTEASE A AT 1.8 ANGSTROMS RESOLUTION. A MODEL FOR SERINE PROTEASE CATALYSIS
3SGBE:117-230; E:16-116,E:231-242STRUCTURE OF THE COMPLEX OF STREPTOMYCES GRISEUS PROTEASE B AND THE THIRD DOMAIN OF THE TURKEY OVOMUCOID INHIBITOR AT 1.8 ANGSTROMS RESOLUTION
4SGAE:116-230; E:16-115,E:231-242STRUCTURES OF PRODUCT AND INHIBITOR COMPLEXES OF STREPTOMYCES GRISEUS PROTEASE A AT 1.8 ANGSTROMS RESOLUTION. A MODEL FOR SERINE PROTEASE CATALYSIS
4SGBE:120-230; E:16-119,E:231-243STRUCTURE OF THE COMPLEX OF STREPTOMYCES GRISEUS PROTEINASE B AND POLYPEPTIDE CHYMOTRYPSIN INHIBITOR-1 FROM RUSSET BURBANK POTATO TUBERS AT 2.1 ANGSTROMS RESOLUTION
5SGAE:116-230; E:16-115,E:231-242STRUCTURES OF PRODUCT AND INHIBITOR COMPLEXES OF STREPTOMYCES GRISEUS PROTEASE A AT 1.8 ANGSTROMS RESOLUTION. A MODEL FOR SERINE PROTEASE CATALYSIS
(-)
Streptomyces griseus. Organism_taxid: 1911. Strain: k1. (17)
1CSOE:117-230; E:16-116,E:231-242CRYSTAL STRUCTURE OF THE OMTKY3 P1 VARIANT OMTKY3-ILE18I IN COMPLEX WITH SGPB
1CT0E:117-230; E:16-116,E:231-242CRYSTAL STRUCTURE OF THE OMTKY3 P1 VARIANT OMTKY3-SER18I IN COMPLEX WITH SGPB
1CT2E:117-230; E:16-116,E:231-242CRYSTAL STRUCTURE OF THE OMTKY3 P1 VARIANT OMTKY3-THR18I IN COMPLEX WITH SGPB
1CT4E:117-230; E:16-116,E:231-242CRYSTAL STRUCTURE OF THE OMTKY3 P1 VARIANT OMTKY3-VAL18I IN COMPLEX WITH SGPB
1SGDE:117-230; E:16-116,E:231-242ASP 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5
1SGEE:117-230; E:16-116,E:231-242GLU 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5
1SGNE:117-230; E:16-116,E:231-242ASN 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B
1SGYE:117-230; E:16-116,E:231-242TYR 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5
2NU2E:117-230; E:16-116,E:231-242ACCOMMODATION OF POSITIVELY-CHARGED RESIDUES IN A HYDROPHOBIC SPECIFICITY POCKET: CRYSTAL STRUCTURES OF SGPB IN COMPLEX WITH OMTKY3 VARIANTS LYS18I AND ARG18I
2NU3E:117-230; E:16-116,E:231-242ACCOMMODATION OF POSITIVELY-CHARGED RESIDUES IN A HYDROPHOBIC SPECIFICITY POCKET: CRYSTAL STRUCTURES OF SGPB IN COMPLEX WITH OMTKY3 VARIANTS LYS18I AND ARG18I
2NU4E:117-230; E:16-116,E:231-242ACCOMMODATION OF POSITIVELY-CHARGED RESIDUES IN A HYDROPHOBIC SPECIFICITY POCKET: CRYSTAL STRUCTURES OF SGPB IN COMPLEX WITH OMTKY3 VARIANTS LYS18I AND ARG18I
2SGDE:117-230; E:16-116,E:231-242ASP 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 10.7
2SGEE:117-230; E:16-116,E:231-242GLU 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 10.7
2SGFE:117-230; E:16-116,E:231-242PHE 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B
2SGPE:117-230; E:16-116,E:231-242PRO 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5
2SGQE:117-230; E:16-116,E:231-242GLN 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5
3SGQE:117-230; E:16-116,E:231-242GLN 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 10.7
(-)
Streptomyces griseus. Organism_taxid: 1911. Strain: k1. (3)
1SGPE:117-230; E:16-116,E:231-242ALA 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B
1SGQE:117-230; E:16-116,E:231-242GLY 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B
1SGRE:117-230; E:16-116,E:231-242LEU 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B
(-)
Thermobifida fusca yx. Organism_taxid: 269800. Strain: yx. (1)
2PFEA:120-230; B:120-230; A:15-119,A:231-245; B:15-119,B:231-245CRYSTAL STRUCTURE OF THERMOBIFIDA FUSCA PROTEASE A (TFPA)
(-)
Thermotoga maritima. Organism_taxid: 2336. (1)
1L1JA:144-251; B:144-251; A:24-143; B:24-143CRYSTAL STRUCTURE OF THE PROTEASE DOMAIN OF AN ATP-INDEPENDENT HEAT SHOCK PROTEASE HTRA
(-)
Tobacco etch virus. Organism_taxid: 12227. (3)
1LVBA:18-98,A:182-206; A:8-17,A:99-181,A:207-221; B:8-17,B:99-181,B:207-221; B:18-98,B:182-206CATALYTICALLY INACTIVE TOBACCO ETCH VIRUS PROTEASE COMPLEXED WITH SUBSTRATE
1LVMA:8-17,A:99-181,A:207-221; B:8-17,B:99-181,B:207-221; A:18-98,A:182-206; B:18-98,B:182-206CATALYTICALLY ACTIVE TOBACCO ETCH VIRUS PROTEASE COMPLEXED WITH PRODUCT
1Q31A:8-17,A:99-181,A:207-221; B:8-17,B:99-181,B:207-221; A:18-98,A:182-206; B:18-98,B:182-206CRYSTAL STRUCTURE OF THE TOBACCO ETCH VIRUS PROTEASE C151A MUTANT
(-)
Tobacco hornworm (Manduca sexta) (1)
1K9OE:16-27,E:121-232; E:28-120,E:233-245CRYSTAL STRUCTURE OF MICHAELIS SERPIN-TRYPSIN COMPLEX
(-)
Transmissible gastroenteritis virus. Organism_taxid: 11149. (2)
1LVOA:14-97; B:14-97; A:98-185; B:98-185; C:98-185; D:98-185; E:98-185; F:98-185; C:14-97; D:14-97; E:14-97; F:14-97STRUCTURE OF CORONAVIRUS MAIN PROTEINASE REVEALS COMBINATION OF A CHYMOTRYPSIN FOLD WITH AN EXTRA ALPHA-HELICAL DOMAIN
1P9UA:14-97; E:14-97; F:14-97; A:98-185; B:98-185; C:98-185; D:98-185; E:98-185; F:98-185; B:14-97; C:14-97; D:14-97CORONAVIRUS MAIN PROTEINASE (3CLPRO) STRUCTURE: BASIS FOR DESIGN OF ANTI-SARS DRUGS
(-)
Transmissible gastroenteritis virus. Organism_taxid: 11149. (1)
2AMPA:14-97; B:14-97; A:98-185; B:98-185CRYSTAL STRUCTURE OF PORCINE TRANSMISSIBLE GASTROENTERITIS VIRUS MPRO IN COMPLEX WITH AN INHIBITOR N1
(-)
Venezuelan equine encephalitis virus. Organism_taxid: 11036. (2)
1EP5A:190-275; B:190-275; C:190-275; A:126-189; B:126-189; C:126-189CRYSTAL STRUCTURE OF THE CONSERVED CORE DOMAIN OF VENEZUALAN EQUINE ENCEPHALITIS CAPSID PROTEIN
1EP6A:190-275; B:126-189; C:126-189; B:190-275; C:190-275; A:126-189CRYSTAL STRUCTURE OF THE CONSERVED CORE DOMAIN OF VENEZUALAN EQUINE ENCEPHALITIS CAPSID PROTEIN
(-)
Wild boar (Sus scrofa) (5)
1E34B:28-120,B:233-245; B:16-27,B:121-232PORCINE PANCREATIC ELASTASE COMPLEXED WITH (3S, 4S)N-PARA-TOLUENESULPHONYL-3-ETHYL-4-(CARBOXYLIC ACID) PYRROLIDIN-2-ONE SOAKED IN PH 9 BUFFER FOR ONE MINUTE
1E35B:28-120,B:233-245; B:16-27,B:121-232PORCINE PANCREATIC ELASTASE COMPLEXED WITH (3S, 4S)N-PARA-TOLUENESULPHONYL -3-ETHYL-4-(CARBOXYLIC ACID)PYRROLIDIN-2-ONE SOAKED IN PH 9 BUFFER FOR TWO MINUTES
1E36B:28-120,B:233-245; B:16-27,B:121-232PORCINE PANCREATIC ELASTASE COMPLEXED WITH (3S, 4S)N-PARA-NITROBENZENESULPHONYL -3-ETHYL-4-(CARBOXYLIC ACID)PYRROLIDIN-2-ONE
1E37B:28-120,B:233-245; B:16-27,B:121-232PORCINE PANCREATIC ELASTASE COMPLEXED WITH (3S, 4S)N-PARA-NITROBENZENESULPHONYL -3-ETHYL-4-(CARBOXYLIC ACID)PYRROLIDIN-2-ONE SOAKED IN PH 9 BUFFER FOR 1 MINUTE
1E38B:28-120,B:233-245; B:16-27,B:121-232PORCINE PANCREATIC ELASTASE COMPLEXED WITH (3S, 4S)N-PARA-NITROBENZENESULPHONYL -3-ETHYL-4-(CARBOXYLIC ACID)PYRROLIDIN-2-ONE SOAKED IN PH 9 BUFFER FOR 2 MINUTES